
<html lang="en"     class="pb-page"  data-request-id="38f50ea7-e806-4faa-9fde-f3e2450eebf4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c00450;issue:issue:10.1021/jmcmar.2020.63.issue-13;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders" /></meta><meta name="dc.Creator" content="Satoru  Noji" /></meta><meta name="dc.Creator" content="Yoshinori  Hara" /></meta><meta name="dc.Creator" content="Tomoya  Miura" /></meta><meta name="dc.Creator" content="Hiroshi  Yamanaka" /></meta><meta name="dc.Creator" content="Katsuya  Maeda" /></meta><meta name="dc.Creator" content="Akimi  Hori" /></meta><meta name="dc.Creator" content="Hiroshi  Yamamoto" /></meta><meta name="dc.Creator" content="Shingo  Obika" /></meta><meta name="dc.Creator" content="Masafumi  Inoue" /></meta><meta name="dc.Creator" content="Yasunori  Hase" /></meta><meta name="dc.Creator" content="Takuya  Orita" /></meta><meta name="dc.Creator" content="Satoki  Doi" /></meta><meta name="dc.Creator" content="Tsuyoshi  Adachi" /></meta><meta name="dc.Creator" content="Atsuo  Tanimoto" /></meta><meta name="dc.Creator" content="Chika  Oki" /></meta><meta name="dc.Creator" content="Yukari  Kimoto" /></meta><meta name="dc.Creator" content="Yoshihiro  Ogawa" /></meta><meta name="dc.Creator" content="Tamotsu  Negoro" /></meta><meta name="dc.Creator" content="Hiromasa  Hashimoto" /></meta><meta name="dc.Creator" content="Makoto  Shiozaki" /></meta><meta name="dc.Description" content="Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reacti..." /></meta><meta name="Description" content="Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reacti..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 8, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00450" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00450" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00450" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00450" /></link>
        
    
    

<title>Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00450" /></meta><meta property="og:title" content="Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0031.jpeg" /></meta><meta property="og:description" content="Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (ent-60), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic dermatitis as the first drug among Janus kinase inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00450"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00450">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00450&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00450&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00450&amp;href=/doi/10.1021/acs.jmedchem.0c00450" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 7163-7185</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00449" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00456" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Satoru Noji</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Satoru Noji</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><span class="conrtib-corresp"><strong>*</strong>For S.N.: phone, +81-72-681-9700; email, <a href="/cdn-cgi/l/email-protection#344755405b46411a5a5b5e5d745e401a575b59"><span class="__cf_email__" data-cfemail="413220352e33346f2f2e2b28012b356f222e2c">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Satoru++Noji">Satoru Noji</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5970-9140" title="Orcid link">http://orcid.org/0000-0002-5970-9140</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yoshinori Hara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yoshinori Hara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yoshinori++Hara">Yoshinori Hara</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tomoya Miura</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tomoya Miura</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tomoya++Miura">Tomoya Miura</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hiroshi Yamanaka</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hiroshi Yamanaka</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hiroshi++Yamanaka">Hiroshi Yamanaka</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katsuya Maeda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katsuya Maeda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katsuya++Maeda">Katsuya Maeda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Akimi Hori</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Akimi Hori</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Akimi++Hori">Akimi Hori</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hiroshi Yamamoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hiroshi Yamamoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hiroshi++Yamamoto">Hiroshi Yamamoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shingo Obika</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shingo Obika</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shingo++Obika">Shingo Obika</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Masafumi Inoue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Masafumi Inoue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Masafumi++Inoue">Masafumi Inoue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yasunori Hase</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yasunori Hase</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yasunori++Hase">Yasunori Hase</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takuya Orita</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takuya Orita</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takuya++Orita">Takuya Orita</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Satoki Doi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Satoki Doi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Satoki++Doi">Satoki Doi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tsuyoshi Adachi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tsuyoshi Adachi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tsuyoshi++Adachi">Tsuyoshi Adachi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Atsuo Tanimoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Atsuo Tanimoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biological Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Atsuo++Tanimoto">Atsuo Tanimoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chika Oki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chika Oki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biological Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chika++Oki">Chika Oki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yukari Kimoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yukari Kimoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biological Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yukari++Kimoto">Yukari Kimoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yoshihiro Ogawa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yoshihiro Ogawa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biological Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yoshihiro++Ogawa">Yoshihiro Ogawa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tamotsu Negoro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tamotsu Negoro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tamotsu++Negoro">Tamotsu Negoro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hiromasa Hashimoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hiromasa Hashimoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hiromasa++Hashimoto">Hiromasa Hashimoto</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Makoto Shiozaki</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Makoto Shiozaki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</div></div><span class="conrtib-corresp"><strong>*</strong>For M.S.: email, <a href="/cdn-cgi/l/email-protection#7d101c16120912530e151412071c16143d1709531e1210"><span class="__cf_email__" data-cfemail="c8a5a9a3a7bca7e6bba0a1a7b2a9a3a188a2bce6aba7a5">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Makoto++Shiozaki">Makoto Shiozaki</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5519-6547" title="Orcid link">http://orcid.org/0000-0001-5519-6547</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00450&amp;href=/doi/10.1021%2Facs.jmedchem.0c00450" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 7163–7185</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 8, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 March 2020</li><li><span class="item_label"><b>Published</b> online</span>8 June 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 July 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00450" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00450</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7163%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSatoru%2BNoji%252C%2BYoshinori%2BHara%252C%2BTomoya%2BMiura%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D13%26contentID%3Dacs.jmedchem.0c00450%26title%3DDiscovery%2Bof%2Ba%2BJanus%2BKinase%2BInhibitor%2BBearing%2Ba%2BHighly%2BThree-Dimensional%2BSpiro%2BScaffold%253A%2BJTE-052%2B%2528Delgocitinib%2529%2Bas%2Ba%2BNew%2BDermatological%2BAgent%2Bto%2BTreat%2BInflammatory%2BSkin%2BDisorders%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7185%26publicationDate%3DJuly%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00450"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2482</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00450" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Satoru&quot;,&quot;last_name&quot;:&quot;Noji&quot;},{&quot;first_name&quot;:&quot;Yoshinori&quot;,&quot;last_name&quot;:&quot;Hara&quot;},{&quot;first_name&quot;:&quot;Tomoya&quot;,&quot;last_name&quot;:&quot;Miura&quot;},{&quot;first_name&quot;:&quot;Hiroshi&quot;,&quot;last_name&quot;:&quot;Yamanaka&quot;},{&quot;first_name&quot;:&quot;Katsuya&quot;,&quot;last_name&quot;:&quot;Maeda&quot;},{&quot;first_name&quot;:&quot;Akimi&quot;,&quot;last_name&quot;:&quot;Hori&quot;},{&quot;first_name&quot;:&quot;Hiroshi&quot;,&quot;last_name&quot;:&quot;Yamamoto&quot;},{&quot;first_name&quot;:&quot;Shingo&quot;,&quot;last_name&quot;:&quot;Obika&quot;},{&quot;first_name&quot;:&quot;Masafumi&quot;,&quot;last_name&quot;:&quot;Inoue&quot;},{&quot;first_name&quot;:&quot;Yasunori&quot;,&quot;last_name&quot;:&quot;Hase&quot;},{&quot;first_name&quot;:&quot;Takuya&quot;,&quot;last_name&quot;:&quot;Orita&quot;},{&quot;first_name&quot;:&quot;Satoki&quot;,&quot;last_name&quot;:&quot;Doi&quot;},{&quot;first_name&quot;:&quot;Tsuyoshi&quot;,&quot;last_name&quot;:&quot;Adachi&quot;},{&quot;first_name&quot;:&quot;Atsuo&quot;,&quot;last_name&quot;:&quot;Tanimoto&quot;},{&quot;first_name&quot;:&quot;Chika&quot;,&quot;last_name&quot;:&quot;Oki&quot;},{&quot;first_name&quot;:&quot;Yukari&quot;,&quot;last_name&quot;:&quot;Kimoto&quot;},{&quot;first_name&quot;:&quot;Yoshihiro&quot;,&quot;last_name&quot;:&quot;Ogawa&quot;},{&quot;first_name&quot;:&quot;Tamotsu&quot;,&quot;last_name&quot;:&quot;Negoro&quot;},{&quot;first_name&quot;:&quot;Hiromasa&quot;,&quot;last_name&quot;:&quot;Hashimoto&quot;},{&quot;first_name&quot;:&quot;Makoto&quot;,&quot;last_name&quot;:&quot;Shiozaki&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;7163-7185&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00450&quot;},&quot;abstract&quot;:&quot;Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (ent-60), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic derma&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00450&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00450" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00450&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00450" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00450&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00450" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00450&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00450&amp;href=/doi/10.1021/acs.jmedchem.0c00450" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00450" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00450" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00450%26sid%3Dliteratum%253Aachs%26pmid%3D32511913%26genre%3Darticle%26aulast%3DNoji%26date%3D2020%26atitle%3DDiscovery%2Bof%2Ba%2BJanus%2BKinase%2BInhibitor%2BBearing%2Ba%2BHighly%2BThree-Dimensional%2BSpiro%2BScaffold%253A%2BJTE-052%2B%2528Delgocitinib%2529%2Bas%2Ba%2BNew%2BDermatological%2BAgent%2Bto%2BTreat%2BInflammatory%2BSkin%2BDisorders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D13%26spage%3D7163%26epage%3D7185%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292161" title="Modification">Modification</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/jmcmar.2020.63.issue-13/20200709/jmcmar.2020.63.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (<i>ent</i>-<b>60</b>), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic dermatitis as the first drug among Janus kinase inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inflammatory skin disorders are some of the most common forms of dermatological disease. Inflammatory skin disorders are characterized by epidermal hyperplasia along with abnormal keratinocyte differentiation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> These disorders encompass a wide range of pathological conditions such as eczema, rosacea, atopic dermatitis (AD), contact dermatitis, pruritus, psoriasis (PS), which afflict roughly 6.1 million patients and impose medical costs of $3 billion annually in the United States alone.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Many of these inflammatory skin disorders are triggered by aberrant immune responses within cells on the surface of the skin, in which cytokine and lymphokine expression is excessively up-regulated.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Recently, it has become clear that keratinocytes play a critical role in producing those immune mediators, causing them to spread throughout the entire epidermis.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> A primary function of epidermal keratinocytes is providing a first-line defense against microorganisms and/or other environmental threats; keratinocytes are alerted and activated once diverse stimuli such as pathogens, ultraviolet (UV) light, and allergens attack the skin barrier. Despite the diverse and complex etiology of these disorders, topical steroids, which are typically known as immunosuppressive agents, have been used broadly to treat them.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> While the efficacy of topical steroids has been confirmed in the clinic, their side effects, such as skin thinning,<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> suggest a need for alternative effective and well-tolerated therapies.</div><div class="NLM_p">Following the appearance of work by Darnell et al.,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Janus kinase (JAK) inhibition has come to be regarded as a potential pathway for the treatment of certain inflammatory and autoimmune diseases.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> The JAK family of proteins (JAK1, JAK2, JAK3, and Tyk2) possess two kinase domains, a genuine kinase domain and a pseudokinase domain having no catalytic activity; hence these proteins are named after the two-faced Roman god Janus. Among the JAK family, critical mutations in JAK3 have been found to lead to severe combined immune deficiency (SCID).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Several research groups have investigated JAK inhibition, including Pfizer.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20">(17−20)</a> In 2006, Pfizer published the results of a phase II clinical study<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> on the compound CP-690,550, also known as tofacitinib (<b>1</b>) (which was originally reported to be a JAK3 inhibitor, but later was reported to be a pan-JAK inhibitor<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>). In this study, 264 patients with active rheumatoid arthritis (RA) were randomized and subsequently received placebo or three different doses of CP-690,550. CP-690,550 achieved both primary and secondary end points in this study, with minor adverse events such as headache and nausea (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of CP-690,550 (tofacitinib).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Structurally, tofacitinib may be regarded as comprising two motifs: a heteroaromatic ring, which adopts a relatively “flat” conformation, and an azacycloalkane group, which, by comparison, displays a relatively greater degree of “three dimensionality”. Prior to our work, little had been published about the structure–activity relationships of JAK inhibitors such as tofacitinib. Thus, in our efforts to develop a new series JAK3 inhibitor compounds, we investigated numerous modifications to both these motifs in an attempt to elucidate the SAR of JAK inhibitors.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Exploration of the Hinge-Binding Motif</h3><div class="NLM_p">It is currently known that several compounds having ATP-competitive kinase inhibitory activity are typically composed of two units: an adenine mimetic (a so-called “hinge binder”) and an accompanying “scaffold” or “head” region. Tofacitinib falls in this category: its pyrrolopyrimidine ring functions as a hinge binder, affecting hydrogen-bonding with the Glu903 and Leu905 residues of the JAK3 protein.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">As part of our work, we synthesized and tested multiple compounds with alternative hinge-binding motifs. For these efforts, compound <b>2</b> (shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) served as our reference compound, and several analogues thereof were synthesized in an attempt to improve upon compound <b>2</b>’s JAK3 inhibitory properties. Additionally, to assess the tendency of these compounds to bind off-target, we also measured the inhibitory effects of these compounds against another kinase: lymphocyte-specific protein tyrosine kinase (LCK).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Some of these compounds are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> below.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Exploration of the Hinge Binder Starting from Compound <b>2</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0016.gif" alt="" id="gr2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0017.gif" alt="" id="gr3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">See Experimental Section for assay protocols. The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">HCl salt form.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Racemate.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.0024 (±0.00069) μM, <i>n</i> = 48.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.34 (±0.064) μM, <i>n</i> = 36.</p></div></div><div></div></div><div class="NLM_p last">Surprisingly, most of these analogues proved to be largely ineffective against JAK3. From this, we surmise that the binding domain of JAK3 demonstrates a preference for pyrrolopyrimidine. We also note that neither the compounds containing monodentate aromatics (<b>3</b> and <b>4</b>) nor aliphatic heterocycles (<b>11</b>–<b>13</b>) show appreciable JAK3 inhibition in vitro, and that the inclusion of certain steric or electrostatic features is rarely tolerated (Me, <i>c</i>-Pr, and 2-Py for <b>7</b>, <b>8</b>, and <b>9</b>, respectively).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Modification of Substituents on the Hinge Binder of Compound <b>10</b></h3><div class="NLM_p">Upon the basis of our experiments in modifying the hinge binding motif, compound <b>10</b>, bearing a phenylamino-pyrimidine substituent in the hinge binding region, was selected for further investigation and modification due to the fact that its JAK3 inhibitory activity and its selectivity for JAK3 over LCK were comparable to those of compound <b>2</b>. As further modifications, we investigated a series of hydrophilic substitutions at the para position of the aniline ring (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, R<sup>2</sup>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Substitution Effects on the Hinge Binder<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0018.gif" alt="" id="gr4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0019.gif" alt="" id="gr5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">See Experimental Section for assay protocols. The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.0024 (±0.00069) μM, <i>n</i> = 48.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.34 (±0.064) μM, <i>n</i> = 36.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.016 (±0.087) μM, <i>n</i> = 34.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Reference compound <b>1</b> gave IC<sub>50</sub> = > 10 μM, <i>n</i> = 29.</p></div></div><div></div></div><div class="NLM_p">Several of these compounds achieved JAK3 inhibition at submicromolar concentrations and also inhibited T cell proliferation at similar concentrations (<b>14</b>, <b>16</b>, and <b>17</b>). Compound <b>15</b>, however, showed no efficacy against T cell proliferation despite its JAK3 inhibitory activity. We believe that this lack of activity against T cell may be attributable to compound <b>15</b>’s poor physical properties (e.g., its low solubility), a belief that is supported by compound <b>15</b>’s inability to inhibit the growth of normal human lung fibroblasts (NHLF), an assay that we used to measure the off-target toxicity of our compounds against cells other than T cells.</div><div class="NLM_p">Additional modifications were undertaken at the R<sup>1</sup> position of the pyrimidine ring of compound <b>10</b> to explore their potential effects on JAK3 potency and specificity. For these experiments, compound <b>16</b> served as our reference compound. Larger substitutions at R<sup>1</sup>, generally resulted in decreasing JAK3 potency, with the methyl group showing better JAK3 potency than the ethyl or trifluoromethyl group (<b>18</b>–<b>20</b>). However, we found the superior LCK selectivity of the trifluoromethyl-bearing compound <b>20</b> to be noteworthy.</div><div class="NLM_p">In an attempt to improve the properties of compound <b>20</b>, modifications to the “head” region were explored. Specifically, several aliphatic heterocycles were introduced at position R<sup>3</sup>. Some of these are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, there was virtually no difference in JAK3 inhibition between compounds <b>21</b> and <b>22</b>. The effect of substituents on the aliphatic ring were also examined. A 2-methylated analogue (<b>25</b>) showed better JAK3 potency than a 3-methylated isomer (<b>23</b>). Unfortunately, the selectivity of compound <b>25</b> to JAK3 over LCK was significantly reduced. More disappointingly, a strong cytotoxic effect was observed for compound <b>25</b> in NHLF assay, with that compound inhibiting the proliferation of NHLF cells at a concentration of 1 μM. Compound <b>23</b>, as well as compound <b>24</b> (bearing a 3-hydroxyl substituent) likewise inhibited NHLF growth without any improvement in JAK3 inhibitory activity. In view of these results, we decided to discontinue our further exploration of compounds which, like compound <b>10</b>, incorporated a phenylamino-pyrimidine moiety in the hinge binding region.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Head Motif Exploration of <b>20</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0020.gif" alt="" id="gr6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0021.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">See Experimental Section for assay protocols. The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Racemate.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.0024 (±0.00069) μM, <i>n</i> = 48.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.34 (±0.064) μM, <i>n</i> = 36.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.016 (±0.0087) μM, <i>n</i> = 34.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">Reference compound <b>1</b> gave IC<sub>50</sub> = > 10 μM, <i>n</i> = 29.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Exploration of the Head Motif</h3><div class="NLM_p">In parallel with our investigations of the hinge binding region, we also investigated modifications to the head region, using compound <b>2</b> as a reference compound (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Rather than limit our investigation to relatively “flat” aromatic moieties, a decision was made also to investigate moieties having relatively greater degrees of “three dimensionality”. With this consideration in mind, we synthesized and tested numerous compounds, including the three cyclic amines (<b>30</b>–<b>32</b>) and the other “head” motifs (<b>26</b>–<b>29</b>) summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. These compounds showed acceptable levels of JAK3 potency and selectivity over LCK. Additionally, we note that the ligand efficiencies (LEs) of compounds <b>30</b> and <b>31</b> exceed that of compound <b>2</b> (0.64, 0.62 vs 0.57). Ligand efficiency (LE) is a theoretical concept that was introduced by Kuntz in 1999<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and has been characterized as a one potential measure of a compound’s “drug-likeness”.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> The LE values of <b>30</b> and <b>31</b> are superior to those of <b>26</b>–<b>29</b>. In view of the promising JAK3, LCK, and LE values for compounds <b>30</b> and <b>31</b>, we decided to investigate those compounds further.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of the Head Motif Composed of Pyrroropyrimidine<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0022.gif" alt="" id="gr8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0023.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">See Experimental Section for assay protocols. The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Racemate.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">HCl salt form.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.0024 (±0.00069) μM, <i>n</i> = 48.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.34 (±0.064) μM, <i>n</i> = 36.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">LE = −1.37 log IC<sub>50</sub> (JAK3) /number of heavy atoms.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, methyl scanning<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> of compounds <b>30</b> and <b>31</b> was conducted. 2- or 3-methylation of the cyclic amines led to a slight improvement of JAK3 potency (<b>33</b>, <b>34</b>, <b>36</b>, and <b>37</b>), whereas the 4-methylpieridine derivative <b>35</b> showed a significant drop in potency. The inclusion of a cyanoacetamide group at the 2- or the 3-position also was examined, with the nitrogen atom therein masked by an additional methyl group (<b>38</b> and <b>39</b>). Interestingly, compound <b>38</b>, bearing a five-membered ring, boosted T cell inhibitory activity, whereas compound <b>39</b>, bearing a six-membered ring, did not show significant T cell inhibitory activity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR of the Head Motif Focused on Cyclic Amines<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0024.gif" alt="" id="gr10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0025.gif" alt="" id="gr11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0026.gif" alt="" id="GRAPHIC-d7e994-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All compounds are racemates. R′ = cyanoacetyl. See Experimental Section for assay protocols. The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.0024 (±0.00069) μM, <i>n</i> = 48.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.34 (±0.064) μM, <i>n</i> = 36.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.016 (±0.0087) μM, <i>n</i> = 34.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Reference compound <b>1</b> gave IC<sub>50</sub> = > 10 μM, <i>n</i> = 29.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Fsp<sup>3</sup> = number of sp<sup>3</sup> hybridized carbons/total carbon count.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></p></div></div><div></div></div><div class="NLM_p">In view of these unexpected results, we continued our investigations into the effects that structural changes to cyclic amino head groups might have on T cell inhibitory activity. Our research contrasts with the work of Pfizer, who in 2010 reported that their JAK inhibitor compounds bearing cyclic amino head motifs were less potent than compounds having an <i>N</i>-methyl-cycloalkyl head motif.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Compound <b>40</b> is an analogue of <b>38</b>, with an extra carbon present between the ring and the cyanoacetimide substituent. However, compound <b>40</b> exhibited no ability to inhibit T cell proliferation. These differences in T cell inhibitory activity between <b>38</b> and <b>40</b> were surprising in view of the general level of structural similarity among these compounds and their comparable JAK3 inhibitory activity.</div><div class="NLM_p">In an effort to examine the potential effects of conformational freedom vs conformational constraints within the head region, a series of fused bicyclic compounds was synthesized. Of these, only compound <b>42</b> achieved T cell inhibitory activity approaching that of compound <b>38</b> while retaining a comparable degree of JAK3 inhibition (IC<sub>50</sub> = 0.20 μM). The JAK3 potencies of the fused bicyclic compounds <b>41</b> and <b>43</b> were significantly reduced, with a concomitant loss of T cell potency.</div><div class="NLM_p">As part of our exploration of conformationally constrained groups, we also synthesized a series of compounds possessing spiro rings. Some of these compounds are shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. As demonstrated by compounds <b>44</b> and <b>45</b>, JAK3 inhibitory activity improved as the size of the terminal ring became larger, although these improvements did not necessarily translate to improved T cell inhibitory activities. Additionally, reduced in vitro potencies were observed for compound <b>46</b>, in which the cyanoacetyl moiety is located at the gamma position toward the nitrogen atom of the inner pyrrolidine ring; these reduced potencies for compound <b>46</b> suggested that the relative position of the cyanoacetyl moiety within the head region could have important effects on activity. Collectively, these results suggested to us that there might be some appropriate combination of ring sizes within a spiro group that might achieve acceptable levels of JAK3 inhibition. In view of these results, we conducted further experiments on compounds that included a piperidine ring as part of the spiro group while varying the size of the terminal ring. Some of these spiro compounds are shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Among compounds <b>47</b>–<b>49</b>, compound <b>47</b> exhibited the best inhibitory activity against both JAK3 and T cell proliferation.</div><div class="NLM_p">In an attempt to improve upon the activity of compound <b>47</b>, we adopted a two-pronged approach, on the one hand synthesizing compounds incorporating other spiro rings and on the other hand investigating other acyl substituents. Our efforts to synthesize other spiro rings created significant synthetic challenges for our chemists. Specifically, the literature at the time was devoid of reliable methods for making a diazaspirocycle incorporating an azetidine ring. We therefore had to develop a reliable method by ourselves, for which our extensive efforts are described later in this publication. In the meantime, our investigations into other acyl substituents yielded results such as those shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Compounds <b>50</b>–<b>53</b> showed reduced cell potency compared to the cyanoacetyl substituent of compound <b>47</b>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR of the Acyl Group on the Head Group<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0027.gif" alt="" id="gr12" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0028.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">All compounds are racemates. See Experimental Section for assay protocols. The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.0024 (±0.00069) μM, <i>n</i> = 48.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.34 (±0.064) μM, <i>n</i> = 36.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.016 (±0.0087) μM, <i>n</i> = 34. <i><sup>e</sup></i>Reference compound <b>1</b> gave IC<sub>50</sub> = > 10 μM, <i>n</i> = 29.</p></div><div class="footnote" id="t6fn5"><sup><sup>f</sup></sup><p class="last">Not tested.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Investigation of Diazaspiroalkane-Based JAK Inhibitors</h3><div class="NLM_p">Compound <b>54</b> was synthesized according to a newly developed method. This compound, incorporating an azetidine ring as part of its spiro group, demonstrated good T cell inhibitory activity (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Encouraged by this result, we made further modifications to this compound. The results are included in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. Among four methylated analogues (<b>55</b>–<b>58</b>), compound <b>57</b>, bearing a methyl adjacent to the quaternary carbon, displayed improved JAK3 potency. The <i>gem</i>-dimethyl analogue <b>58</b> displayed comparatively less JAK3 potency, although its difluoro analogue <b>59</b> achieved JAK3 and T cell results comparable to those of <b>57</b>. Compound <b>60</b> and <b>61</b> and pyrrolidine analogues of <b>57</b> and <b>59</b>, respectively, displayed activity against T cell proliferation roughly comparable to that of compounds <b>57</b> and <b>59</b>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. SAR of Azetidine-Associated Diazaspirocycle Derivatives<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0029.gif" alt="" id="gr14" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0030.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">All compounds are racemates. R′ = cyanoacetyl. See Experimental Section for assay protocols. The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Single diastereomer (the absolute stereochemistry was not defined.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Both of the diastereomers were obtained. Data for the more potent compound in terms of JAK3 inhibitory activity is shown.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.0024 (±0.00069) μM, <i>n</i> = 48.</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.34 (±0.064) μM, <i>n</i> = 36.</p></div><div class="footnote" id="t7fn6"><sup><sup>f</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.016 (±0.0087) μM, <i>n</i> = 34.</p></div><div class="footnote" id="t7fn7"><sup><sup>g</sup></sup><p class="last">Reference compound <b>1</b> gave IC<sub>50</sub> > 10 μM, <i>n</i> = 29.</p></div><div class="footnote" id="t7fn8"><sup><sup>h</sup></sup><p class="last">Fsp<sup>3</sup> = number of sp<sup>3</sup> hybridized carbons/total carbon count.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></p></div><div class="footnote" id="t7fn9"><sup><sup>i</sup></sup><p class="last">Not tested.</p></div></div><div></div></div><div class="NLM_p">The spiro-based compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a> were isolated in enantiomerically pure form and characterized in pharmacokinetic assays. Although these compounds displayed comparable IC<sub>50</sub> values in in vitro JAK3 inhibitory and T cell proliferation assays, meaningful differences appeared among them in assessing their pharmacokinetic profiles.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Representative JAK Inhibitors Possessing a Spirodiazacycloalkane<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (μM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">MS (%, 60 min)</th><th class="rowsep1 colsep0" align="center">CL monkey<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center" char=".">JAK3<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">T cell (IL-2)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">monkey</th><th class="colsep0 rowsep0" align="center">(L/h/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>ent</i>-<b>47</b></td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.041</td><td class="colsep0 rowsep0" align="char" char=".">75.7</td><td class="colsep0 rowsep0" align="char" char=".">29.4</td><td class="colsep0 rowsep0" align="center">N.T.<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>ent</i>-<b>54</b></td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">0.017</td><td class="colsep0 rowsep0" align="char" char=".">93.4</td><td class="colsep0 rowsep0" align="char" char=".">85.2</td><td class="colsep0 rowsep0" align="center">0.76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>ent</i>-<b>57</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0040</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">73.4</td><td class="colsep0 rowsep0" align="char" char=".">25.1</td><td class="colsep0 rowsep0" align="center">N.T.<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>ent</i>-<b>59</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0060</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">88.4</td><td class="colsep0 rowsep0" align="char" char=".">64.6</td><td class="colsep0 rowsep0" align="center">N.T.<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>ent</i>-<b>60</b> (JTE-052)</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">0.0089</td><td class="colsep0 rowsep0" align="char" char=".">97.4</td><td class="colsep0 rowsep0" align="char" char=".">99.6</td><td class="colsep0 rowsep0" align="center">0.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>ent</i>-<b>61</b></td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.033</td><td class="colsep0 rowsep0" align="char" char=".">99.4</td><td class="colsep0 rowsep0" align="char" char=".">95.4</td><td class="colsep0 rowsep0" align="center">0.35</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">See Experimental Section for assay protocols. The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.0024 (±0.00069) μM, <i>n</i> = 48.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">Reference compound <b>1</b> gave mean (±SD) IC<sub>50</sub> = 0.016 (±0.0087) μM, <i>n</i> = 34.</p></div><div class="footnote" id="t8fn4"><sup><sup>d</sup></sup><p class="last">Administered intravenously at 0.1 mg/kg.</p></div><div class="footnote" id="t8fn5"><sup><sup>e</sup></sup><p class="last">Not tested.</p></div></div></div><div class="NLM_p">Generally, compounds incorporating a piperidine ring (<i>ent</i>-<b>47</b>–<i>ent</i>-<b>59</b>) were discovered to be more readily metabolized, while the pyrrolidine analogues, <i>ent</i>-<b>60</b> and <i>ent</i>-<b>61</b>, were metabolically more stable across the tested species.</div><div class="NLM_p">Among the two pyrrolidine analogues, <i>ent</i>-<b>60</b> exhibited both greater potency against T cells and a lower clearance rate in monkeys than <i>ent</i>-<b>61</b>, thereby suggesting that <i>ent</i>-<b>60</b> might be more potent and display longer-lasting effects in an in vivo setting. Additionally, it was decided that the synthesis of <i>ent</i>-<b>61</b> imposed cost ineffectiveness that could be avoided with <i>ent</i>-<b>60</b>. Accordingly, <i>ent</i>-<b>60</b> was selected as a candidate for clinical development and was renamed JTE-052.</div><div class="NLM_p">To clarify the mechanism of high potency of JTE-052 against JAK3, X-ray cocrystal analysis was performed with compound <b>60</b>. Only one of the enantiomers gave a good crystal with a high resolution of 1.98 Å, suggesting that this enantiomer (<i>ent</i>-<b>60</b>) was an active isomer (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> According to the structure, the cyanoacetyl group made orthogonal dipolar interactions with main chain atoms (Gly829–Lys830 and Gly834–Ser835), while the azetidine motif occupied the lipophilic pocket neighborhood the JAK3 hinge region with the 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine ring, making hydrogen bond interactions with JAK3 hinge region of Glu903 (2.6 Å) and Leu905 (2.9 Å). It was thus presumed that the potent JAK3 activity of JTE-052 was attributed to those interactions.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0002.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystallographic structure of JAK3 (human) in complex with JTE-052 focusing on binding site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C3N">7C3N</a>). Hydrogen bonds are depicted as dashed lines (yellow). Surfaces are shown around JTE-052 as meshed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As a part of our further characterizations, the selectivity of JTE-052 for JAK3 was investigated in comparison with the other members of the JAK family and a panel of 50 other human kinases. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, JTE-052 was found to exhibit inhibitory activity across all JAK family members (JAK3, JAK1, JAK2, and Tyk2) and inhibited JAK1 and JAK2 at nanomolar concentrations. As can be seen from the data in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, the inhibitory activity of JTE-052 across the JAK family differs from that of tofacitinib; interestingly, JTE-052 exhibits relatively greater inhibitory activity against JAK1 and JAK2 than JAK3 compared to tofacitinib, and its selectivity for the JAK family over LCK is improved in comparison with tofacitinib. JTE-052 also proved to be highly selective for the JAK family members, with no significant inhibition of non-JAK kinases under 1 μM except over ROCK-II.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Surprisingly, the potency of JTE-052 in whole-cell assays is not linearly correlated with its potency against JAK kinases, as was sometimes observed in other kinase inhibitor programs.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> For example, we expected that the IC<sub>50</sub> values of JTE-052 against IL-6/GM-CSF signaling would be correlated with JTE-052’s activity against each JAK isozyme. However, the results in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a> below show that JTE-052 suppressed JAK1-dependent signaling at an IC<sub>50</sub> value 10-fold below the IC<sub>50</sub> value required to suppress JAK2-dependent signaling (IL-31/GM-CSF). The exact mechanism of such discrepancy between the enzymatic inhibition and the cell potency is not fully understood; it seemed that potency against JAK1 enzyme predominantly accounted for the results of cytokine signaling inhibitions. This suggestion is supported, for example, by the reported <i>K</i><sub>m</sub> value for JAK1, which is about 10 times that of JAK3, making JAK1 easier to inhibit than JAK3 at the same ATP concentration.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Consequently, it is likely that much of the efficacy observed in the in vivo models is driven by JAK1. Regardless, JTE-052’s effective suppression of IL-2 and IL-31 signaling pathways further bolstered its potential as a clinical candidate.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. In Vitro Profiles of JTE-052.<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">enzymes IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">JAK3</th><th class="colsep0 rowsep0" align="center" char=".">JAK1</th><th class="colsep0 rowsep0" align="center" char=".">JAK2</th><th class="colsep0 rowsep0" align="center" char=".">TyK2</th><th class="colsep0 rowsep0" align="center" char=".">LCK</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JTE-052</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="char" char=".">0.0028</td><td class="colsep0 rowsep0" align="char" char=".">0.0026</td><td class="colsep0 rowsep0" align="char" char=".">0.058</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tofacitinib</td><td class="colsep0 rowsep0" align="char" char=".">0.0011</td><td class="colsep0 rowsep0" align="char" char=".">0.0029</td><td class="colsep0 rowsep0" align="char" char=".">0.0012</td><td class="colsep0 rowsep0" align="char" char=".">0.042</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">cytokine signaling IC<sub>50</sub> (μM) in human PBMCs</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">IL-2<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a> JAK1/JAK3</th><th class="colsep0 rowsep0" align="center" char=".">IL-6<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a> JAK1/JAK2</th><th class="colsep0 rowsep0" align="center" char=".">IL-31<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a> JAK1/JAK2</th><th class="colsep0 rowsep0" align="center" char=".">IL-23<a class="ref internalNav" href="#t9fn5" aria-label="e">e</a> JAK2/Tyk2</th><th class="colsep0 rowsep0" align="center" char=".">GM-CSF<a class="ref internalNav" href="#t9fn6" aria-label="f">f</a> JAK2/JAK2</th><th class="colsep0 rowsep0" align="center" char=".">INF-α<a class="ref internalNav" href="#t9fn7" aria-label="g">g</a> JAK1/Tyk2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JTE-052</td><td class="colsep0 rowsep0" align="char" char=".">0.040</td><td class="colsep0 rowsep0" align="char" char=".">0.033</td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.084</td><td class="colsep0 rowsep0" align="char" char=".">0.30</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> values are the average of at least two determinations.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">The phosphorylation levels of Stat5 in CD3<sup>+</sup>CD4<sup>+</sup> cells stimulated with IL-2 were measured.</p></div><div class="footnote" id="t9fn3"><sup><sup>c</sup></sup><p class="last">The phosphorylation levels of Stat3 in CD3<sup>–</sup>CD4<sup>+</sup> cells stimulated with IL-6 were measured.</p></div><div class="footnote" id="t9fn4"><sup><sup>d</sup></sup><p class="last">The phosphorylation levels of Stat3 in A549 cells stimulated with IL31 were measured.</p></div><div class="footnote" id="t9fn5"><sup><sup>e</sup></sup><p class="last">The phosphorylation levels of Stat3 in CD3<sup>+</sup>CD4<sup>+</sup>cells stimulated with IL-23 were measured.</p></div><div class="footnote" id="t9fn6"><sup><sup>f</sup></sup><p class="last">The phosphorylation levels of Stat5 in CD3<sup>–</sup>CD4<sup>+</sup> cells stimulated with GM-CSF were measured.</p></div><div class="footnote" id="t9fn7"><sup><sup>g</sup></sup><p class="last">The phosphorylation levels of Stat1 in CD3<sup>+</sup>CD4<sup>+</sup> cells stimulated with INF-α were measured.</p></div></div></div><div class="NLM_p">Pharmacokinetic properties of JTE-052 were characterized (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). In these tests, the solubility of JTE-052 proved acceptable in several media, and protein binding was low in the tested species.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Physicochemical Properties and PK Profiles of JTE-052</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">Caco2</th><th class="rowsep1 colsep0" colspan="3" align="center">solubility (μM)</th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">protein binding (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i> (pH 7)</th><th class="colsep0 rowsep0" align="center" char="."><i>P</i><sub>app</sub> 10 cm<sup>–8</sup></th><th class="colsep0 rowsep0" align="center" char=".">sol (μM)</th><th class="colsep0 rowsep0" align="center">PBS</th><th class="colsep0 rowsep0" align="center">Fassif</th><th class="colsep0 rowsep0" align="center">Fessif</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">dog</th><th class="colsep0 rowsep0" align="center" char=".">monkey</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="center">>95</td><td class="colsep0 rowsep0" align="center">>475</td><td class="colsep0 rowsep0" align="center">>475</td><td class="colsep0 rowsep0" align="char" char=".">40.7</td><td class="colsep0 rowsep0" align="char" char=".">37.2</td><td class="colsep0 rowsep0" align="char" char=".">27.1</td><td class="colsep0 rowsep0" align="char" char=".">26.6</td></tr></tbody></table></div></div><div class="NLM_p">JTE-052 was also metabolically stable in both liver microsomes and hepatocytes, with stability values in human cells greater than those in rat and monkey cells (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>). The in vivo PK profiles of JTE-052 were also satisfactory showing over 50% of bioavailability across the species (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>).</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Metabolic Stability of JTE-052</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">metabolic stability (60 min, %)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center" char=".">monkey</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">microsome</td><td class="colsep0 rowsep0" align="char" char=".">97.4</td><td class="colsep0 rowsep0" align="char" char=".">90.2</td><td class="colsep0 rowsep0" align="center">97.2</td><td class="colsep0 rowsep0" align="char" char=".">99.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte</td><td class="colsep0 rowsep0" align="char" char=".">99.3</td><td class="colsep0 rowsep0" align="char" char=".">94.7</td><td class="colsep0 rowsep0" align="center">N.T.<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">84.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">Not tested.</p></div></div></div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. In Vivo PK Profiles of JTE-052</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">iv PK parameters<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">po PK parameters<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub>β (h)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>tot</sub> (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vd<sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">MRT (h)</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">124</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">iv administration at corresponding dose in 10% DMSO.</p></div><div class="footnote" id="t12fn2"><sup><sup>b</sup></sup><p class="last">po administraion at corresponding dose in 0.5% MC.</p></div></div></div><div class="NLM_p">To explore the in vivo pharmacological effects of JTE-052, a rat adjuvant-induced arthritis (AIA) model was chosen based on the robustness and the reproducibility of this animal model.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a, dose-dependent suppression of paw swelling was observed; complete suppression of paw swelling was observed at a dose of 30 mg/kg of JTE-052 upon oral administration. The antidermatitis effects of JTE-052 were confirmed in a rat 2,4-dinitrochlorobenzene (DNCB)-induced dermatitis model;<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> in this model, complete suppression of ear swelling was achieved at an oral dose of 10 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). Additionally, topical formulations of JTE-052 for AD treatment were examined in the rat DNCB model (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c). Treatment using 1% JTE-052 in a petroleum-based ointment produced significant suppression of ear swelling; three-times-a-day administration of the JTE-052 ointment almost completely suppressed ear swelling in this model.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0003.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vivo potency of JTE-052. (a) Effect of JTE-052 at 30, 3, and 0.3 mg/kg by po administration on the hind paw volume in a rat adjuvant-induced arthritis (AIA) model. The results are expressed as mean ± SD (<i>n</i> = 4). †, ‡: <i>p</i> < 0.05, <i>p</i> < 0.01 vs vehicle group by Dunnett’s test. (b) Effect of JTE-052 at 10 and 1 mg/kg by po administration on the ear thickness in a rat DNCB-induced chronic dermatitis model. The results are expressed as mean ± SD (<i>n</i> = 3–4). †, ‡: <i>p</i> < 0.05, <i>p</i> < 0.01 vs vehicle group by Dunnett’s test. §: <i>p</i> < 0.05 vs vehicle group by Steel test. (c) Effect of JTE-052 ointment at once a daily and three times a day on the ear thickness in a rat DNCB-induced chronic dermatitis model. The results are expressed as mean ± SD (<i>n</i> = 3–4). ‡: <i>p</i> < 0.01 vs vehicle group by Dunnett’s test. §, §§: <i>p</i> < 0.05, <i>p</i> < 0.01 vs vehicle group by Steel test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Chemistry</h3><div id="sec2_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Synthesis of JAK Inhibitors Listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a></h4><div class="NLM_p">Synthetic pathways of JAK inhibitors listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> are categorized into two groups depending on the key reactions, <i>N</i>-arylation and reductive amination, respectively (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Regarding the <i>N</i>-arylation-centered pathway, an aryl chloride was first coupled with <i>N</i>-methylcyclohexylamine at elevated temperature with or without a metal catalysis, followed by simple transformations to give <b>3</b>–<b>10</b>. Meanwhile, <b>11</b>–<b>13</b> were synthesized via reductive amination, in which cyclohexylmethyl amine or an aminolactam was treated with an appropriate ketone in the presence of NaBH(OAc)<sub>3</sub>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0005.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of JAK Inhibitors Composed of Various Hinge Binders (<b>3</b>–<b>13</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) for <b>3</b>, 4-chloroquinazoline, <i>i</i>-Pr<sub>2</sub>NEt, THF, microwave, 80 °C; for <b>4</b>, (i) 4-chloroquinoline, Pd<sub>2</sub>(dba)<sub>3</sub>, DAVEPHOS, NaO<i>t</i>-Bu, 1,4-dioxane, 80 °C, (ii) 4 N HCl in EtOAc; for <b>7</b> and <b>8</b>, corresponding heteroaryl chloride, <i>n</i>-BuOH, 145 °C; (b) <i>N</i>-methylcyclohexylamine, EtOH, 80 °C; (c) (i)TFA, anisole, 70 °C, (ii) 4 N NaOH, EtOH, 120 °C, (iii) SOCl<sub>2</sub>, toluene, 60 °C, (iv) 28% NH<sub>3</sub> aq, THF, rt; (d) (i) AcCl, Et<sub>3</sub>N, DMAP, CHCl<sub>3</sub>, 0 °C, (ii) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O; (e) for <b>9</b>, 2-aminopyridine, Pd(OAc)<sub>2</sub>, DPEphos, K<sub>2</sub>CO<sub>3</sub>, THF, 80 °C; for <b>10</b>, ethyl 4-aminobenzoate, Pd(OAc)<sub>2</sub>, DPEphos, K<sub>2</sub>CO<sub>3</sub>, THF, 80 °C; (f) (i) for <b>11</b> and <b>12</b>, corresponding amino lactam, NaBH(OAc)<sub>3</sub>, AcOH, CHCl<sub>3</sub>, rt, (ii) HCHO, NaBH(OAc)<sub>3</sub>, AcOH, CHCl<sub>3</sub>, rt; for <b>13</b>, (i) <i>N</i>-methylcyclohexylamine, TsOH, toluene, 90 °C then NaBH<sub>4</sub>, EtOH, rt, (ii) 4 N HCl in EtOAc, rt.</p></p></figure></div><div id="sec2_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Synthesis of JAK Inhibitors Listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></h4><div class="NLM_p">Compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> were synthesized through the <i>N</i>-arylation-centered protocol as well (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Starting from compound <b>68</b>, 4-aminobenzoate was coupled in the presence of Pd catalyst, and the ester substituent on the benzene ring was further derivatized to the corresponding alcohol (<b>14</b>), carboxylic acid (<b>15</b>), and amide functionalities (<b>16</b>–<b>20</b>). Compound <b>21</b>–<b>25</b> were synthesized similarly, although compound <b>72</b> was chosen as the common intermediate to be coupled with cyclic amino motifs in the final step (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0006.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of JAK Inhibitors Listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> (<b>14</b>–<b>20</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl 4-aminobenzoate, Pd(OAc)<sub>2</sub>, DPEphos, K<sub>2</sub>CO<sub>3</sub>, THF, 80 °C; (b) LiAlH<sub>4</sub>, THF, rt; (c) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O, 50 °C; (d) NH<sub>4</sub>Cl or NHMe<sub>2</sub>, <i>i</i>-Pr<sub>2</sub>NEt, WSC·HCl, HOBt·H<sub>2</sub>O, DMF, rt.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0007.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Biaryl Amine-Based JAK Inhibitors Listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> (<b>21</b>–<b>25</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-aminobenzamide, <i>i</i>-Pr<sub>2</sub>NEt, THF, rt; (b) corresponding amine, <i>i</i>-Pr<sub>2</sub>NEt, DMA, 80 °C.</p></p></figure></div><div id="sec2_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Synthesis of Analogues of Compound <b>2</b></h4><div class="NLM_p">Synthesis of compound <b>26</b>–<b>29</b>, analogues of compound <b>2</b> are illustrated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Suzuki-type cross-coupling of <b>73</b> with vinyl borane afforded <b>26</b>, which was successively derivatized to <b>27</b> via hydrogenation reaction. Coupling of <b>73</b> with cyclohexanol also proceeded smoothly, and <i>O</i>-arylated product <b>29</b> was obtained under the mild condition. Halogen–metal exchange was carried out by treatment of <b>74</b> with <i>i</i>-PrMgCl, and the resultant aryl Grignard reagent was coupled with cyclohexyl chloride, leading to compound <b>28</b> after deprotection of the tosyl group</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0008.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of JAK Inhibitors Bearing a Pyrrolopyrimidine (<b>26</b>–<b>29</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-(1-cyclohexylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 N Na<sub>2</sub>CO<sub>3</sub>, DME, microwave, 150 °C; (b) (i) cyclohexanol, NaH, THF, 80 °C, (ii) 4 N HCl in EtOAc, rt; (c) (i) H<sub>2</sub> (1 atm), Pd/C, EtOAc, rt, (ii) 4 N HCl in EtOAc, rt; (d) (i) cyclohexanecarbonyl chloride, <i>i</i>-PrMgCl, bis[2-<i>N</i>,<i>N</i>-dimethylaminoethyl]ether, THF, 0 °C, (ii) 2 N NaOH, THF, MeOH, rt.</p></p></figure></div><div id="sec2_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Synthesis of JAK Inhibitors Possessing an Azacycloalkane Head Motif</h4><div class="NLM_p">Generally, JAK inhibitors bearing an azacycloalkane headgroup were synthesized by <i>N</i>-arylation of <b>73</b> with the assistance of microwave heating, which was followed by deprotection and successive cyanoacetylation when needed (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0009.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of JAK Inhibitors Bearing a Pyrrolopyrimidine (<b>30</b>–<b>53</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) corresponding cyclic amine, <i>t</i>-BuOH, microwave, 100 °C; (b) correponding cyclic amime, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 100 °C; (c) 4 N HCl in EtOAc rt; (d) for <b>38</b>–<b>49</b>, 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile, <i>i</i>-Pr<sub>2</sub>NEt, 1,4-dioxane, 80 °C; for <b>50</b>, AcCl, Et<sub>3</sub>N, CHCl<sub>3</sub>, 0 °C; for <b>51</b>, (i) acetoxyacetyl chloride, Et<sub>3</sub>N, CHCl<sub>3</sub>, 0 °C, (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; for <b>52</b>, 2-methoxyacetyl chloride, Et<sub>3</sub>N, CHCl<sub>3</sub>, 0 °C; for <b>53</b>, 4-nitrophenyl (cyanomethyl)carbamate, <i>i</i>-Pr<sub>2</sub>NEt, DMA, rt.</p></p></figure></div><div id="sec2_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Synthetic Exploration for an Azetidine-Associated Diazaspiroalkane</h4><div class="NLM_p">Synthetic strategies to obtain novel diazaspirocycle motifs are depicted in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Path A was first investigated starting from an azetidine carboxylate.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0004.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Synthetic strategy for a diazaspiroalkane containing an azetidine ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After Boc protection of commercially available compound <b>77</b>, the carboxylic acid was converted to the cyano group (<b>80</b>), followed by its α-alkylation to give <b>81</b>. Subsequent Raney Nickel reduction was hoped to afford the desired product via self-cyclization; however, the reaction did not work, and only a complex mixture was obtained (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0010.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Route Scouting Based on Path A from Compound <b>77</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, 0.5 N NaOH, 1,4-dioxane, 0 °C to rt (62%); (b) CDI, NH<sub>4</sub>Cl, Et<sub>3</sub>N, THF, 0 °C to rt (quant); (c) TFAA, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt (45%); (d) KHMDS, 1-bromo-3-chloropropane, THF, −78 °C to rt (17%); (e) H<sub>2</sub> (4 atm), Raney Ni, 28% NH<sub>3</sub> aq MeOH, rt.</p></p></figure><div class="NLM_p">Because the chloroalkyl moiety seemed to be labile and may have been the possible cause for complications, a more conservative approach was next examined (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Cbz-protected azetidine carboxylate <b>83</b> was treated with allyl bromide in the presence of K<sub>2</sub>CO<sub>3</sub>, and the resultant ester was subjected to Claisen rearrangement to translocate the allyl substituent on the azetidine ring. Although optimal conditions were not fully explored, pathways involving hydroboration of compound <b>84</b> were explored. Unfortunately, several trials attempting to produce the targeted dialkylamine (<b>88</b>) either by way of <i>N</i>-alkylation or reductive amination was not successful, which brought us to path B, using a piperidine-based compound as a starter.</div><figure id="sch7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0011.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Route Scouting Based on Path A from Compound <b>83</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, EtI, DMF, rt, (97%); (b) LiHMDS, allyl bromide, THF, −78 °C (88%); (c) BH<sub>3</sub>, THF, rt then 4 N NaOH, H<sub>2</sub>O<sub>2</sub>, 0 °C, (29%); (d) CBr<sub>4</sub>, PPh<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt (62%); (e) BnNH<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C (trace); (f) DMP CH<sub>2</sub>Cl<sub>2</sub>, rt (75%).</p></p></figure><div class="NLM_p">Initially, [2 + 2]-cyclization was attempted with compound <b>91</b>, which was easily obtained from commercially available <b>90</b>. The result was also disappointing, and no sign of spiro ring formation was observed (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).</div><figure id="sch8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0012.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Route Scouting Based on Path B from Compound <b>90</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ph<sub>3</sub>P<sup>+</sup>MeBr<sup>–</sup>, KO<i>t</i>-Bu, THF, rt, (85%); (b) ClSO<sub>2</sub>NCO, Et<sub>2</sub>O, rt.</p></p></figure><div class="NLM_p">A Horner–Wadsworth–Emmons reaction with <b>90</b> followed by 1,4-addition of methanolic ammonia successfully provided every necessary unit for constructing the desired spirocycle (<b>99</b>). After ester hydrolysis, the resultant amino acid <b>95</b> was treated with tris(2-oxo-3-benzoxazolinnyl phosphine oxide<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and Et<sub>3</sub>N to form the targeted spirocyclic skeleton (<b>96</b>). After protecting the amide NH with benzyl group (<b>97</b>), Boc deprotection and subsequent LAH reduction finally achieved to affording compound <b>99</b>. Followed by coupling with pyrrolopyrimidine, deprotection, and cyanoacetylation, our targeted compound <b>54</b> was successfully obtained (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>).</div><figure id="sch9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0013.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of JAK Inhibitor Bearing a Spirocycle (<b>54</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (EtO)<sub>2</sub>POCH<sub>2</sub>CO<sub>2</sub>Et, NaH, THF, 0 °C to rt; (b) NH<sub>3</sub> in MeOH, 80 °C; (c) 2 N NaOH, MeOH, rt; (d) tris(2-oxo-3-benzoxazolinnyl phosphine oxide, Et<sub>3</sub>N, CH<sub>3</sub>CN, 100 °C; (e) BnBr, NaH, DMF, rt; (f) 4 N HCl in EtOAc, rt then satd NaHCO<sub>3</sub>; (g) LiAlH<sub>4</sub>, H<sub>2</sub>SO<sub>4</sub>, THF, 0 °C; (h) (i) <b>73</b>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 100 °C, (ii) Pd/C, H<sub>2</sub> (4 atm), MeOH, rt, (iii) 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile, <i>i</i>-Pr<sub>2</sub>NEt, 1,4-dioxane, 100 °C.</p></p></figure><div class="NLM_p">Additionally, an alternative synthetic approach to cover broader range of diazaspiroalkanes was explored (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>). Starting from the 3-pyrrolidine or 3-piperidine carboxylic acid <b>100</b>, allyl ester formation (<b>101</b>) followed by Claisen rearrangement gave the α-allylated carboxylate <b>102</b>, which was subjected to a Curtius rearrangement reaction. The reaction proceeded smoothly, and <b>103</b> was converted to <b>104</b> by way of ozonolysis and subsequent reduction. Cbz group of <b>104</b> was thus removed by hydrogenolysis, and the resultant β-amino alcohol was derivatized to the aminoethyl bromide, which automatically formed the azetidine ring. After reprotecting the nitrogen atom with Cbz group (<b>105</b>), Boc protetion was removed to give <b>106</b>, which was advanced to <b>55</b>–<b>61</b> according to the general synthetic method described before in this report (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><figure id="sch10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0014.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of JAK Inhibitors Bearing Various Spirocycles (<b>55</b>–<b>61</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BrCH<sub>2</sub>CH═CR<sup>2</sup>R<sup>3</sup>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) LiHMDS, THF, −78 °C to rt then TMSCl, −78 °C to rt; (c) (i) DPPA, Et<sub>3</sub>N, toluene, 100 °C, then BnOH, DMAP, 100 °C; (d) O<sub>3</sub>, CHCl<sub>3</sub>, MeOH, −78 °C then NaBH<sub>4</sub>, −78 °C to rt; (e) (i) H<sub>2</sub> (1 atm), Pd/C, THF, rt, (ii) Et<sub>3</sub>N, Ph<sub>3</sub>P, CBr<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, (iii) <i>i</i>-Pr<sub>2</sub>NEt, CbzCl, 0 °C; (f) 4 N HCl in 1,4-dioxane, CHCl<sub>3</sub>, rt; (g) (i) <b>73</b>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 100 °C, (ii) Pd/C, H<sub>2</sub> (4 atm), THF, MeOH, rt; (h) 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile, <i>i</i>-Pr<sub>2</sub>NEt, 1,4-dioxane, 80 °C.</p></p></figure></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Stereoselective Synthesis of JTE-052</h3><div class="NLM_p">To develop a stereoselective synthetic route for JTE-052, (<i>S</i>)-benzylalaninol was selected as a starting material whose inherent chirality dictated the stereochemistry of the final product. First, <i>N</i>-alkylation of this starting material with <i>t</i>-butyl bromoacetate was carried out, and the concomitant alcohol (<b>109</b>) was successively chlorinated, resulting in intramolecular <i>N</i>-alkylation to form a highly reactive aziridinium ring (<b>111</b>). Upon heating, an accompanying chloride anion attached to the constrained ring and compound <b>112</b> was eventually obtained due to its thermodynamic stability over the corresponding regioisomer. This compound was then treated with LHMDS at −78 °C and intramolecular cyclization proceeded in a S<sub>N</sub>2 fashion to give <b>113</b> as a single enantiomer.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> After modifying protecting groups, α-alkylation of the carboxylate (<b>114</b>) with sterically demanding prenyl bromide was carried out and the reaction underwent anti to the methyl substituent, so that the carbon skeleton of the spirocycle motif was obtained with high enantiomeric selectivity. To introduce a nitrogen atom for the pyrroridine motif, <b>115</b> was subjected to ozonolysis and reductive amination with benzylamine followed (<b>116</b>). The Boc on the azetidine was transiently removed to relieve steric constraints so that pyrrolidinone ring was formed by the intramolecular amidation (<b>117</b>). After LAH reduction, the nitrogen of the azetidine was reprotected with Boc group and the fully protected head motif of JTE-052 was obtained in an enantiomerically pure form (<b>118</b>). The headgroup was coupled with the hinge binder after <i>N</i>-benzyl deprotection, and the resultant <b>119</b> led to JTE-052 by Boc deprotection and subsequent cyanoacetylation (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>).</div><figure id="sch11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0015.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Stereoselective Synthesis of JTE-052<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BrCH<sub>2</sub>CO<sub>2</sub><i>t</i>-Bu, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C; (b) SOCl<sub>2</sub>, DMF, 60 °C; (c) LiHMDS, HMPA, THF, −78 to 0 °C; (d) H<sub>2</sub> (4 atm) Pd(OH)<sub>2</sub>/C, (BOC)<sub>2</sub>O, THF, MeOH, rt; (e) BrCH<sub>2</sub>CH═CMe<sub>2</sub>, LiHMDS, THF, −78 °C to −20 °C; (f) O<sub>3</sub>, PPh<sub>3</sub>, CHCl<sub>3</sub>, MeOH, −78 °C; (g) BnNH<sub>2</sub>, NaBH(OAc)<sub>3</sub>, THF, rt; (h) 4 N HCl in 1,4-dioxane, H<sub>2</sub>O; (i) HATU, <i>I</i>-Pr<sub>2</sub>NEt, DMF, rt; (j) LiAlH<sub>4</sub>, H<sub>2</sub>SO<sub>4</sub>, THF, 0 °C then (BOC)<sub>2</sub>O, rt; (k) H<sub>2</sub> (4 atm) Pd(OH)<sub>2</sub>/C, MeOH, rt; (l)<b>73</b>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 100 °C; (m) 4 N HCl in 1,4-dioxane, CHCl<sub>3</sub>, MeOH, 60 °C; (n) 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile, <i>i</i>-Pr<sub>2</sub>NEt, 1,4-dioxane, 100 °C.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While smaller molecules generally may exhibit better physicochemical properties such as solubility and cell membrane permeability, they may also potentially bind more targets, which may lead to loss of target specificity. To overcome this potential loss of target specificity, one may wish to consider increasing molecular complexity. Three-dimensionality, which can be characterized by an Fsp<sup>3</sup> value, is one aspect of molecular complexity.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> Upon further review, it is noteworthy that the Fsp<sup>3</sup> values for several JAK inhibitors we synthesized, including compound <b>47</b> (0.53) and JTE-052 (0.50), exceed the benchmark value (0.47)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> of many marketed drugs.</div><div class="NLM_p">Among several cytokine signaling pathways in which JAK enzymes are involved, the IL-31 pathway is of particular interest, as transgenic mice in which that pathway is perturbed were previously reported to develop both skin lesions and serological abnormalities,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> mirroring diagnostic criteria for human AD.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Additionally, barrier defects in the skin surface are commonly observed in AD patients, which stimulate IL-4 secretion from Th2 cells. Elevated IL-4 production in turn suppresses lipid production and exacerbates barrier disruption.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The inhibition of JAK signaling pathways thus may be an effective strategy to treat AD patients and restore barrier function.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> As a matter of fact, topical tofacitinib in 2016 was reported to be effective for the treatment of AD patients,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and the development of JAK inhibitors as anti-AD drugs is currently an active field.<a onclick="showRef(event, 'ref55 ref50'); return false;" href="javascript:void(0);" class="ref ref55 ref50">(50,51)</a></div><div class="NLM_p last">Clinical trials on JTE-052, known as “delgocitinib”, for a treatment of atopic dermatitis (AD) have been completed.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(52,53)</a> In view of delgocitinib ointment’s results in clinical trials, we submitted an New Drug Application (NDA),<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(54)</a> and have recently received marketing approval for the treatment of atopic dermatitis in Japan.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(55)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86387" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86387" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Chemistry</h3><div class="NLM_p">Unless otherwise specified, materials were obtained from commercial suppliers and used without further purification. <sup>1</sup>H NMR spectra and <sup>13</sup>C NMR spectra were recorded on a JEOL JNM-AL400, Bruker AVANCEIII 400, or Varian MERCURY plus 400 spectrometer in a solution of CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> using tetramethylsilane as the internal standard. Chemical shifts are expressed as δ (ppm) values for protons relative to the internal standard. Standard abbreviations indicating multiplicity were used as follows: s = singlet, br s = broad singlet, d = doublet, dd = double doublet, dt = double triplet, t = triplet, q = quartet, and m = multiplet. All compounds gave spectra consistent with their assigned structures. HRMS spectra were recorded on an LC-MS system composed of Agilent 1290 Infinity LC and Thermo Fisher LTQ-Orbitrap Velos. Optical rotation was measured at 20 °C with a Rudolph Research Analytical AUTOPOL V spectrometer. Combustion analyses were performed with a Perkin–Elmer 2400 series II CHNS/O analyzer, and all values were within ±0.4% of the calculated values. Preparative HPLC was performed on a Japan Analytical Industry Co., Ltd. LC-908 instrument. Analytical HPLC was performed on a SHIMADZU Prominence instrument. Single-crystal X-ray analysis was performed with Rigaku R-AXIS RAPID analysis system. Microwave reactions were performed using a Biotage Initiatior eight instrument. The purities of the assayed compounds were determined by analytical HPLC under following conditions [Column: Shimadzu Shim-pack XR-ODS (3 mm × 50 mm, 2.2 μm); mobile phase A, 0.1% TFA in water; mobile phase B, 0.1% TFA in CH<sub>3</sub>CN; gradient, 10% B to 90% B from 0 to 5 min, 90% B from 5 to 7 min, 90% B to 10% B from 7 to 7.5 min, 10% B from 7.5 to 10 min; flow rate, 1.0 mL/min; detection wavelength, 254 nm] and was ≥95%. The detailed synthesis of compounds <b>3</b>–<b>43</b> are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 3-(7-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decan-1-yl)-3-oxopropanenitrile (<b>47</b>)</h4><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Step 1</h5><div class="NLM_p last">A mixture of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (94 mg, 0.611 mmol), <i>t</i>-butyl 1,7-diazaspiro[4.5]decane-1-carboxylate (176 mg, 0.733 mmol), and K<sub>2</sub>CO<sub>3</sub> (253 mg, 1.83 mmol) in H<sub>2</sub>O (1 mL) was stirred at 100 °C overnight. After cooling to room temperature, the mixture was diluted with EtOAc and H<sub>2</sub>O. The resulting mixture was extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (EtOAc:CHCl<sub>3</sub> = 1:2 to 2:1 (v/v)) to afford <i>t</i>-butyl 7-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decane-1-carboxylate (189 mg, 86% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 10.90–10.58 (m, 1H), 8.30 (br s, 1H), 7.07 (br s, 1H), 6.48–5.65 (m, 1H), 4.87–4.66 (m, 1H), 4.62–4.52 (m, 1H), 3.95–3.82 (m, 0.6H), 3.75–3.50 (m, 1.4H), 3.50–3.31 (m, 1H), 3.20–3.04 (m, 0.6H), 3.04–2.85 (m, 1H), 2.74–2.58 (m, 0.4H), 2.14–1.98 (m, 1H), 1.90–1.40 (m, 6H), 1.54 (s, 3.6H), 1.48 (s, 5.4H).</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Step 2</h5><div class="NLM_p last">To a solution of this compound obtained in the previous step (189 mg, 0.528 mmol) in EtOAc (1.0 mL) was added 2 N HCl in MeOH (1.5 mL) and 4 N HCl in EtOAc (3.0 mL) at room temperature. After being stirred at room temperature for 3 h, the mixture was concentrated. The residue was neutralized with 4 N NaOH (0.29 mL) and extracted with CHCl<sub>3</sub>. The organic layer was washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the resultant solids were purified by trituration with Et<sub>2</sub>O to give 7-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decane (108 mg, 80% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 9.26 (br s, 1H), 8.28 (s, 1H), 7.04 (d, <i>J</i> = 3.7 Hz, 1H), 6.52 (d, <i>J</i> = 3.7 Hz, 1H), 3.92–3.86 (m, 2H), 3.81 (d, <i>J</i> = 13.0 Hz, 1H), 3.72 (d, <i>J</i> = 13.0 Hz, 1H), 3.10–3.00 (m, 2H), 1.94–1.80 (m, 3H), 1.78–1.70 (m, 5H), 1.55–1.47 (m, 1H).</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Step 3</h5><div class="NLM_p">A mixture of this compound obtained in the previous step (70 mg, 0.272 mmol) and 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile (67 mg, 0.410 mmol) in 1,4-dioxane (1.4 mL) was stirred at 80 °C overnight. After cooling to room temperature and evaporation, the residue was purified by preparative TLC (CHCl<sub>3</sub>:MeOH = 10:1 (v/v)) to give the title compound <b>47</b> (104 mg, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.64 (br s, 1H), 8.10 (s, 1H), 7.16 (dd, <i>J</i> = 3.4, 2.6 Hz, 1H), 6.57 (dd, <i>J</i> = 3.6, 1.6 Hz, 1H), 4.73–4.66 (m, 1H), 4.52 (d, <i>J</i> = 12.5 Hz, 1H), 3.93 (s, 2H), 3.83 (d, <i>J</i> = 12.9 Hz, 1H), 3.58–3.51 (m, 1H), 3.46–3.39 (m, 1H), 2.99–2.84 (m, 2H), 1.90–1.70 (m, 4H), 1.67–1.57 (m, 2H), 1.56–1.49 (m, 1H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>O 325.1771, found 325.1700. Purity: 100%. Chiral resolution of compound <b>47</b> to obtained <i>ent</i>-<b>47</b> as follows. Compound <b>47</b> (50 mg) was subjected to nomal phase preparative HPLC under following condition [column: Daicel Chiralcel AD (20 mm × 250 mm); mobile phase, MeOH] to afford second eluting isomer (<i>ent</i>-<b>47</b>) (16 mg). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.69 (br s, 1H), 8.09 (s, 1H), 7.19–7.15 (m, 1H), 6.59–6.55 (m, 1H), 4.74–4.66 (m, 1H), 4.55–4.47 (m, 1H), 3.95 (s, 2H), 3.86–3.78 (m, 1H), 3.57–3.48 (m, 1H), 3.45–3.37 (m, 1H), 2.99–2.82 (m, 2H), 1.89–1.68 (m, 4H), 1.66–1.56 (m, 2H), 1.55–1.47 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 162.03, 156.72, 152.35, 151.03, 121.61, 116.46, 101.94, 101.20, 65.82, 49.14, 48.84, 45.45, 35.08, 32.08, 27.85, 23.48, 22.41. HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>O 325.1771, found 325.1766. Purity: 100.0%. [α]<sup>20</sup><sub>D</sub> +185.58° (<i>c</i> 1.04, MeOH).</div><div class="NLM_p last">The following compounds (<b>44</b>–<b>46</b> and <b>48</b>–<b>49</b>) were prepared by using the procedures described for the synthesis of <b>47</b>. In these cases, corresponding amines were used instead of <i>t</i>-butyl 1,7-diazaspiro[4.5]decane-1-carboxylate.</div></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3-(7-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.4]nonan-1-yl)-3-oxopropanenitrile (<b>44</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.59 (br s, 1H), 8.08 (s, 1H), 7.10 (dd, <i>J</i> = 3.4, 2.4 Hz, 1H), 6.56–6.52 (m, 1H), 4.36–4.17 (m, 1H), 4.10–3.94 (m, 1H), 3.99 (s, 2H), 3.76–3.19 (m, 4H), 3.05–2.92 (m, 1H), 2.01–1.94 (m, 2H), 1.93–1.83 (m, 2H), 1.81–1.72 (m, 1H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>O 311.1615, found 311.1603. Purity: 100%.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-(2-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-2,6-diazaspiro[4.5]decan-6-yl)-3-oxopropanenitrile (<b>45</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.60 (br s, 1H), 8.08 (s, 1H), 7.13–7.10 (m, 1H), 6.57–6.51 (m, 1H), 4.32–4.26 (m, 1H), 4.07 (s, 2H), 4.00–3.50 (m, 3H), 3.48–3.32 (m, 2H), 2.60–2.52 (m, 1H), 2.30–2.08 (m, 1H), 1.82–1.44 (m, 6H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>O 325.1771, found 325.1764. Purity: 99.0%.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-(7-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-2,7-diazaspiro[4.4]nonan-2-yl)-3-oxopropanenitrile (<b>46</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.58 (s, 1H), 8.07 (d, <i>J</i> = 2.3 Hz, 1H), 7.12–7.09 (m, 1H), 6.60–6.56 (m, 1H), 3.96–3.89 (m, 2H), 3.88–3.60 (m, 4H), 3.57–3.40 (m, 4H), 2.06–1.84 (m, 4H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>O 311.1615, found 311.1607. Purity: 100%.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-(8-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,8-diazaspiro[5.5]undecan-1-yl)-3-oxopropanenitrile (<b>48</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.68 (br s, 1H), 8.10 (s, 1H), 7.17 (dd, <i>J</i> = 3.5, 2.6 Hz, 1H), 6.59 (dd, <i>J</i> = 3.7, 1.9 Hz, 1H), 4.64–4.59 (m, 1H), 4.51–4.44 (m, 1H), 4.26–4.21 (m, 1H), 4.07 (d, <i>J</i> = 18.8 Hz, 1H), 4.01 (d, <i>J</i> = 18.6 Hz, 1H), 3.31–3.13 (m, 2H), 2.77–2.67 (m, 1H), 1.86–1.37 (m, 10H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>N<sub>6</sub>O 339.1928, found 339.1927. Purity: 100%.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-(2-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-2,7-diazaspiro[5.6]dodecan-7-yl)-3-oxopropanenitrile (<b>49</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.63 (br s, 1H), 8.09 (s, 1H), 7.15 (dd, <i>J</i> = 3.5, 2.6 Hz, 1H), 6.64 (dd, <i>J</i> = 3.6, 2.0 Hz, 1H), 4.53 (d, <i>J</i> = 13.2 Hz, 1H), 4.38–4.29 (m, 1H), 4.18 (d, <i>J</i> = 13.0 Hz, 1H), 4.02 (s, 2H), 3.35–3.31 (m, 3H), 2.63–2.55 (m, 1H), 1.88–1.77 (m, 2H), 1.74–1.50 (m, 6H), 1.47–1.34 (m, 3H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>25</sub>N<sub>6</sub>O 353.2084, found 353.2076. Purity: 100%.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 1-(7-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decan-1-yl)ethan-1-one (<b>50</b>)</h4><div class="NLM_p last">To a solution of 7-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decane (25 mg, 0.097 mmol) in CHCl<sub>3</sub> (1.0 mL) was added <i>i</i>-Pr<sub>2</sub>NEt (0.051 mL, 0.29 mmol) and Ac<sub>2</sub>O (0.018 mL, 0.19 mmol) at 0 °C. After being stirred for 1 h at 0 °C, the mixture was diluted with CHCl<sub>3</sub> and satd NaHCO<sub>3</sub>. The resulting mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by preparative TLC (CHCl<sub>3</sub>:MeOH = 10:1 (v/v)) to give the title compound <b>50</b> (21.8 mg, 75% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.65 (br s, 1H), 8.09 (s, 1H), 7.15 (dd, <i>J</i> = 3.4, 2.5 Hz, 1H), 6.57 (dd, <i>J</i> = 3.6, 1.9 Hz, 1H), 4.73–4.65 (m, 1H), 4.47 (d, <i>J</i> = 12.1 Hz, 1H), 3.90 (d, <i>J</i> = 12.4 Hz, 1H), 3.62–3.54 (m, 1H), 3.48–3.41 (m, 1H), 3.00–2.88 (m, 2H), 1.97 (s, 3H), 1.88–1.67 (m, 4H), 1.65–1.53 (m, 2H), 1.50–1.43 (m, 1H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>22</sub>N<sub>5</sub>O 300.1819, found 300.1817. Purity: 97.4%.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 1-(7-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decan-1-yl)-2-hydroxyethan-1-one (<b>51</b>)</h4><div id="sec4_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> Step 1</h5><div class="NLM_p last">To a solution of 7-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decane (32 mg, 0.13 mmol) in CHCl<sub>3</sub> (0.6 mL) was added Et<sub>3</sub>N (0.019 mL, 0.14 mmol) and acetoxyacetyl chloride (0.015 mL, 0.14 mmol) at 0 °C. After being stirred for 1 h at 0 °C, the mixture was diluted with CHCl<sub>3</sub> and satd NaHCO<sub>3</sub>. The resulting mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by preparative TLC (CHCl<sub>3</sub>:MeOH = 10:1 (v/v)) to give 2-(7-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decan-1-yl)-2-oxoethyl acetate (17 mg, 38% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 10.68 (s, 1H), 8.28 (s, 1H), 7.08 (d, <i>J</i> = 3.2 Hz, 1H), 6.51 (d, <i>J</i> = 3.5 Hz, 1H), 4.72 (d, <i>J</i> = 12.8 Hz, 1H), 4.67–4.59 (m, 2H), 4.04 (d, <i>J</i> = 12.8 Hz, 1H), 3.58–3.42 (m, 2H), 3.22–3.07 (m, 2H), 2.51–2.31 (m, 1H), 2.22 (s, 3H), 2.15–2.06 (m, 1H), 2.03–1.82 (m, 3H), 1.80–1.55 (m, 3H).</div></div><div id="sec4_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Step 2</h5><div class="NLM_p last">A mixture of this compound obtained in the previous step (15 mg, 0.042 mmol) and K<sub>2</sub>CO<sub>3</sub> (17 mg, 0.12 mmol) in MeOH (0.7 mL) was stirred at room temperature overnight. After the mixture was diluted with EtOAc and H<sub>2</sub>O, the mixture was extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O and brine. After filtration and concentration, the residue was purified by preparative TLC (CHCl<sub>3</sub>:MeOH = 10:1 (v/v)) to give the title compound <b>51</b> (1.3 mg, 9.8% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 10.67–10.25 (m, 1H), 8.30 (s, 1H), 7.11–7.07 (m, 1H), 6.52 (d, <i>J</i> = 3.2 Hz, 1H), 4.78–4.71 (m, 1H), 4.70–4.64 (m, 1H), 4.09 (d, <i>J</i> = 15.3 Hz, 1H), 4.04–3.98 (m, 1H), 4.03 (d, <i>J</i> = 15.3 Hz, 1H), 3.67 (br s, 1H), 3.50–3.42 (m, 1H), 3.41–3.32 (m, 1H), 3.26–3.17 (m, 1H), 3.17–3.08 (m, 1H), 2.18–2.10 (m, 1H), 2.04–1.58 (m, 6H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> 316.1768, found 316.1575. Purity: 100%.</div></div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(7-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decan-1-yl)-2-methoxyethan-1-one (<b>52</b>)</h4><div class="NLM_p last">To a solution of 7-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decane (50 mg, 0.194 mmol) in CHCl<sub>3</sub> (1.0 mL) was added Et<sub>3</sub>N (0.030 mL, 0.21 mmol) and 2-methoxyacetyl chloride (0.020 mL, 0.21 mmol) at 0 °C. After being stirred for 1 h at 0 °C, the mixture was diluted with CHCl<sub>3</sub> and satd NaHCO<sub>3</sub>. The resulting mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by preparative TLC (CHCl<sub>3</sub>:MeOH = 10:1 (v/v)) to give the title compound <b>52</b> (44 mg, 68% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.67 (br s, 1H), 8.08 (s, 1H), 7.15 (dd, <i>J</i> = 3.5, 2.3 Hz, 1H), 6.56 (dd, <i>J</i> = 3.6, 1.7 Hz, 1H), 4.72–4.66 (m, 1H), 4.48 (d, <i>J</i> = 12.5 Hz, 1H), 3.98 (d, <i>J</i> = 14.6 Hz, 1H), 3.94 (d, <i>J</i> = 14.8 Hz, 1H), 3.89 (d, <i>J</i> = 13.0 Hz, 1H), 3.53–3.46 (m, 1H), 3.39–3.34 (m, 1H), 3.30 (s, 3H), 2.99–2.89 (m, 2H), 1.85–1.66 (m, 4H), 1.62–1.52 (m, 2H), 1.51–1.45 (m, 1H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>24</sub>N<sub>5</sub>O<sub>2</sub> 330.1911, found 330.1918. Purity: 99.0%.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(Cyanomethyl)-7-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decane-1-carboxamide (<b>53</b>)</h4><div class="NLM_p last">To a solution of 7-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,7-diazaspiro[4.5]decane (28 mg, 0.11 mmol) in DMA (0.3 mL) was added <i>i</i>-Pr<sub>2</sub>NEt (0.028 mL, 0.16 mmol) and 4-nitrophenyl (cyanomethyl)carbamate (31 mg, 0.163 mmol) at 0 °C. After being stirred for 1 h at 0 °C, the mixture was diluted with CHCl<sub>3</sub> and satd NaHCO<sub>3</sub>. The resulting mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by preparative TLC (CHCl<sub>3</sub>:MeOH = 10:1 (v/v)) to give the title compound <b>53</b> (10 mg, 27% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.68 (br s, 1H), 8.10 (s, 1H), 7.16 (dd, <i>J</i> = 3.5, 2.6 Hz, 1H), 6.82 (t, <i>J</i> = 5.6 Hz, 1H), 6.59 (dd, <i>J</i> = 3.7, 1.9 Hz, 1H), 4.75–4.67 (m, 1H), 4.51–4.45 (m, 1H), 4.03 (d, <i>J</i> = 5.8 Hz, 2H), 3.86–3.81 (m, 1H), 3.44–3.37 (m, 1H), 3.32–3.25 (m, 1H), 2.97–2.85 (m, 2H), 1.88–1.69 (m, 4H), 1.66–1.52 (m, 2H), 1.52–1.45 (m, 1H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>N<sub>7</sub>O 340.188, found 340.1868. Purity: 98.7%.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 3-(6-(7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.5]nonan-1-yl)-3-oxopropanenitrile (<b>54</b>)</h4><div id="sec4_1_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Step 1</h5><div class="NLM_p last">To a suspension of NaH (482 mg, 12.1 mmol) in THF was added triethyl phosphonoacetate (2.39 mL, 12.1 mmol) at 0 °C. After being stirred for 0.5 h at 0 °C, to the mixture was added 1-boc-3-piperidone (2.0 g, 10.0 mmol). The resulting mixture was stirred for 5 h at room temperature. After the mixture was quenched by addition of H<sub>2</sub>O, the mixture was extracted with EtOAc. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (<i>n</i>-hexane:EtOAc = 5:1) to give the crude of <i>t</i>-butyl-3-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate (<b>93</b>) (2.71g, 98% yield) as a <i>E</i>/<i>Z</i> mixture. A mixture of this compound obtained in the previous step (2.71g, 10.1 mmol) and NH<sub>3</sub> in MeOH (27 mL) was stirred at 70 °C in a sealed tube overnight. After being to cooled to room temperature and removal of solvent in vacuo, the residue was purified by flash chromatography (acetone:CHCl<sub>3</sub> = 1:4 to 1:1 (v/v)) to give <i>t</i>-butyl 3-amino-3-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate (<b>94</b>) (631 mg, 23% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 3.69 (s, 3H), 3.52–3.09 (m, 4H), 2.43 (s, 2H), 1.72–1.47 (m, 6H), 1.45 (s, 9H).</div></div><div id="sec4_1_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Step 2</h5><div class="NLM_p last">A mixture of this compound obtained above (631 mg, 2.32 mmol) and 2 N NaOH (1.74 mL, 3.48 mmol) in MeOH (6.3 mL) was stirred at room temperature overnight. After neutralization by addition of 1 N HCl, the mixture was concentrated in vacuo. After addition of MeOH and CH<sub>3</sub>CN, the precipitate was removed by filtration and filtrate was evaporated. The obtained residue was purified by trituration with EtOAc to give the crude of 2-(3-amino-1-(<i>t</i>-butoxycarbonyl)piperidin-3-yl)acetic acid (<b>95</b>) (613 mg). <sup>1</sup>H NMR (400Mz, DMSO-<i>d</i><sub>6</sub>) δ: 8.51 (br s, 1H), 3.68–2.95 (m, 6H), 2.09 (s, 2H), 1.70–1.52 (m, 3H), 1.52–1.34 (m, 1H), 1.39 (s, 9H).</div></div><div id="sec4_1_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> Step 3</h5><div class="NLM_p last">A mixture of this compound obtained in the previous step (491 mg, 1.90 mmol), tris(2-oxo-3-benzoxazolinnyl phosphine oxide (855 mg, 1.90 mmol), and Et<sub>3</sub>N (0.53 mL, 3.81 mmol) in CH<sub>3</sub>CN (190 mL) was stirred at 100 °C overnight. After being cooled to room temperature, insoluble materials were removed by filtration and the filtrate was concentrated. The residue was purified by flash chromatography (CHCl<sub>3</sub>:EtOAc = 75:25 to 66:33 (v/v)) to give <i>t</i>-butyl 2-oxo-1,6-diazaspiro[3.5]nonane-6-carboxylate (<b>96</b>) (391 mg, 85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 6.03 (br s, 1H), 3.57 (d, <i>J</i> = 13.2 Hz, 1H), 3.47–3.39 (m, 1H), 3.42 (d, <i>J</i> = 13.2 Hz, 1H), 3.37–3.28 (m, 1H), 2.78 (d, <i>J</i> = 14.8 Hz, 1H), 2.64 (d, <i>J</i> = 14.8 Hz, 1H), 1.90–1.75 (m, 2H), 1.68–1.59 (m, 2H), 1.46 (s, 9H).</div></div><div id="sec4_1_11_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Step 4</h5><div class="NLM_p last">A mixture of this compound obtained in the previous step (391 mg, 1.63 mmol) and NaH (98 mg, 2.44 mmol) was stirred for 15 min at room temperature, followed by addition of benzyl bromide (0.23 mL, 1.96 mmol). After being stirred for 1 h at room temperature, a reaction mixture was quenched by addition of 10% citric acid aqueous solution. The resulting mixture was extracted with EtOAc. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (<i>n</i>-hexane:EtOAc = 2:1 to 1:1 (v/v)) to give <i>t</i>-butyl 1-benzyl-2-oxo-1,6-diazaspiro[3.5]nonane-6-carboxylate (<b>97</b>) (362 mg, 67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.39–7.22 (m, 5H), 4.49–4.23 (m, 2H), 4.04–3.61 (m, 2H), 2.96–2.70 (m, 2H), 2.70–2.50 (m, 2H), 1.71–1.52 (m, 4H), 1.44 (s, 9H).</div></div><div id="sec4_1_11_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Step 5</h5><div class="NLM_p last">To a solution of this compound obtained in the previous step (361 mg, 1.09 mmol) in EtOAc (0.5 mL) was added 4 N HCl in EtOAc (4 mL). After being stirred for 2 h at room temperature followed by removal of solvent, H<sub>2</sub>O was poured in the mixture. To the resulting mixture was added satd NaHCO<sub>3</sub> and extracted with a solution of EtOAc and MeOH. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration, the filtrate was concentrated to give 1-benzyl-1,6-diazaspiro[3.5]nonan-2-one (<b>98</b>) (226 mg, 90% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.36–7.24 (m, 5H), 4.48 (d, <i>J</i> = 15.3 Hz, 1H), 4.26 (d, <i>J</i> = 15.3 Hz, 1H), 2.92–2.80 (m, 2H), 2.76–2.68 (m, 2H), 2.63 (dd, <i>J</i> = 11.9, 1.0 Hz, 1H), 2.45–2.37 (m, 1H), 1.80–1.38 (m, 5H).</div></div><div id="sec4_1_11_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Step 6</h5><div class="NLM_p last">To a suspension of LiAlH<sub>4</sub> (25 mg, 0.65 mmol) in THF (0.5 mL) was added H<sub>2</sub>SO<sub>4</sub> at 0 °C. After being stirred 1 h at 0 °C, to the reaction mixture was added a solution of the compound obtained in the previous step (50 mg, 0.22 mmol) in THF (0.25 mL). The resulting mixture was stirred for 1.5 h at room temperature followed by addition of H<sub>2</sub>O (0.025 mL), 4N NaOH (0.025 mL), and H<sub>2</sub>O (0.050 mL). After the insoluble materials were removed by filtration, the filtrate was concentrated to give 1-benzyl-1,6-diazaspiro[3.5]nonane (<b>99</b>) (45.2 mg, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.34–7.18 (m, 5H), 3.68 (d, <i>J</i> = 12.9 Hz, 1H), 3.63 (d, <i>J</i> = 12.9 Hz, 1H), 3.26–3.20 (m, 1H), 3.17–3.10 (m, 1H), 3.06–3.01 (m, 1H), 2.91–2.84 (m, 1H), 2.61 (dd, <i>J</i> = 11.7, 0.8 Hz, 1H), 2.45–2.37 (m, 1H), 2.07–1.89 (m, 3H), 1.71–1.39 (m, 4H).</div></div><div id="sec4_1_11_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Step 7</h5><div class="NLM_p last">A mixture of this compound obtained in the previous step (194 mg, 0.897 mmol), 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (138 mg, 0.897 mmol), and K<sub>2</sub>CO<sub>3</sub> (372 mg, 2.69 mmol) in H<sub>2</sub>O (2.0 mL) was stirred at 100 °C overnight. After being cooled to room temperature, the mixture was diluted with EtOAc and H<sub>2</sub>O. The resulting mixture was extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (CHCl<sub>3</sub>:acetone = 3:1 to 2:1 (v/v)) to give 4-(1-benzyl-1,6-diazaspiro[3.5]nonan-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (178 mg, 60% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 10.08 (br s, 1H), 8.33 (s, 1H), 7.37–7.19 (m, 5H), 7.09–7.06 (m, 1H), 6.64–6.61 (m, 1H), 4.73 (d, <i>J</i> = 12.9 Hz, 1H), 4.54–4.46 (m, 1H), 3.74 (s, 2H), 3.34–3.27 (m, 2H), 3.22–3.14 (m, 1H), 3.13–3.04 (m, 1H), 2.14–1.98 (m, 2H), 1.89–1.63 (m, 4H).</div></div><div id="sec4_1_11_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> Step 8</h5><div class="NLM_p last">A solution of this compound obtained in the previous step (100 mg, 0.300 mmol) in MeOH (1.0 mL) was treated with 10% Pd(OH)<sub>2</sub> on activated carbon (100 mg) and stirred under a hydrogen atmosphere (4 atm) for 2 h at room temperature. After removal of the palladium catalyst by Celite filtration, the filtrate was concentrated to afford 4-(1,6-diazaspiro[3.5]nonan-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (90 mg, quantitative). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.19 (s, 1H), 7.02 (d, <i>J</i> = 3.6 Hz, 1H), 6.35–6.30 (m, 1H), 4.60–4.44 (m, 1H), 4.08–3.97 (m, 1H), 3.84–3.74 (m, 1H), 3.74–3.64 (m, 1H), 3.60–3.42 (m, 2H), 2.32–2.13 (m, 3H), 2.10–1.60 (m, 4H).</div></div><div id="sec4_1_11_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Step 9</h5><div class="NLM_p last">Compound <b>54</b> was prepared by coupling of this compound obtained in the previous step with 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile following the procedure described for the synthesis of the compound <b>47</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.71 (br s, 1H), 8.13 (s, 1H), 7.20 (dd, <i>J</i> = 3.5, 2.4 Hz, 1H), 6.64 (dd, <i>J</i> = 3.6, 1.9 Hz, 1H), 4.96 (d, <i>J</i> = 12.6 Hz, 1H), 4.67–4.60 (m, 1H), 4.11–4.04 (m, 1H), 4.00–3.93 (m, 1H), 3.70 (s, 2H), 3.53 (d, <i>J</i> = 12.6 Hz, 1H), 2.98–2.90 (m, 1H), 2.39–2.31 (m, 1H), 2.01–1.93 (m, 3H), 1.83–1.75 (m, 1H), 1.58–1.46 (m, 1H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>O 311.1615, found 311.1616. Purity: 100.0%. Chiral resolution of compound <b>54</b> to obtained <i>ent</i>-<b>54</b> was same procedure described for the synthesis of <i>ent</i>-<b>47</b> as first eluting isomer. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.73 (br s, 1H), 8.13 (s, 1H), 7.22–7.18 (m, 1H), 6.67–6.63 (m, 1H), 4.96 (d, <i>J</i> = 12.6 Hz, 1H), 4.68–4.60 (m, 1H), 4.11–4.03 (m, 1H), 4.01–3.93 (m, 1H), 3.71 (s, 2H), 3.53 (d, <i>J</i> = 12.6 Hz, 1H), 2.98–2.88 (m, 1H), 2.40–2.30 (m, 1H), 2.03–1.90 (m, 3H), 1.83–1.75 (m, 1H), 1.59–1.45 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 162.13, 156.77, 152.41, 150.93, 121.83, 116.22, 102.13, 101.26, 67.97, 50.84, 45.57, 45.31, 33.37, 26.42, 23.82, 22.10. HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>O 311.1615, found 311.1610. Purity: 100.0%. [α]<sup>20</sup><sub>D</sub> +210.00° (<i>c</i> 1.01, MeOH).</div></div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-(7-Methyl-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.5]nonan-1-yl)-3-oxopropanenitrile (<b>55</b>)</h4><div id="sec4_1_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> Step 1</h5><div class="NLM_p last">To a mixture of 1-(<i>t</i>-butoxycarbonyl)-6-methylpiperidine-3-carboxylic acid (2.80 g, 11.5 mmol) and K<sub>2</sub>CO<sub>3</sub> (2.39 g, 17.3 mmol) in DMF (14 mL) was added ally bromide (1.29 mL, 15.0 mmol) at room temperature. After being stirred at room temperature overnight, the mixture was diluted with H<sub>2</sub>O and a solution of <i>n</i>-hexane and EtOAc (1:1, v/v). The resulting mixture was extracted with EtOAc, and the organic layer was washed with H<sub>2</sub>O and brine and dried over MgSO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (<i>n</i>-hexane:EtOAc = 100:0 to 80:20 (v/v)) to give the 3-allyl 1-(<i>t</i>-butyl) 6-methylpiperidine-1,3-dicarboxylate (3.19 g, 98% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.98–5.85 (m, 1H), 5.36–5.19 (m, 2H), 4.62–4.57 (m, 2H), 4.48–4.07 (m, 1.8H), 3.10–3.04 (m, 0.2H), 2.97–2.85 (m, 0.8H), 2.62–2.58 (m, 0.2H), 2.47–2.37 (m, 0.8H), 2.08–2.00 (m, 0.2H), 1.95–1.27 (m, 4H), 1.46 (s, 7.2H), 1.45 (s, 1.8H), 1.13 (d, <i>J</i> = 6.8 Hz, 3H).</div></div><div id="sec4_1_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> Step 2</h5><div class="NLM_p last">To a solution of 1.1 M LiHMDS in THF (11.6 mL, 12.8 mmol) was added dropwise a solution of this compound obtained in the previous step (1.86 g, 6.56 mmol) in THF (30 mL) at −78 °C. The reaction mixture was warmed to 0 °C and then stirred for 1 h. After the mixture was cooled to −78 °C, to the reaction mixture was added dropwise trimethylsilyl chloride (1.90 mL, 14.8 mmol). The resulting mixture was gradually warmed to −50 °C and stirred for 2 h. The reaction mixture was quenched by H<sub>2</sub>O at 0 °C, and the mixture was extracted with <i>n</i>-hexane. The aqueous layer was acidified with 2 M H<sub>2</sub>SO<sub>4</sub> and extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O and brine and dried over MgSO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (CHCl<sub>3</sub>:MeOH = 99:1 to 90:10 (v/v)) to give 3-allyl-1-(<i>t</i>-butoxycarbonyl)-6-methylpiperidine-3-carboxylic acid (1.21 g, 65% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.83–5.68 (m, 1H), 5.15–5.06 (m, 2H), 4.44–4.34 (m, 1.4H), 4.01 (d, <i>J</i> = 13.9 Hz, 0.6H), 3.07 (d, <i>J</i> = 13.9 Hz, 0.7H), 2.67 (d, <i>J</i> = 13.9 Hz, 0.3H), 2.49 (dd, <i>J</i> = 13.9, 6.7 Hz, 0.7H), 2.37–2.21 (m, 1.3H), 2.11–2.03 (m, 0.3H), 1.98–1.79 (m, 1.7H), 1.73–1.66 (m, 0.6H), 1.54–1.25 (m, 1.4H), 1.46 (s, 6.3H), 1.45 (s, 2.7H), 1.13 (d, <i>J</i> = 6.7 Hz, 2.1H), 1.11 (d, <i>J</i> = 6.7 Hz, 0.9H).</div></div><div id="sec4_1_12_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> Step 3</h5><div class="NLM_p last">A mixture of this compound obtained in the previous step (1.20 g, 4.23 mmol) and Et<sub>3</sub>N (0.89 mL, 6.35 mmol) and DPPA (1.19 mL, 5.51 mmol) in toluene (12 mL) was stirred for 2 h at 100 °C. After being cooled to room temperature, to the reaction mixture was added benzyl alcohol (1.31 mL, 12.7 mmol) followed by DMAP (104 mg, 0.85 mmol). The resulting mixture was stirred at 100 °C overnight. After concentration, the residue was purified by flash chromatography (<i>n</i>-hexane:EtOAc = 100:0 to 70:30 (v/v)) to give the <i>t</i>-butyl 5-allyl-5-(((benzyloxy)carbonyl)amino)-2-methylpiperidine-1-carboxylate (1.65 g, 99% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.42–7.29 (m, 5H), 5.85–5.70 (m, 1H), 5.19–5.01 (m, 4H), 4.68 (br s, 1H), 4.42–4.33 (m, 0.7H), 4.06–3.94 (m, 1.3H), 3.21 (d, <i>J</i> = 12.8 Hz, 0.7H), 2.69 (d, <i>J</i> = 14.1 Hz, 0.3H), 2.56 (dd, <i>J</i> = 14.1, 6.6 Hz, 0.7H), 2.40–2.27 (m, 0.3H), 2.24–2.07 (m, 1H), 1.87–1.75 (m, 1H), 1.67–1.27 (m, 3H), 1.46 (s, 6.3H), 1.45 (s, 2.7H), 1.19 (d, <i>J</i> = 6.4 Hz, 2.1H), 1.11 (d, <i>J</i> = 6.8 Hz, 0.9H).</div></div><div id="sec4_1_12_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Step 4</h5><div class="NLM_p last">A solution of this compound obtained in the previous step (1.65 g, 4.25 mmol) in CHCl<sub>3</sub> (16.5 mL) and MeOH (16.5 mL) was cooled to −78 °C and then bubbled through O<sub>3</sub> gas for 3 h. To the reaction mixture was added NaBH<sub>4</sub> (482 mg, 12.7 mmol) at the same temperature, and then the mixture was warmed to room temperature for a period of 2 h. Saturated NaHCO<sub>3</sub> was poured into the mixture, and the mixture was extracted with EtOAc. The organic layer was washed with brine and dried over MgSO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (<i>n</i>-hexane:EtOAc = 100:0 to 40:60 (v/v)) to give <i>t</i>-butyl 5-(((benzyloxy)carbonyl)amino)-5-(2-hydroxyethyl)-2-methylpiperidine-1-carboxylate (950 mg, 60% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.39–7.28 (m, 5H), 5.74 (br s, 1H), 5.05 (s, 2H), 4.40–4.27 (m, 1H), 3.97 (d, <i>J</i> = 12.4 Hz, 1H), 3.91–3.75 (m, 2H), 3.38 (d, <i>J</i> = 12.4 Hz, 1H), 2.46–2.29 (m, 1H), 2.00–1.38 (m, 6H), 1.45 (s, 9H), 1.21 (d, <i>J</i> = 6.7 Hz, 3H).</div></div><div id="sec4_1_12_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Step 5</h5><div class="NLM_p last">A solution of this compound obtained in the previous step (285 mg, 0.73 mmol) in THF (4.0 mL) was treated with 10% palladium on activated carbon (60 mg) and stirred under a hydrogen atmosphere (4 atm) for 1 h at room temperature. After removal of the palladium catalyst by Celite filtration, the filtrate was concentrated to afford the crude of <i>t</i>-butyl 5-amino-5-(2-hydroxyethyl)-2-methylpiperidine-1-carboxylate (158 mg, 84% yield). This crude product was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (7.0 mL) and cooled to 0 °C. To the mixture was added PPh<sub>3</sub> (357 mg, 1.36 mmol), followed by Et<sub>3</sub>N (0.378 mL, 2.71 mmol) and CBr<sub>4</sub> (451 mg, 1.36 mmol). After being stirred for 1.5 h at room temperature, the mixture was diluted with satd NaHCO<sub>3</sub> and EtOAc. The resulting mixture was extracted with EtOAc. The organic layer was washed with satd NaHCO<sub>3</sub> and brine and dried over MgSO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (CHCl<sub>3</sub>:MeOH:28% NH<sub>3</sub> aq = 95:3:2 to 83:15:2 (v/v)) to give <i>t</i>-butyl 7-methyl-1,6-diazaspiro[3.5]nonane-6-carboxylate (178 mg, 82% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 4.38–4.28 (m, 1H), 4.17 (d, <i>J</i> = 13.2 Hz, 1H), 3.56–3.43 (m, 2H), 2.66 (d, <i>J</i> = 13.0 Hz, 1H), 2.17–2.08 (m, 1H), 2.05–1.96 (m, 1H), 1.89–1.82 (m, 1H), 1.74–1.39 (m, 3H), 1.47 (s, 9H), 1.10 (d, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_1_12_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Step 6</h5><div class="NLM_p last">To a solution of this compound obtained in the previous step (149 mg, 0.62 mmol) in CHCl<sub>3</sub> (1.5 mL) was added <i>i</i>-Pr<sub>2</sub>NEt (0.14 mL, 0.78 mmol) and CbzCl (0.11 mL, 0.78 mmol) at 0 °C. After being stirred for 3.5 h at room temperature, the reaction mixture was concentrated. The residue was purified by flash chromatography (<i>n</i>-hexane:EtOAc = 100:0 to 75:25 (v/v)) to give 1-benzyl 6-(<i>t</i>-butyl) 7-methyl-1,6-diazaspiro[3.5]nonane-1,6-dicarboxylate (206 mg, 89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.40–7.29 (m, 5H), 5.12 (s, 1.2H), 5.07 (s, 0.8H), 4.45–4.35 (m, 0.6H), 4.28–4.18 (m, 0.4H), 4.12–4.02 (m, 0.4H), 3.97–3.81 (m, 2.6H), 3.55–3.36 (m, 0.4H), 3.34–3.17 (m, 0.6H), 2.58–1.86 (m, 3H), 1.74–1.39 (m, 3H), 1.46 (s, 9H), 1.22–1.13 (m, 1.2H), 1.07–0.98 (m, 1.8H).</div></div><div id="sec4_1_12_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Step 7</h5><div class="NLM_p last">To a solution of this compound obtained in the previous step (176 mg, 0.47 mmol) in CHCl<sub>3</sub> (1.0 mL) was added 4 N HCl in 1,4-dioxane (1.0 mL) at room temperature. After being stirred for 1 h, the mixture was neutralized with 1 N NaOH and extracted with EtOAc. The organic layer was washed with satd NaHCO<sub>3</sub> and brine, dried over MgSO<sub>4</sub>, and filtrated. The filtrate was concentrated to give the crude of benzyl 7-methyl-1,6-diazaspiro[3.5]nonane-1-carboxylate. A mixture of this crude product (130 mg, 0.47 mmol), 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (72 mg, 0.47 mmol), and K<sub>2</sub>CO<sub>3</sub> (195 mg, 1.41 mmol) in H<sub>2</sub>O (0.72 mL) was heated to 110 °C overnight. The mixture was diluted with CHCl<sub>3</sub> and extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over MgSO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (EtOAc:MeOH = 100:0 to 90:10 (v/v)) to give benzyl 7-methyl-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.5]nonane-1-carboxylate (99.6 mg, 56% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 10.44–10.38 (m, 1H), 8.31 (s, 1H), 7.41–7.28 (m, 5H), 7.08 (s, 1H), 6.53–6.50 (m, 1H), 5.16 (s, 1.2H), 5.11 (s, 0.8H), 5.03–4.85 (m, 2H), 4.06–3.86 (m, 2H), 3.81–3.74 (m, 0.4H), 3.61–3.51 (m, 0.6H), 2.77–2.65 (m, 0.4H), 2.53–2.41 (m, 0.6H), 2.29–2.16 (m, 1H), 2.00–1.59 (m, 4H), 1.39 (d, <i>J</i> = 6.8 Hz, 1.2H), 1.23 (d, <i>J</i> = 6.4 Hz, 1.8H).</div></div><div id="sec4_1_12_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Step 8</h5><div class="NLM_p last">A solution of this compound obtained in the previous step (99.6 mg, 0.25 mmol) in THF (0.5 mL) and MeOH (0.5 mL) was treated with 10% palladium on activated carbon (50 mg) and stirred under a hydrogen atmosphere (4 atm) for 4 h at room temperature. After removal of the palladium catalyst by Celite filtration, the filtrate was concentrated to afford 4-(7-methyl-1,6-diazaspiro[3.5]nonan-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (62 mg, 96% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.65 (br s, 1H), 8.12 (s, 1H), 7.17 (d, <i>J</i> = 3.5 Hz, 1H), 6.57 (d, <i>J</i> = 3.5 Hz, 1H), 4.97–4.88 (m, 1H), 4.85 (d, <i>J</i> = 13.2 Hz, 1H), 3.43–3.26 (m, 2H), 2.87 (d, <i>J</i> = 13.0 Hz, 1H), 2.02–1.49 (m, 7H), 1.19 (d, <i>J</i> = 6.8 Hz, 3H).</div></div><div id="sec4_1_12_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Step 9</h5><div class="NLM_p">Compound <b>55</b> was prepared by coupling of this compound obtained in the previous step with 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile following the procedure described for the synthesis of the compound <b>47</b>. The crude product was purified by preparative TLC (CHCl<sub>3</sub>:MeOH = 85:15 (v/v)) to give the compound <b>55</b> (53 mg, 53% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 10.33 (br s, 1H), 8.31 (s, 1H), 7.09 (dd, <i>J</i> = 3.5, 2.0 Hz, 1H), 6.53–6.49 (m, 1H), 5.08–4.99 (m, 1H), 4.97–4.88 (m, 1H), 4.29–4.21 (m, 1H), 4.18–4.11 (m, 1H), 3.88–3.81 (m, 1H), 3.25 (s, 2H), 2.88–2.79 (m, 1H), 2.44–2.36 (m, 1H), 2.10–2.02 (m, 1H), 1.92–1.79 (m, 2H), 1.78–1.71 (m, 1H), 1.42 (d, <i>J</i> = 7.1 Hz, 3H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>O 325.1771, found 325.1758. Purity: 98.8%.</div><div class="NLM_p last">The following compounds <b>56</b>–<b>61</b> were prepared by using the above procedures. In these cases, corresponding carboxylic acid and allyl bromide were used as starting materials.</div></div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 3-(8-Methyl-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.5]nonan-1-yl)-3-oxopropanenitrile (<b>56</b>)</h4><div class="NLM_p last">Compound <b>56</b> was prepared from 1-(<i>t</i>-butoxycarbonyl)-5-methylpiperidine-3-carboxylic acid and allyl bromide as starting materials by using the procedure described for the synthesis of the compound <b>55</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.73 (br s, 1H), 8.12 (s, 1H), 7.22–7.19 (m, 1H), 6.65–6.62 (m, 1H), 4.99–4.92 (m, 1H), 4.64–4.57 (m, 1H), 4.09–4.01 (m, 1H), 4.00–3.92 (m, 1H), 3.69 (s, 2H), 3.49–3.44 (m, 1H), 2.60–2.52 (m, 1H), 2.08–1.90 (m, 4H), 1.75–1.65 (m, 1H), 0.98 (d, <i>J</i> = 6.5 Hz, 3H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>O 325.1771, found 325.1759. Purity: 100%.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 3-(3-Methyl-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.5]nonan-1-yl)-3-oxopropanenitrile (<b>57</b>)</h4><div class="NLM_p last">Compound <b>57</b> was prepared from 1-(<i>t</i>-butoxycarbonyl)piperidine-3-carboxylic acid and 3-bromo-2-methyl-1-propene as starting materials by using the procedure described for the synthesis of the compound <b>55</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.70 (br s, 1H), 8.14 (s, 1H), 7.18 (dd, <i>J</i> = 3.7, 2.6 Hz, 1H), 6.64 (dd, <i>J</i> = 3.7, 1.9 Hz, 1H), 5.02–4.96 (m, 1H), 4.65–4.59 (m, 1H), 4.11–4.05 (m, 1H), 3.70 (d, <i>J</i> = 18.8 Hz, 1H), 3.65 (d, <i>J</i> = 18.8 Hz, 1H), 3.59–3.54 (m, 1H), 3.46–3.42 (m, 1H), 2.97–2.88 (m, 1H), 2.47–2.33 (m, 2H), 2.00–1.93 (m, 1H), 1.87–1.79 (m, 1H), 1.63–1.50 (m, 1H), 0.90 (d, <i>J</i> = 7.2 Hz, 3H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>O 325.1771, found 325.1760. Purity: 100%. Chiral resolution of compound <b>57</b> to obtained <i>ent</i>-<b>57</b> was same procedure described for the synthesis of <i>ent</i>-<b>47</b> as first eluting isomer. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.71 (br s, 1H), 8.12 (s, 1H), 7.20 (dd, <i>J</i> = 3.5, 2.4 Hz, 1H), 6.65 (dd, <i>J</i> = 3.6, 1.9 Hz, 1H), 4.93–4.88 (m, 1H), 4.64–4.58 (m, 1H), 4.24–4.18 (m, 1H), 3.67 (s, 2H), 3.61 (d, <i>J</i> = 12.8 Hz, 1H), 3.46–3.41 (m, 1H), 3.03–2.95 (m, 1H), 2.42–2.35 (m, 1H), 2.34–2.25 (m, 1H), 2.15–2.08 (m, 1H), 1.83–1.77 (m, 1H), 1.57–1.43 (m, 1H), 1.01 (d, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 162.48, 156.69, 152.39, 150.96, 121.83, 116.21, 102.08, 101.21, 69.12, 53.16, 51.88, 45.35, 32.39, 27.76, 23.98, 23.05, 14.86. HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>O 325.1771, found 325.1759. Purity: 97.5%. [α]<sup>20</sup><sub>D</sub> +168.10° (<i>c</i> 1.05, MeOH).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 3-(3,3-Dimethyl-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.5]nonan-1-yl)-3-oxopropanenitrile (<b>58</b>)</h4><div class="NLM_p last">Compound <b>58</b> was prepared from 1-(<i>t</i>-butoxycarbonyl)piperidine-3-carboxylic acid and 1-bromo-3-methyl-2-butene as starting materials by using the procedure described for the synthesis of the compound <b>55</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.70 (br s, 1H), 8.15 (s, 1H), 7.19 (dd, <i>J</i> = 3.6, 2.5 Hz, 1H), 6.65 (dd, <i>J</i> = 3.6, 1.9 Hz, 1H), 5.11–5.03 (m, 1H), 4.60–4.52 (m, 1H), 3.78 (d, <i>J</i> = 7.9 Hz, 1H), 3.70 (d, <i>J</i> = 18.7 Hz, 1H), 3.65 (d, <i>J</i> = 18.7 Hz, 1H), 3.52 (d, <i>J</i> = 7.9 Hz, 1H), 3.50–3.46 (m, 1H), 3.07–2.99 (m, 1H), 2.34–2.25 (m, 1H), 2.23–2.18 (m, 1H), 1.91–1.83 (m, 1H), 1.57–1.44 (m, 1H), 1.23 (s, 3H), 0.99 (s, 3H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>24</sub>N<sub>6</sub>O 339.1928, found 339.1910. Purity: 100%.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 3-(3,3-Difluoro-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.5]nonan-1-yl)-3-oxopropanenitrile (<b>59</b>)</h4><div class="NLM_p last">Compound <b>59</b> was prepared from 1-(<i>t</i>-butoxycarbonyl)piperidine-3-carboxylic acid and 3-bromo-3,3-difluoropropene as starting materials by using the procedure described for the synthesis of the compound <b>55</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.73 (br s, 1H), 8.15 (s, 1H), 7.21 (dd, <i>J</i> = 3.4, 2.6 Hz, 1H), 6.64 (dd, <i>J</i> = 3.6, 2.0 Hz, 1H), 5.14–5.07 (m, 1H), 4.70–4.46 (m, 3H), 3.83 (d, <i>J</i> = 18.9 Hz, 1H), 3.77 (d, <i>J</i> = 18.9 Hz, 1H), 3.62–3.56 (m, 1H), 3.00–2.91 (m, 1H), 2.40–2.29 (m, 1H), 2.27–2.20 (m, 1H), 1.99–1.91 (m, 1H), 1.63–1.49 (m, 1H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>17</sub>F<sub>2</sub>N<sub>6</sub>O 347.1426, found 347.1416. Purity: 99.7%. Chiral resolution of compound <b>59</b> to obtained <i>ent</i>-<b>59</b> was same procedure described for the synthesis of <i>ent</i>-<b>47</b> as first eluting isomer. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.74 (br s, 1H), 8.15 (s, 1H), 7.22–7.19 (m, 1H), 6.65–6.62 (m, 1H), 5.13–5.07 (m, 1H), 4.69–4.46 (m, 3H), 3.83 (d, <i>J</i> = 18.8 Hz, 1H), 3.77 (d, <i>J</i> = 19.2 Hz, 1H), 3.61–3.55 (m, 1H), 2.99–2.91 (m, 1H), 2.39–2.29 (m, 1H), 2.26–2.19 (m, 1H), 1.99–1.91 (m, 1H), 1.63–1.48 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 162.48, 156.56, 152.42, 150.71, 122.01, 115.71, 102.82, 101.19, 75.13, 59.25, 45.65, 45.59, 45.02, 27.26, 24.80, 23.14. HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>17</sub>F<sub>2</sub>N<sub>6</sub>O 347.1426, found 347.1418. Purity: 100.0%. [α]<sup>20</sup><sub>D</sub> +139.52° (<i>c</i> 1.04, MeOH).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 3-(3-Methyl-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (<b>60</b>)</h4><div class="NLM_p last">Compound <b>60</b> was prepared from 1-(<i>t</i>-butoxycarbonyl)pyrrolidine-3-carboxylic acid and (<i>E</i>)-1-bromo-2-butene as starting materials by using the procedure described for the synthesis of the compound <b>55</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.59 (br s, 1H), 8.07 (s, 1H), 7.11 (dd, <i>J</i> = 3.2, 2.6 Hz, 1H), 6.57 (dd, <i>J</i> = 3.4, 1.7 Hz, 1H), 4.18–4.12 (m, 1H), 4.08–3.92 (m, 3H), 3.84–3.72 (m, 1H), 3.70 (d, <i>J</i> = 18.8 Hz, 1H), 3.65 (d, <i>J</i> = 18.8 Hz, 1H), 3.59–3.54 (m, 1H), 2.68–2.58 (m, 2H), 2.22–2.11 (m, 1H), 1.11 (d, <i>J</i> = 7.2 Hz, 3H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>O 311.1615, found 311.1605. Purity: 100%. Chiral resolution of compound <b>60</b> to obtained <i>ent</i>-<b>60</b> (JTE-052) was same procedure described for the synthesis of <i>ent</i>-<b>47</b> as second eluting isomer. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.60 (br s, 1H), 8.08 (s, 1H), 7.11 (dd, <i>J</i> = 3.5, 2.4 Hz, 1H), 6.58 (dd, <i>J</i> = 3.4, 1.9 Hz, 1H), 4.18–4.14 (m, 1H), 4.09–3.93 (m, 3H), 3.84–3.73 (m, 1H), 3.71 (d, <i>J</i> = 19.0 Hz, 1H), 3.66 (d, <i>J</i> = 18.7 Hz, 1H), 3.58 (dd, <i>J</i> = 8.2, 6.0 Hz, 1H), 2.70–2.58 (m, 2H), 2.24–2.12 (m, 1H), 1.12 (d, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 161.58, 154.43, 151.00, 150.85, 120.51, 115.62, 102.28, 100.61, 73.87, 53.23, 49.92, 46.27, 35.71, 33.00, 23.38, 14.89. HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>O 311.1615, found 311.1606. Purity: 100.0%. [α]<sup>20</sup><sub>D</sub> +47.09° (<i>c</i> 0.55, MeOH). Anal. (C<sub>16</sub>H<sub>18</sub>N<sub>6</sub>O) Calcd: C 61.92%, H 5.85%, N 27.08%, Found: C 61.84%, H, 5.85%, N, 26.86%. Absolutely configuration of <i>ent</i>-<b>60</b> (JTE-052) was determined by single X-ray crystal structure analysis provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 3-(3,3-Difluoro-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (<b>61</b>)</h4><div class="NLM_p last">Compound <b>61</b> was prepared from 1-(<i>t</i>-butoxycarbonyl)pyrrolidine-3-carboxylic acid and 3-bromo-3,3-difluoropropene as starting materials by using the procedure described for the synthesis of the compound <b>55</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.67 (br s, 1H), 8.11 (s, 1H), 7.16 (dd, <i>J</i> = 3.3, 2.4 Hz, 1H), 6.58 (dd, <i>J</i> = 3.5, 2.0 Hz, 1H), 4.65–4.57 (m, 2H), 4.23–4.14 (m, 2H), 4.12–4.01 (m, 1H), 3.89–3.78 (m, 1H), 3.85 (d, <i>J</i> = 19.2 Hz, 1H), 3.79 (d, <i>J</i> = 19.0 Hz, 1H), 2.66–2.58 (m, 1H), 2.56–2.46 (m, 1H). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>15</sub>F<sub>2</sub>N<sub>6</sub>O 333.1270, found 333.1250. Purity: 99.4%. Chiral resolution of compound <b>61</b> to obtained <i>ent</i><b>-61</b> was the same procedure described for the synthesis of <i>ent</i>-<b>47</b> using Daicel Chiralcel OD column as first eluting isomer. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.68 (br s, 1H), 8.11 (s, 1H), 7.17–7.14 (m, 1H), 6.58 (dd, <i>J</i> = 3.3, 1.8 Hz, 1H), 4.66–4.58 (m, 2H), 4.24–4.13 (m, 2H), 4.12–4.02 (m, 1H), 3.89–3.78 (m, 3H), 2.68–2.58 (m, 1H), 2.56–2.45 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 162.57, 154.85, 151.44, 151.42, 121.53, 115.60, 102.83, 100.85, 80.52, 60.14, 49.45, 49.37, 47.01, 29.03, 24.75. HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>15</sub>F<sub>2</sub>N<sub>6</sub>O 333.1270, found 333.1265. Purity: 100.0%. [α]<sup>20</sup><sub>D</sub> +46.67° (<i>c</i> 0.54, MeOH).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Stereoselective Synthesis of JTE-052 as Described below</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Step 1</h4><div class="NLM_p last">To a mixture of (<i>S</i>)-benzylalaninol (<b>108</b>) (111 g, 673 mmol) and K<sub>2</sub>CO<sub>3</sub> (111 g, 807 mmol) in DMF (556 mL) was added dropwise <i>t</i>-butyl 2-bromoacetate (109 mL, 740 mmol) at 0 °C. After being stirred at room temperature overnight, the mixture was quenched by addition of 6 N HCl (pH = ca. 2). The resulting mixture was extracted with toluene, and the organic layer was washed with 0.1 N HCl. The combined aqueous layer was neutralized with 4 N NaOH and extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O, satd NaHCO<sub>3</sub>, and brine and then dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration and concentration in vacuo gave <i>t</i>-butyl (<i>S</i>)-<i>N</i>-benzyl-<i>N</i>-(1-hydroxypropan-2-yl)glycinate (<b>109</b>) (160.0 g, 89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.40–7.22 (m, 5H), 4.05–3.97 (m, 0.4H), 3.93–3.81 (m, 2H), 3.70–3.65 (m, 0.6H), 3.44–3.38 (m, 0.6H), 3.29 (s, 0.8H), 3.27 (d, <i>J</i> = 2.4 Hz, 1.2H), 3.24–3.15 (m, 0.6H), 3.05–2.99 (m, 0.4H), 2.94–2.88 (m, 0.4H), 1.50 (d, <i>J</i> = 6.4 Hz, 1.2H), 1.48 (s, 3.6H), 1.45 (s, 5.4H), 1.23 (d, <i>J</i> = 6.8 Hz, 1.8H).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Step 2</h4><div class="NLM_p last">To a solution of this compound obtained in the previous step (160 g, 573 mmol) in CHCl<sub>3</sub> (640 mL) was added dropwise thionyl chloride (50.0 mL, 687 mmol) at 0 °C and the mixture was stirred at 60 °C for 2 h. After being stirred at 0 °C, the mixture was quenched by addition of satd NaHCO<sub>3</sub> and extracted with CHCl<sub>3</sub>. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated, and concentrated in vacuo to give crude of <i>t</i>-butyl (<i>S</i>)-<i>N</i>-benzyl-<i>N</i>-(1-chloropropan-2-yl)glycinate (173 g). A solution of the crude of this compound obtained in previous step (173 g) in DMF (520 mL) was stirred at 80 °C for 2.5 h. After being stirred at 0 °C, the mixture was diluted with H<sub>2</sub>O and extracted with <i>n</i>-hexane/EtOAc (2/1 (v/v)). The combined organic layer was washed with H<sub>2</sub>O and brine. After concentration in vacuo, the crude product was purified by flash chromatography (<i>n</i>-hexane/EtOAc 50:1 to 40:1 (v/v)) to give <i>t</i>-butyl (<i>R</i>)-<i>N</i>-benzyl-<i>N</i>-(2-chloropropyl)glycinate (<b>112</b>) (127 g, 75% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.37–7.29 (m, 4H), 7.28–7.23 (m, 1H), 4.05–3.97 (m, 1H), 3.91 (d, <i>J</i> = 13.5 Hz, 1H), 3.86 (d, <i>J</i> = 13.7 Hz, 1H), 3.29 (s, 2H), 3.03 (dd, <i>J</i> = 13.9, 6.6 Hz, 1H), 2.91 (dd, <i>J</i> = 13.9, 6.8 Hz, 1H), 1.50 (d, <i>J</i> = 6.4 Hz, 3H), 1.48 (s, 9H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Step 3</h4><div class="NLM_p last">To a mixture of this compound obtained in the previous step (60.0 g, 202 mmol) and hexamethylphosphoric triamide (36.0 mL) in THF (360 mL) was added dropwise 1.0 M lithium bis(trimethylsilyl)amide in THF (242 mL, 242 mmol) at −78 °C. After the reaction mixture was warmed to 0 °C for the period of 1.5 h, the mixture was quenched by addition of satd NH<sub>4</sub>Cl followed by H<sub>2</sub>O at the same temperature. The resulting mixture was extracted with EtOAc. The organic layer was washed with H<sub>2</sub>O and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration in vacuo, the residue was purified by flash chromatography (<i>n</i>-hexane/EtOAc 50/1 to 4/1 (v/v)) to give <i>t</i>-butyl (2<i>R</i>,3<i>S</i>)-1-benzyl-3-methylazetidine-2-carboxylate (<b>113</b>) (50.9 g, 97% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.34–7.21 (m, 5H), 3.75 (d, <i>J</i> = 12.6 Hz, 1H), 3.70–3.67 (m, 1H), 3.58 (d, <i>J</i> = 12.6 Hz, 1H), 3.05–3.01 (m, 1H), 2.99–2.95 (m, 1H), 2.70–2.59 (m, 1H), 1.41 (s, 9H), 1.24 (d, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Step 4</h4><div class="NLM_p last">A mixture of this compound obtained in the previous step (43.5 g, 167 mmol) and di-<i>t</i>-butyl dicarbonate (38.2 g, 175 mmol) in THF (130 mL) and MeOH (130 mL) was treated with 20% palladium hydroxide on activated carbon (3.5 g) and stirred under a hydrogen atmosphere (4 atm) at room temperature for 2 h. After removal of the palladium catalyst by Celite filtration, the filtrate was concentrated in vacuo to afford di-<i>t</i>-butyl (2<i>R</i>,3<i>S</i>)-3-methylazetidine-1,2-dicarboxylate (<b>114</b>) (45.2 g, 99% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 4.44 (d, <i>J</i> = 8.8 Hz, 1H), 3.99–3.77 (m, 1H), 3.45–3.37 (m, 1H), 3.00–2.88 (m, 1H), 1.45 (s, 9H), 1.40–1.30 (m, 9H), 1.02 (d, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Step 5</h4><div class="NLM_p last">To a mixture of this compound obtained in the previous step (45.2 g, 166 mmol), and 1-bromo-3-methylbut-2-ene (25.4 mL, 216 mmol) in THF (380 mL) was added dropwise 1.0 M lithium bis(trimethylsilyl)amide in THF (200 mL, 200 mmol) at −78 °C. After the reaction mixture was warmed to −20 °C for the period of 40 min and stirred for 20 min at the same temperature, the mixture was quenched by addition of satd NH<sub>4</sub>Cl followed by H<sub>2</sub>O. The resulting mixture was extracted with <i>n</i>-hexane/EtOAc (1/1 (v/v)). The organic layer was washed with H<sub>2</sub>O and brine and dried over MgSO<sub>4</sub>. After filtration and concentration in vacuo, the residue was purified by flash chromatography (<i>n</i>-hexane/EtOAc 15:1 to 8:1 (v/v)) to give di-<i>t</i>-butyl (2<i>R</i>,3<i>S</i>)-3-methyl-2-(3-methylbut-2-en-1-yl)azetidine-1,2-dicarboxylate (<b>115</b>) (44.5 g, 79% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 5.29–5.21 (m, 1H), 3.77–3.72 (m, 1H), 3.49–3.44 (m, 1H), 2.73–2.52 (m, 3H), 1.76–1.74 (m, 3H), 1.66–1.65 (m, 3H), 1.51 (s, 9H), 1.43 (s, 9H), 1.05 (d, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Step 6</h4><div class="NLM_p last">A solution of this compound obtained in the previous step (44.5 g, 131 mmol) in CHCl<sub>3</sub> (310 mL) and MeOH (310 mL) was cooled to −78 °C and then bubbled through O<sub>3</sub> gas for 1 h. The reaction mixture was quenched by addition of a solution of triphenylphosphine (44.7 g, 170 mmol) in CHCl<sub>3</sub> (45 mL) at −78 °C. After being warmed to room temperature, saturated aqueous solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> was poured into the mixture. The resulting mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over MgSO<sub>4</sub>. Filtration and concentration in vacuo gave crude of di-<i>t</i>-butyl (2<i>R</i>,3<i>S</i>)-3-methyl-2-(2-oxoethyl)azetidine-1,2-dicarboxylate (95.0 g). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.65 (t, <i>J</i> = 2.6 Hz, 1H), 3.79–3.74 (m, 1H), 3.45–3.40 (m, 1H), 2.99–2.80 (m, 3H), 1.46 (s, 9H), 1.34 (s, 9H), 1.06 (d, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Step 7</h4><div class="NLM_p last">To a solution of this compound obtained in the previous step (95.0 g) in THF (300 mL) was added benzylamine (34 mL, 328 mmol) at room temperature, and the mixture was stirred at same temperature for 2 h. After being cooled to 0 °C, to the mixture was added NaBH(OAc)<sub>3</sub> (83.3 g, 393 mmol) and the resulting mixture was stirred at room temperature for 1.5 h. The mixture was diluted with H<sub>2</sub>O and extracted with <i>n</i>-hexane/EtOAc (1/3 (v/v)). The organic layer was washed with H<sub>2</sub>O, brine, and 10% aqueous solution of citric acid. The combined aqueous layer was neutralized with 4 N NaOH and extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over MgSO<sub>4</sub>. After filtration, the filtrate was concentrated in vacuo to give the di-<i>t</i>-butyl (2<i>R</i>,3<i>S</i>)-2-(2-(benzylamino)ethyl)-3-methylazetidine-1,2-dicarboxylate (<b>116</b>) (46.6 g, 89% yield from <b>115</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.34–7.26 (m, 4H), 7.22–7.17 (m, 1H), 3.74–3.65 (m, 2H), 3.61 (t, <i>J</i> = 7.8 Hz, 1H), 3.28 (t, <i>J</i> = 7.5 Hz, 1H), 2.76–2.66 (m, 2H), 2.57–2.45 (m, 1H), 2.15 (br s, 1H), 2.05–1.89 (m, 2H), 1.42 (s, 9H), 1.27 (s, 9H), 0.96 (d, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Step 8</h4><div class="NLM_p last">A solution of this compound obtained in the previous step (46.5 g, 115 mmol) in H<sub>2</sub>O (4.1 mL) was added 4 N HCl in 1,4-dioxane (230 mL) at room temperature. After being stirred at 80 °C for 2 h, the mixture was concentrated in vacuo. The crude product was purified by trituration with <i>n</i>-hexane/EtOAc (1/1 (v/v)) to give (2<i>R</i>,3<i>S</i>)-2-(2-(benzylamino)ethyl)-3-methylazetidine-2-carboxylic acid (30.1 g, 82% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.24 (br s, 1H), 9.64 (br s, 2H), 8.90 (br s, 1H), 7.58–7.53 (m, 2H), 7.47–7.41 (m, 3H), 4.21–4.10 (m, 2H), 4.02–3.94 (m, 1H), 3.46–3.37 (m, 1H), 3.20–3.10 (m, 1H), 2.99–2.85 (m, 2H), 2.69–2.54 (m, 2H), 1.10 (d, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Step 9</h4><div class="NLM_p last">To a suspension of this compound obtained in the previous step (29.1 g, 90.6 mmol) and <i>i</i>-Pr<sub>2</sub>NEt (65.0 mL, 362 mmol) in CHCl<sub>3</sub> (290 mL) was added 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate (41.3 g, 109 mmol) at room temperature. After being stirred at the same temperature, satd NaHCO<sub>3</sub> was poured into the mixture. The resulting mixture was extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over MgSO<sub>4</sub>. After filtration and concentration in vacuo, the residue was purified by flash chromatography (CHCl<sub>3</sub>/MeOH 20:1 to 10:1 (v/v)) to give (3<i>S</i>,4<i>R</i>)-6-benzyl-3-methyl-1,6-diazaspiro[3.4]octan-5-one (<b>117)</b> (21.3 g, 78% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.38–7.31 (m, 2H), 7.30–7.22 (m, 3H), 4.52 (d, <i>J</i> = 14.8 Hz, 1H), 4.29 (d, <i>J</i> = 14.8 Hz, 1H), 3.35–3.27 (m, 2H), 3.22–3.17 (m, 1H), 3.05 (dd, <i>J</i> = 9.5, 4.0 Hz, 2H), 2.77–2.66 (m, 1H), 2.16–2.10 (m, 1H), 1.96–1.87 (m, 1H), 0.94 (d, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Step 10</h4><div class="NLM_p last">To a suspension of LiAlH<sub>4</sub> (6.80 g, 178 mmol) in THF (300 mL) was added dropwise H<sub>2</sub>SO<sub>4</sub> (4.8 mL, 88.8 mmol) at 0 °C. After being stirred for 0.5 h, to the mixture was added dropwise a solution of the compound obtained in the previous step (21.3 g, 74.0 mmol) in THF (100 mL) at same temperature and successively stirred for 1 h. The resulting mixture was quenched by addition of H<sub>2</sub>O followed by 4 N NaOH and H<sub>2</sub>O. After the reaction mixture was stirred at 0 °C for 0.5 h, the insoluble materials were removed by Celite filtration. To the resulting filtrate was added (BOC)<sub>2</sub>O (19.4 g, 218 mmol) at room temperature. After being stirred for 3 h, the mixture was diluted with satd NH<sub>4</sub>Cl and added <i>n</i>-hexane. The organic layer was separated and washed with 10% aqueous solution of citric acid. The combined aqueous layer was neutralized with 4 N NaOH and extracted with CHCl<sub>3</sub>. The organic layer was washed with brine and dried over MgSO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (CHCl<sub>3</sub>/MeOH 40:1 to 20:1 (v/v)) to give <i>t</i>-butyl (3<i>S</i>,4<i>R</i>)-6-benzyl-3-methyl-1,6-diazaspiro[3.4]octane-1-carboxylate (<b>118</b>) (15.6 g, 67% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.34–7.27 (m, 4H), 7.26–7.21 (m, 1H), 3.84–3.69 (m, 1H), 3.62–3.47 (m, 2H), 3.19–3.05 (m, 1H), 3.02–2.92 (m, 1H), 2.76–2.69 (m, 1H), 2.47–2.24 (m, 4H), 1.95–1.77 (m, 1H), 1.36 (s, 9H), 1.03 (d, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Step 11</h4><div class="NLM_p last">A solution of this compound obtained in the previous step (10.0 g, 31.6 mmol) in THF (50 mL) and MeOH (50 mL) was treated with 20% palladium hydroxide on activated carbon (2.0 g) and stirred under a hydrogen atmosphere (4 atm) at room temperature for 24 h. After removal of the palladium catalyst by Celite filtration, the filtrate was concentrated in vacuo to afford <i>t</i>-butyl (3<i>S</i>,4<i>R</i>)-3-methyl-1,6-diazaspiro[3.4]octane-1-carboxylate (7.3 g, quantitative). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 3.88–3.71 (m, 1H), 3.44–3.06 (m, 2H), 3.02–2.64 (m, 4H), 2.55–2.38 (m, 1H), 2.31–2.15 (m, 1H), 1.81–1.72 (m, 1H), 1.37 (s, 9H), 1.07 (d, <i>J</i> = 7.0 Hz, 3H).</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Step 12</h4><div class="NLM_p last">A mixture of this compound obtained in the previous step (6.9 g, 30.5 mmol), 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (4.3 g, 27.7 mmol) and K<sub>2</sub>CO<sub>3</sub> (7.7 g, 55.4 mmol) in H<sub>2</sub>O (65 mL) was stirred at 110 °C for 4 h. After being cooled to room temperature, the mixture was diluted with H<sub>2</sub>O. The resulting mixture was extracted with CHCl<sub>3</sub>/MeOH (1/1 (v/v)). The organic layer was washed with H<sub>2</sub>O, satd NH<sub>4</sub>Cl, and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (CHCl<sub>3</sub>/MeOH 50:1 to 20:1 (v/v)) to give <i>t</i>-butyl (3<i>S</i>,4<i>R</i>)-3-methyl-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octane-1-carboxylate (<b>119</b>) (9.5 g, 99%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.59 (br s, 1H), 8.09 (s, 1H), 7.12–7.09 (m, 1H), 6.64–6.59 (m, 1H), 4.09–3.66 (m, 5H), 3.39–3.21 (m, 1H), 2.64–2.44 (m, 2H), 2.27–2.06 (m, 1H), 1.36 (s, 3H), 1.21 (s, 6H), 1.11 (d, <i>J</i> = 6.5 Hz, 3H).</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Step 13</h4><div class="NLM_p last">To a solution of this compound obtained in the previous step (9.5 g, 27.7 mmol) in CHCl<sub>3</sub> (50 mL) and MeOH (100 mL) was added 4 N HCl in 1,4-dioxane (50 mL) at room temperature. After being stirred at 60 °C for 0.5 h, the mixture was concentrated to afford 4-((3<i>S</i>,4<i>R</i>)-3-methyl-1,6-diazaspiro[3.4]octan-6-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine hydrochloride (<b>120</b>) (9.3 g, quantitative). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.91 (br s, 1H), 9.97–9.64 (m, 2H), 8.45–8.35 (m, 1H), 7.58–7.47 (m, 1H), 7.04–6.92 (m, 1H), 4.99–4.65 (m, 1H), 4.32–3.21 (m, 7H), 3.04–2.90 (m, 1H), 2.46–2.31 (m, 1H), 1.27 (d, <i>J</i> = 6.0 Hz, 3H).</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> Step 14</h4><div class="NLM_p last">A mixture of this compound obtained in the previous step (8.8 g, 27.7 mmol), 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile (6.8 g, 41.6 mmol), and <i>i</i>-Pr<sub>2</sub>NEt (20.0 mL, 111 mmol) in 1,4-dioxane (100 mL) was stirred at 100 °C for 1 h. After being cooled to room temperature, satd NaHCO<sub>3</sub> was poured into the mixture. The resulting mixture was extracted with CHCl<sub>3</sub>/MeOH (10/1, (v/v)). The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the residue was purified by flash chromatography (CHCl<sub>3</sub>/MeOH 30:1 to 9:1 (v/v)) and successively trituration with <i>n</i>-heptane/EtOH (5/1 (v/v)) to give 3-((3<i>S</i>,4<i>R</i>)-3-methyl-6-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (JTE-052) (6.1 g, 71% yield).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Biological Assay Experimental Procedure</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Enzyme Assay</h4><div class="NLM_p last">Recombinant kinases of human JAK1 (850–end) and Tyk2 (871–end) were purchased from Carna Biosciences Inc. (Kobe, Japan), and those of JAK2 (808–end), JAK3 (781–end) and LCK (full-length) were from Millipore Corporation (Billerica, MA). HTRF KinEASE–TK kit was from Cisbio Bioassays (Codolet, France). Each enzyme reaction was performed with JAK1, JAK2, JAK3, Tyk2, and LCK enzyme (0.54, 0.004, 0.02, 0.09, and 0.008 μg/mL protein, respectively), 1 μM TK-Substrate–Biotin (Cisbio Bioassays), ATP at the<i>K</i><sub>m</sub> specific for each enzyme (30, 20, 5, 30, and 30 μM respectively), 5 mM MgCl, 1 mM dithiothreitol, 50 nM supplement enzymatic buffer (Cisbio Bioassays), and 1% DMSO in 1× enzymatic buffer (Cisbio Bioassays). After the incubation for 60 min at room temperature, enzymatic reaction was stopped by detection reagent containing ethylenediaminetetraacetic acid, Sa-XL665 and TK-Antibody-Cryptate (Cisbio Bioassays), and fluorescence was measured.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> Cellular Assays</h4><div class="NLM_p last">Human peripheral blood was obtained from healthy volunteers with informed consent on the basis of the Declaration of Helsinki. For determination of T cell proliferation induced by IL-2, T cells isolated from human peripheral blood were precultured with 10 μg/mL PHA-M for 3 days and plated in 96-well plates at 1.0 × 10<sup>4</sup> cells/well in the presence of compounds. Following preincubation with the compound for 30 min at 37 °C, the cells were stimulated with 20 ng/mL recombinant human IL-2 and incubated for 3 days at 37 °C. [<sup>3</sup>H]Thymidine (37 kBq) was added during the culture period. Then the cells were harvested with a 96-well harvester and counted in a scintillation counter. For determination of cytotoxicity, fibroblast proliferation was measured. NHLFs were plated in 96-well plates at 1 × 10<sup>3</sup> cells/well in the presence of compound without the addition of cytokines. The cells were then cultured for 3 days, and [<sup>3</sup>H]thymidine uptake was measured as described above. For determination of cytokine signaling, human peripheral blood mononuclear cells (hPBMCs; 3 × 10<sup>6</sup> cells/tube) or A549 cells (5 × 10<sup>5</sup> cells/well) were incubated with a test compound for 30 min at 37 °C and then treated with IL-2 (100 ng/mL), IL-6 (100 ng/mL), IL-23 (100 ng/mL), IFN-α (100 ng/mL), GM-CSF (1 ng/mL), or IL-31 (100 ng/mL) for an additional 15 min. To terminate the stimulation, the cells were fixed with fixation buffer (BD Biosciences, San Jose, CA). The fixed cells were incubated with Perm Buffer II (BD Biosciences) on ice and then incubated with fluorochrome-labeled anti-CD3, anti-CD4, or antiphospho-Stat antibodies for 30 min at room temperature. The cytokine-induced Stat phosphorylation was analyzed and quantified using a Cytomics FC500 (Beckman Coulter Inc., Brea, CA). In the case of IL-23 stimulation, hPBMCs were precultured with 10 μg/mL phytohemagglutinin-M (Sigma-Aldrich Co.) for 3 days to enhance their response to IL-23.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> Animals</h4><div class="NLM_p last">Lewis rats and BN rats were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan). Husbandry conditions were maintained as follows: temperature of 23.0 ± 3.0 °C, humidity of 55 ± 15%, 12 h lighting time (lights on at 8 a.m., lights off at 8 p.m.), CRF-1 pelletized diet (Oriental Yeast Co., Ltd., Tokyo, Japan) supplied ad libitum, and UV-irradiated tap water supplied ad libitum. Animals were treated in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications no. 8023, revised 1978). Animal study protocols were approved by the Institutional Animal Care and Use Committee of the Central Pharmaceutical Research Institute, Japan Tobacco, Inc.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Adjuvant Induced Arthritis in Rat</h4><div class="NLM_p last">Lewis rats were injected with 0.1 mL of 5 mg/mL heat-killed <i>Mycobacterium tuberculosis</i> H37Ra (Difco Laboratories, Detroit, MI) suspended in liquid paraffin into the base of the tail on day 1 under anesthesia. The compounds were given orally once daily from day 1 to day 28. As an index of paw swelling, the increase in hind paw volume from baseline was measured by a water displacement method using a plethysmometer (Muromachi Kikai Co. Ltd., Tokyo, Japan).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> DNCB-Induced Chronic Dermatitis in Rat</h4><div class="NLM_p last">First, 30 μL of 0.5% DNCB dissolved in acetone/olive oil (4:1) were applied to ears of BN rats on days 1, 3, 7, 9, 12, 14, 16, 19, and 21. The compounds were then administered orally or topically once a day from day 1 to day 21. Ear thickness was measured as an index of ear swelling with a digital thickness gauge (Digimatic Indicator; Mitutoyo Corporation, Kawasaki, Japan) 6 h after DNCB application and expressed as the increase in thickness from baseline.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00450" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00450?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00450</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis for compound <b>3</b>–<b>43</b>; HPLC chromatograms of <i>ent</i>-<b>47</b>, <i>ent</i>-<b>54</b>, <i>ent</i>-<b>57</b>, <i>ent</i>-<b>59</b>, <i>ent</i>-<b>60</b> (JTE-052), and <i>ent</i>-<b>61</b>; chiral HPLC chromatograms of <i>ent</i>-<b>47</b>, <i>ent</i>-<b>54</b>, <i>ent</i>-<b>57</b>, <i>ent</i>-<b>59</b>, <i>ent</i>-<b>60</b> (JTE-052), and <i>ent</i>-<b>61</b>; X-ray crystallographic structure of JAK3 (human) in complex with JTE-052 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C3N">7C3N</a>); kinase panel for <i>ent</i>-<b>60</b> (JTE-052); single molecule X-ray crystallographic analysis data for <i>ent</i>-<b>60</b> (JTE-052) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings list (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf">jm0c00450_si_001.pdf (778.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_002.csv">jm0c00450_si_002.csv (2.83 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00450" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoru Noji</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5970-9140" title="Orcid link">http://orcid.org/0000-0002-5970-9140</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#691a081d061b1c470706030029031d470a0604"><span class="__cf_email__" data-cfemail="a7d4c6d3c8d5d289c9c8cdcee7cdd389c4c8ca">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Makoto Shiozaki</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5519-6547" title="Orcid link">http://orcid.org/0000-0001-5519-6547</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bdd0dcd6d2c9d293ced5d4d2c7dcd6d4fdd7c993ded2d0"><span class="__cf_email__" data-cfemail="c8a5a9a3a7bca7e6bba0a1a7b2a9a3a188a2bce6aba7a5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshinori Hara</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomoya Miura</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroshi Yamanaka</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katsuya Maeda</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akimi Hori</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroshi Yamamoto</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shingo Obika</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masafumi Inoue</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasunori Hase</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takuya Orita</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satoki Doi</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsuyoshi Adachi</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Atsuo Tanimoto</span> - <span class="hlFld-Affiliation affiliation">Biological Pharmacological Research Laboratories, Central Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chika Oki</span> - <span class="hlFld-Affiliation affiliation">Biological Pharmacological Research Laboratories, Central Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yukari Kimoto</span> - <span class="hlFld-Affiliation affiliation">Biological Pharmacological Research Laboratories, Central Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshihiro Ogawa</span> - <span class="hlFld-Affiliation affiliation">Biological Pharmacological Research Laboratories, Central Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tamotsu Negoro</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical
Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiromasa Hashimoto</span> - <span class="hlFld-Affiliation affiliation">Chemical
Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i105">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Jun-ichi Haruta and Dr. Hisashi Shinkai for support. We are also grateful to Yasushi Ono, Eita Nagao, and Kenji Fukuda for analytical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine 5′-triphosphate</p></td></tr><tr><td class="NLM_term">LCK</td><td class="NLM_def"><p class="first last">lymphocyte-specific protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">NHLF</td><td class="NLM_def"><p class="first last">normal human lung fibroblasts</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">Fsp<sup>3</sup></td><td class="NLM_def"><p class="first last">fraction sp<sup>3</sup></p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte macrophage colony-stimulating factor</p></td></tr><tr><td class="NLM_term">INF-α</td><td class="NLM_def"><p class="first last">interferon-α</p></td></tr><tr><td class="NLM_term">ROCK-II</td><td class="NLM_def"><p class="first last">Rho associated coiled-coil containing protein kinase II</p></td></tr><tr><td class="NLM_term">AIA</td><td class="NLM_def"><p class="first last">adjuvant-induced arthritis</p></td></tr><tr><td class="NLM_term">DNCB</td><td class="NLM_def"><p class="first last">2,4-dinitrochlorobenzene</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">atopic dermatitis</p></td></tr><tr><td class="NLM_term">DEVEPHOS</td><td class="NLM_def"><p class="first last">2-(dicyclohexylphosphino)-2′-(dimethylamino)biphenyl</p></td></tr><tr><td class="NLM_term">DPEphos</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)diphenyl ether</p></td></tr><tr><td class="NLM_term">WSC·HCl</td><td class="NLM_def"><p class="first last">water-soluble carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HOBt·H<sub>2</sub>O</td><td class="NLM_def"><p class="first last">1-hydroxy-1<i>H</i>-benzotriazole hydrate</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic anhydride</p></td></tr><tr><td class="NLM_term">KHMDS</td><td class="NLM_def"><p class="first last">potassium hexamethyldisilazide</p></td></tr><tr><td class="NLM_term">LiHMDS</td><td class="NLM_def"><p class="first last">lithium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">DPPA</td><td class="NLM_def"><p class="first last">diphenylphosphoryl azide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethyl-4-aminopyridine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i107">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eyerich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyerich, S.</span></span> <span> </span><span class="NLM_article-title">Immune response patterns in non-communicable inflammatory skin diseases</span>. <i>J. Eur. Acad. Dermatol. Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1111/jdv.14673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fjdv.14673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=29114938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ovFCiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=692-703&author=K.+Eyerichauthor=S.+Eyerich&title=Immune+response+patterns+in+non-communicable+inflammatory+skin+diseases&doi=10.1111%2Fjdv.14673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Immune response patterns in non-communicable inflammatory skin diseases</span></div><div class="casAuthors">Eyerich K; Eyerich S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the European Academy of Dermatology and Venereology : JEADV</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">692-703</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-communicable inflammatory skin diseases (ncISD) such as psoriasis or atopic eczema are a major cause of global disease burden.  Due to their impact and complexity, ncISD represent a major challenge of modern medicine.  Dermatology textbooks describe more than 100 different ncISD based on clinical phenotype and histological architecture.  In the last decades, this historical description was complemented by increasing molecular knowledge - and this knowledge is now being translated into specific therapeutics.  Combining the enormous advances made in lymphocyte immunology and molecular genetics with clinical and histological phenotyping reveals six immune response patterns of the skin - type I immune cells cause the lichenoid pattern characterized by immune-mediated cell death of keratinocytes; type II immune cells underlie the eczematous pattern with impaired epidermal barrier, infection and eosinophils as well as the bullous pattern with loss of epithelial integrity; Th17 cells and ILC3 mediate the psoriatic pattern characterized by acanthosis, high metabolic activity and neutrophils; dysbalance of regulatory T cells causes either the fibrogenic pattern with rarefication of cells and dermal thickening or the granulomatous pattern defined by formation of granulomas.  With more and more specific therapeutic agents approved, classifying ncISD also according to their immune response pattern will become highly relevant.  This review defines the six immune response patterns of ncISD and highlights therapeutic strategies targeting key lymphocyte mediators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLKUvEbSnBDpSWdIdmEou5fW6udTcc2eZZZzMQIpE-Lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ovFCiuw%253D%253D&md5=c77cce34f1f25f922e4cc176dded5944</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fjdv.14673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjdv.14673%26sid%3Dliteratum%253Aachs%26aulast%3DEyerich%26aufirst%3DK.%26aulast%3DEyerich%26aufirst%3DS.%26atitle%3DImmune%2520response%2520patterns%2520in%2520non-communicable%2520inflammatory%2520skin%2520diseases%26jtitle%3DJ.%2520Eur.%2520Acad.%2520Dermatol.%2520Venereol.%26date%3D2018%26volume%3D32%26spage%3D692%26epage%3D703%26doi%3D10.1111%2Fjdv.14673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resneck, J. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognia, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Beek, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sober, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerenz, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith Begolka, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyano, J. V.</span></span> <span> </span><span class="NLM_article-title">The burden of skin disease in the United States</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">958</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2016.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaad.2016.12.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=28259441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BC1czivVSiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=958-972&author=H.+W.+Limauthor=S.+A.+B.+Collinsauthor=J.+J.+S.+Resneckauthor=J.+L.+Bologniaauthor=J.+A.+Hodgeauthor=T.+A.+Rohrerauthor=M.+J.+Van+Beekauthor=D.+J.+Margolisauthor=A.+J.+Soberauthor=M.+A.+Weinstockauthor=D.+R.+Nerenzauthor=W.+Smith+Begolkaauthor=J.+V.+Moyano&title=The+burden+of+skin+disease+in+the+United+States&doi=10.1016%2Fj.jaad.2016.12.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The burden of skin disease in the United States</span></div><div class="casAuthors">Lim Henry W; Collins Scott A B; Resneck Jack S Jr; Bolognia Jean L; Hodge Julie A; Rohrer Thomas A; Van Beek Marta J; Margolis David J; Sober Arthur J; Weinstock Martin A; Nerenz David R; Smith Begolka Wendy; Moyano Jose V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">958-972.e2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the publication of the last US national burden of skin disease report in 2006, there have been substantial changes in the practice of dermatology and the US health care system.  These include the development of new treatment modalities, marked increases in the cost of medications, increasingly complex payer rules and regulations, and an aging of the US population.  Recognizing the need for up-to-date data to inform researchers, policy makers, public stakeholders, and health care providers about the impact of skin disease on patients and US society, the American Academy of Dermatology produced a new national burden of skin disease report.  Using 2013 claims data from private and governmental insurance providers, this report analyzed the prevalence, cost, and mortality attributable to 24 skin disease categories in the US population.  In this first of 3 articles, the presented data demonstrate that nearly 85 million Americans were seen by a physician for at least 1 skin disease in 2013.  This led to an estimated direct health care cost of $75 billion and an indirect lost opportunity cost of $11 billion.  Further, mortality was noted in half of the 24 skin disease categories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrK0VuDKPusWHOrQ6qeX-mfW6udTcc2eZZZzMQIpE-Lrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czivVSiuw%253D%253D&md5=6885422c743b0171162dcfed2b5ff3dd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.12.043%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DH.%2BW.%26aulast%3DCollins%26aufirst%3DS.%2BA.%2BB.%26aulast%3DResneck%26aufirst%3DJ.%2BJ.%2BS.%26aulast%3DBolognia%26aufirst%3DJ.%2BL.%26aulast%3DHodge%26aufirst%3DJ.%2BA.%26aulast%3DRohrer%26aufirst%3DT.%2BA.%26aulast%3DVan%2BBeek%26aufirst%3DM.%2BJ.%26aulast%3DMargolis%26aufirst%3DD.%2BJ.%26aulast%3DSober%26aufirst%3DA.%2BJ.%26aulast%3DWeinstock%26aufirst%3DM.%2BA.%26aulast%3DNerenz%26aufirst%3DD.%2BR.%26aulast%3DSmith%2BBegolka%26aufirst%3DW.%26aulast%3DMoyano%26aufirst%3DJ.%2BV.%26atitle%3DThe%2520burden%2520of%2520skin%2520disease%2520in%2520the%2520United%2520States%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2017%26volume%3D76%26spage%3D958%26epage%3D972%26doi%3D10.1016%2Fj.jaad.2016.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span> <span> </span><span class="NLM_article-title">The translational revolution and use of biologics in patients with inflammatory skin diseases</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2014.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaci.2014.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=25541257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1ersbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=324-336&author=S.+Nodaauthor=J.+G.+Kruegerauthor=E.+Guttman-Yassky&title=The+translational+revolution+and+use+of+biologics+in+patients+with+inflammatory+skin+diseases&doi=10.1016%2Fj.jaci.2014.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The translational revolution and use of biologics in patients with inflammatory skin diseases</span></div><div class="casAuthors">Noda, Shinji; Krueger, James G.; Guttman-Yassky, Emma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-336</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation.  Although T-cell infiltration characterizes both diseases, T-cell polarization differs.  Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/TH17 polarized.  In patients with AD, although therapeutic development is approx. a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (TH2, TH22, and IL-23/TH17).  These clin. trials and subsequent mol. analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZC48i_pyLyLVg90H21EOLACvtfcHk0lglaUsKbrha3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1ersbw%253D&md5=8dc31b8b2cc1a0bab77b543818c1dcff</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2014.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2014.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DNoda%26aufirst%3DS.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26atitle%3DThe%2520translational%2520revolution%2520and%2520use%2520of%2520biologics%2520in%2520patients%2520with%2520inflammatory%2520skin%2520diseases%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D135%26spage%3D324%26epage%3D336%26doi%3D10.1016%2Fj.jaci.2014.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasparakis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haase, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestle, F. O.</span></span> <span> </span><span class="NLM_article-title">Mechanisms regulating skin immunity and inflammation</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1038/nri3646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnri3646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=24722477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlajtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=289-301&author=M.+Pasparakisauthor=I.+Haaseauthor=F.+O.+Nestle&title=Mechanisms+regulating+skin+immunity+and+inflammation&doi=10.1038%2Fnri3646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms regulating skin immunity and inflammation</span></div><div class="casAuthors">Pasparakis, Manolis; Haase, Ingo; Nestle, Frank O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">289-301</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immune responses in the skin are important for host defense against pathogenic microorganisms.  However, dysregulated immune reactions can cause chronic inflammatory skin diseases.  Extensive crosstalk between the different cellular and microbial components of the skin regulates local immune responses to ensure efficient host defense, to maintain and restore homeostasis, and to prevent chronic disease.  In this Review, we discuss recent findings that highlight the complex regulatory networks that control skin immunity, and we provide new paradigms for the mechanisms that regulate skin immune responses in host defense and in chronic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6YV0xbMejgLVg90H21EOLACvtfcHk0lglaUsKbrha3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlajtrk%253D&md5=383246bd46717d6695fc4b6bcd363d49</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnri3646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3646%26sid%3Dliteratum%253Aachs%26aulast%3DPasparakis%26aufirst%3DM.%26aulast%3DHaase%26aufirst%3DI.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26atitle%3DMechanisms%2520regulating%2520skin%2520immunity%2520and%2520inflammation%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D14%26spage%3D289%26epage%3D301%26doi%3D10.1038%2Fnri3646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, N.</span></span> <span> </span><span class="NLM_article-title">Atopic dermatitis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)00149-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2FS0140-6736%2815%2900149-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=26377142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BC283jtVShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=1109-1122&author=S.+Weidingerauthor=N.+Novak&title=Atopic+dermatitis&doi=10.1016%2FS0140-6736%2815%2900149-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic dermatitis</span></div><div class="casAuthors">Weidinger Stephan; Novak Natalija</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10023</span>),
    <span class="NLM_cas:pages">1109-1122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (also known as atopic eczema) is a chronic inflammatory skin disease that is characterised by intense itching and recurrent eczematous lesions.  Although it most often starts in infancy and affects two of ten children, it is also highly prevalent in adults.  It is the leading non-fatal health burden attributable to skin diseases, inflicts a substantial psychosocial burden on patients and their relatives, and increases the risk of food allergy, asthma, allergic rhinitis, other immune-mediated inflammatory diseases, and mental health disorders.  Originally regarded as a childhood disorder mediated by an imbalance towards a T-helper-2 response and exaggerated IgE responses to allergens, it is now recognised as a lifelong disposition with variable clinical manifestations and expressivity, in which defects of the epidermal barrier are central.  Present prevention and treatment focus on restoration of epidermal barrier function, which is best achieved through the use of emollients.  Topical corticosteroids are still the first-line therapy for acute flares, but they are also used proactively along with topical calcineurin inhibitors to maintain remission.  Non-specific immunosuppressive drugs are used in severe refractory cases, but targeted disease-modifying drugs are being developed.  We need to improve understanding of the heterogeneity of the disease and its subtypes, the role of atopy and autoimmunity, the mechanisms behind disease-associated itch, and the comparative effectiveness and safety of therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCv4mFAtl09MrRqEXsZufAfW6udTcc2eY6WxJcRzLN6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jtVShsQ%253D%253D&md5=02bc2d67207d07d0a6b24f1da996792e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2900149-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252900149-X%26sid%3Dliteratum%253Aachs%26aulast%3DWeidinger%26aufirst%3DS.%26aulast%3DNovak%26aufirst%3DN.%26atitle%3DAtopic%2520dermatitis%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26spage%3D1109%26epage%3D1122%26doi%3D10.1016%2FS0140-6736%2815%2900149-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boehncke, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, M. P.</span></span> <span> </span><span class="NLM_article-title">Psoriasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)61909-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2FS0140-6736%2814%2961909-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=26025581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpt1Sht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=983-994&author=W.+H.+Boehnckeauthor=M.+P.+Schon&title=Psoriasis&doi=10.1016%2FS0140-6736%2814%2961909-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Psoriasis</span></div><div class="casAuthors">Boehncke, Wolf-Henning; Schon, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9997</span>),
    <span class="NLM_cas:pages">983-994</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Psoriasis is an immune-mediated, genetic disease manifesting in the skin or joints or both.  A diverse team of clinicians with a range of expertise is often needed to treat the disease.  Psoriasis provides many challenges including high prevalence, chronicity, disfiguration, disability, and assocd. comorbidity.  Understanding the role of immune function in psoriasis and the interplay between the innate and adaptive immune system has helped to manage this complex disease, which affects patients far beyond the skin.  In this Seminar, we highlight the clin. diversity of psoriasis and assocd. comorbid diseases.  We describe recent developments in psoriasis epidemiol., pathogenesis, and genetics to better understand present trends in psoriasis management.  Our key objective is to raise awareness of the complexity of this multifaceted disease, the potential of state-of-the-art therapeutic approaches, and the need for early diagnosis and comprehensive management of patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2TaF6yGN8bVg90H21EOLACvtfcHk0ljDdIDDGg1krQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpt1Sht7s%253D&md5=616839f94122d1c1d167b9bd068283bd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961909-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961909-7%26sid%3Dliteratum%253Aachs%26aulast%3DBoehncke%26aufirst%3DW.%2BH.%26aulast%3DSchon%26aufirst%3DM.%2BP.%26atitle%3DPsoriasis%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D983%26epage%3D994%26doi%3D10.1016%2FS0140-6736%2814%2961909-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bewley, A.</span></span> <span> </span><span class="NLM_article-title">Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2133.2008.08479.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fj.1365-2133.2008.08479.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=18294314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ksFansQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2008&pages=917-920&author=A.+Bewley&title=Expert+consensus%3A+time+for+a+change+in+the+way+we+advise+our+patients+to+use+topical+corticosteroids&doi=10.1111%2Fj.1365-2133.2008.08479.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids</span></div><div class="casAuthors">Bewley A</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">917-20</span>
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    </div><div class="casAbstract">Topical corticosteroids form the mainstay of treatment for many skin conditions.  If used appropriately, they are safe and effective, and side-effects are generally uncommon.  Current advice to patients to apply topical corticosteroid preparations 'sparingly' or 'thinly' contributes to 'steroid phobia', increasing the risk of poor clinical response and treatment failure.  Such cautionary advice also overlooks the fact that the vast majority of patients are prescribed topical corticosteroids of mild potency for which the evidence suggests that the risk of harm is minimal.  In the patient's mind, the current advice groups all steroids together regardless of their potential for adverse effects.  The advice also tends to reinforce an erroneous concern that the risks from topical corticosteroids may be similar to those from systemic corticosteroids.  We propose a change to make the pharmacy labelling of topical corticosteroids more accurately reflect the low risk of harm from corticosteroids of low to moderate potency and the importance of applying sufficient medication to achieve a satisfactory clinical response.  This change could provide the focus for updated, evidence-based education for healthcare professionals in prescribing of topical corticosteroids and help in the provision of more appropriate advice to patients.  We recommend that patients are informed that treatment should not exceed prescribed quantities, and continuing treatment should be under careful medical supervision.  We also recommend that topical corticosteroid products include clear 'fingertip unit' instructions, preferably with images of a 'fingertip unit' and a chart to show the number of units required for specific areas of the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnM1hKrqgj0vSAs_PE1QvifW6udTcc2eakEsgzY7aMD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ksFansQ%253D%253D&md5=1dcea70b7d942fe4065227d50436431c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2008.08479.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2008.08479.x%26sid%3Dliteratum%253Aachs%26aulast%3DBewley%26aufirst%3DA.%26atitle%3DExpert%2520consensus%253A%2520time%2520for%2520a%2520change%2520in%2520the%2520way%2520we%2520advise%2520our%2520patients%2520to%2520use%2520topical%2520corticosteroids%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2008%26volume%3D158%26spage%3D917%26epage%3D920%26doi%3D10.1111%2Fj.1365-2133.2008.08479.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alomar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deleuran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink-Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipozencic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oranje, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwennesen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidenari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stingl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szalai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szepietowski, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taieb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werfel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darsow, U.</span></span> <span> </span><span class="NLM_article-title">Guidelines for treatment of atopic eczema (atopic dermatitis) part I</span>. <i>J. Eur. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1060</span>, <span class="refDoi"> DOI: 10.1111/j.1468-3083.2012.04635.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fj.1468-3083.2012.04635.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=22805051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKjtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1045-1060&author=J.+Ringauthor=A.+Alomarauthor=T.+Bieberauthor=M.+Deleuranauthor=A.+Fink-Wagnerauthor=C.+Gelmettiauthor=U.+Gielerauthor=J.+Lipozencicauthor=T.+Lugerauthor=A.+P.+Oranjeauthor=T.+Schaferauthor=T.+Schwennesenauthor=S.+Seidenariauthor=D.+Simonauthor=S.+Standerauthor=G.+Stinglauthor=S.+Szalaiauthor=J.+C.+Szepietowskiauthor=A.+Taiebauthor=T.+Werfelauthor=A.+Wollenbergauthor=U.+Darsow&title=Guidelines+for+treatment+of+atopic+eczema+%28atopic+dermatitis%29+part+I&doi=10.1111%2Fj.1468-3083.2012.04635.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines for treatment of atopic eczema (atopic dermatitis) Part I</span></div><div class="casAuthors">Ring, J.; Alomar, A.; Bieber, T.; Deleuran, M.; Fink-Wagner, A.; Gelmetti, C.; Gieler, U.; Lipozencic, J.; Luger, T.; Oranje, A. P.; Schaefer, T.; Schwennesen, T.; Seidenari, S.; Simon, D.; Staender, S.; Stingl, G.; Szalai, S.; Szepietowski, J. C.; Taieb, A.; Werfel, T.; Wollenberg, A.; Darsow, U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the European Academy of Dermatology and Venereology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1045-1060</span>CODEN:
                <span class="NLM_cas:coden">JEAVEQ</span>;
        ISSN:<span class="NLM_cas:issn">1468-3083</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national std. Appraisal of Guidelines Research and Evaluation.  The consensus process consisted of a nominal group process and a DELPHI procedure.  Management of AE must consider the individual symptomatic variability of the disease.  Basic therapy is focused on hydrating topical treatment, and avoidance of specific and unspecific provocation factors.  Anti-inflammatory treatment based on topical glucocorticosteroids and topical calcineurin inhibitors (TCI) is used for exacerbation management and more recently for proactive therapy in selected cases.  Topical corticosteroids remain the mainstay of therapy, but the TCI tacrolimus and pimecrolimus are preferred in certain locations.  Systemic immune-suppressive treatment is an option for severe refractory cases.  Microbial colonization and superinfection may induce disease exacerbation and can justify addnl. antimicrobial treatment.  Adjuvant therapy includes UV irradn. preferably with UVA1 wavelength or UVB 311 nm.  Dietary recommendations should be specific and given only in diagnosed individual food allergy.  Allergen-specific immunotherapy to aeroallergens may be useful in selected cases.  Stress-induced exacerbations may make psychosomatic counselling recommendable.  "Eczema school" educational programs have been proven to be helpful.  Pruritus is targeted with the majority of the recommended therapies, but some patients need addnl. antipruritic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDDo36QS4CF7Vg90H21EOLACvtfcHk0ljDdIDDGg1krQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKjtbrP&md5=2222a565d3ef4eb2c7118cfa00316c4a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-3083.2012.04635.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-3083.2012.04635.x%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DJ.%26aulast%3DAlomar%26aufirst%3DA.%26aulast%3DBieber%26aufirst%3DT.%26aulast%3DDeleuran%26aufirst%3DM.%26aulast%3DFink-Wagner%26aufirst%3DA.%26aulast%3DGelmetti%26aufirst%3DC.%26aulast%3DGieler%26aufirst%3DU.%26aulast%3DLipozencic%26aufirst%3DJ.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DOranje%26aufirst%3DA.%2BP.%26aulast%3DSchafer%26aufirst%3DT.%26aulast%3DSchwennesen%26aufirst%3DT.%26aulast%3DSeidenari%26aufirst%3DS.%26aulast%3DSimon%26aufirst%3DD.%26aulast%3DStander%26aufirst%3DS.%26aulast%3DStingl%26aufirst%3DG.%26aulast%3DSzalai%26aufirst%3DS.%26aulast%3DSzepietowski%26aufirst%3DJ.%2BC.%26aulast%3DTaieb%26aufirst%3DA.%26aulast%3DWerfel%26aufirst%3DT.%26aulast%3DWollenberg%26aufirst%3DA.%26aulast%3DDarsow%26aufirst%3DU.%26atitle%3DGuidelines%2520for%2520treatment%2520of%2520atopic%2520eczema%2520%2528atopic%2520dermatitis%2529%2520part%2520I%26jtitle%3DJ.%2520Eur.%2520Acad.%2520Dermatol.%26date%3D2012%26volume%3D26%26spage%3D1045%26epage%3D1060%26doi%3D10.1111%2Fj.1468-3083.2012.04635.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmets, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfand, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, J. Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhees, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutner, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, R.</span></span> <span> </span><span class="NLM_article-title">Guidelines of care for the management of psoriasis and psoriatic arthritis section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2008.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaad.2008.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=19217694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BD1M3hsVWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=643-659&author=A.+Menterauthor=N.+J.+Kormanauthor=C.+A.+Elmetsauthor=S.+R.+Feldmanauthor=J.+M.+Gelfandauthor=K.+B.+Gordonauthor=A.+Gottliebauthor=J.+Y.+M.+Kooauthor=M.+Lebwohlauthor=H.+W.+Limauthor=A.+S.+Van+Voorheesauthor=K.+R.+Beutnerauthor=R.+Bhushan&title=Guidelines+of+care+for+the+management+of+psoriasis+and+psoriatic+arthritis+section+3.+Guidelines+of+care+for+the+management+and+treatment+of+psoriasis+with+topical+therapies&doi=10.1016%2Fj.jaad.2008.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</span></div><div class="casAuthors">Menter Alan; Korman Neil J; Elmets Craig A; Feldman Steven R; Gelfand Joel M; Gordon Kenneth B; Gottlieb Alice; Koo John Y M; Lebwohl Mark; Lim Henry W; Van Voorhees Abby S; Beutner Karl R; Bhushan Reva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">643-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Psoriasis is a common, chronic, inflammatory, multi-system disease with predominantly skin and joint manifestations affecting approximately 2% of the population.  In this third of 6 sections of the guidelines of care for psoriasis, we discuss the use of topical medications for the treatment of psoriasis.  The majority of patients with psoriasis have limited disease (<5% body surface area involvement) and can be treated with topical agents, which generally provide a high efficacy-to-safety ratio.  Topical agents may also be used adjunctively for patients with more extensive psoriasis undergoing therapy with either ultraviolet light, systemic or biologic medications.  However, the use of topical agents as monotherapy in the setting of extensive disease or in the setting of limited, but recalcitrant, disease is not routinely recommended.  Treatment should be tailored to meet individual patients' needs.  We will discuss the efficacy and safety of as well as offer recommendations for the use of topical corticosteroids, vitamin D analogues, tazarotene, tacrolimus, pimecrolimus, emollients, salicylic acid, anthralin, coal tar, as well as combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNrA_ozK6QJHy-c-E1v-fmfW6udTcc2ebrJfLQ0tC9H7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3hsVWnug%253D%253D&md5=c4975aee4050bd186fb5ff428a8f23bd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2008.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2008.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DKorman%26aufirst%3DN.%2BJ.%26aulast%3DElmets%26aufirst%3DC.%2BA.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGelfand%26aufirst%3DJ.%2BM.%26aulast%3DGordon%26aufirst%3DK.%2BB.%26aulast%3DGottlieb%26aufirst%3DA.%26aulast%3DKoo%26aufirst%3DJ.%2BY.%2BM.%26aulast%3DLebwohl%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DH.%2BW.%26aulast%3DVan%2BVoorhees%26aufirst%3DA.%2BS.%26aulast%3DBeutner%26aufirst%3DK.%2BR.%26aulast%3DBhushan%26aufirst%3DR.%26atitle%3DGuidelines%2520of%2520care%2520for%2520the%2520management%2520of%2520psoriasis%2520and%2520psoriatic%2520arthritis%2520section%25203.%2520Guidelines%2520of%2520care%2520for%2520the%2520management%2520and%2520treatment%2520of%2520psoriasis%2520with%2520topical%2520therapies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2009%26volume%3D60%26spage%3D643%26epage%3D659%26doi%3D10.1016%2Fj.jaad.2008.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paller, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic pipeline for atopic dermatitis: end of the drought?</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">633</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2017.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaci.2017.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=28887947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BC1cbmtlSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=633-643&author=A.+S.+Pallerauthor=K.+Kabashimaauthor=T.+Bieber&title=Therapeutic+pipeline+for+atopic+dermatitis%3A+end+of+the+drought%3F&doi=10.1016%2Fj.jaci.2017.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic pipeline for atopic dermatitis: End of the drought?</span></div><div class="casAuthors">Paller Amy S; Kabashima Kenji; Bieber Thomas</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">633-643</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic immunosuppressants.  The pipeline of more targeted topical and systemic therapies is expanding based on our growing understanding of the mechanism for AD and is particularly focused on suppressing the skewed immune activation.  Most agents are in phase 2 clinical trials.  Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available in late 2016 in the United States for mild-to-moderate AD, with other PDE4 inhibitors, an agonist of the aryl hydrocarbon receptor, Janus kinase inhibitors, and commensal organisms also in trials for topical application.  The first highly effective mAb for AD, dupilumab, targets the IL-4/IL-13 receptor and was approved in early 2017 in the United States for moderate-to-severe adult AD.  Other biologics similarly inhibit TH2 cytokines (thymic stromal lymphopoietin, IL-4, IL-5, IL-13, and the itch-specific cytokine IL-31 and their receptors) or TH22/TH17 cytokines, levels of which are increased in lesional skin.  Orally administered small-molecule inhibitors that suppress inflammation (targeting chemoattractant receptor-homologous molecules expressed on TH2 lymphocytes, PDE4, the histamine 4 receptor, and Janus kinase) or specifically itching (eg, NK1R inhibitors) are also being studied.  Comparing biomarkers with individual responses to experimental agents will help to determine subphenotypes within AD that predict prognosis and treatment responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWd6Thbey6Prt7lRqEFUJVfW6udTcc2ebrJfLQ0tC9H7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbmtlSrsQ%253D%253D&md5=66000cb56b3e306b9d09a2bba7cb9135</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2017.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2017.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DPaller%26aufirst%3DA.%2BS.%26aulast%3DKabashima%26aufirst%3DK.%26aulast%3DBieber%26aufirst%3DT.%26atitle%3DTherapeutic%2520pipeline%2520for%2520atopic%2520dermatitis%253A%2520end%2520of%2520the%2520drought%253F%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2017%26volume%3D140%26spage%3D633%26epage%3D643%26doi%3D10.1016%2Fj.jaci.2017.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengge, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzicka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cork, M. J.</span></span> <span> </span><span class="NLM_article-title">Adverse effects of topical glucocorticosteroids</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2005.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaad.2005.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=16384751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BD2MnpsF2isw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=1-15&author=U.+R.+Henggeauthor=T.+Ruzickaauthor=R.+A.+Schwartzauthor=M.+J.+Cork&title=Adverse+effects+of+topical+glucocorticosteroids&doi=10.1016%2Fj.jaad.2005.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of topical glucocorticosteroids</span></div><div class="casAuthors">Hengge Ulrich R; Ruzicka Thomas; Schwartz Robert A; Cork Michael J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15; quiz 16-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Topical corticosteroids were introduced into medicine about 50 years ago.  They represent a significant milestone in dermatologic therapy.  Despite encouragement to report observed adverse drug reactions, the clinical practice of reporting is poor and incomplete.  Likewise, adverse effects and safety of topical corticosteroids are neglected in the medical literature.  The authors provide an updated review of their adverse-effect profile.  Children are more prone to the development of systemic reactions to topically applied medication because of their higher ratio of total body surface area to body weight.  Cutaneous adverse effects occur regularly with prolonged treatment and are dependent on the chemical nature of the drug, the vehicle, and the location of its application.  The most frequent adverse effects include atrophy, striae, rosacea, perioral dermatitis, acne, and purpura.  Those that occur with lower frequency include hypertrichosis, pigmentation alterations, delayed wound healing, and exacerbation of skin infections.  Of particular interest is the rate of contact sensitization against corticosteroids, which is considerably higher than generally believed.  Systemic reactions such as hyperglycemia, glaucoma, and adrenal insufficiency have also been reported to follow topical application.  The authors provide an updated review of local and systemic adverse effects upon administration of topical corticosteroids, including the latest FDA report on the safety of such steroids in children.  LEARNING OBJECTIVE:  At the completion of this learning activity, participants should be familiar with topical corticosteroids and their proper use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrXh2cb8QSTLqxQ2mb9Pu8fW6udTcc2ebrJfLQ0tC9H7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnpsF2isw%253D%253D&md5=08f66f7a68bc5d643bd4198f22a7fb53</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2005.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2005.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DHengge%26aufirst%3DU.%2BR.%26aulast%3DRuzicka%26aufirst%3DT.%26aulast%3DSchwartz%26aufirst%3DR.%2BA.%26aulast%3DCork%26aufirst%3DM.%2BJ.%26atitle%3DAdverse%2520effects%2520of%2520topical%2520glucocorticosteroids%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2006%26volume%3D54%26spage%3D1%26epage%3D15%26doi%3D10.1016%2Fj.jaad.2005.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, G. R.</span></span> <span> </span><span class="NLM_article-title">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1421</span>, <span class="refDoi"> DOI: 10.1126/science.8197455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1126%2Fscience.8197455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=8197455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=1415-1421&author=J.+E.+J.+Darnellauthor=I.+M.+Kerrauthor=G.+R.+Stark&title=Jak-STAT+pathways+and+transcriptional+activation+in+response+to+IFNs+and+other+extracellular+signaling+proteins&doi=10.1126%2Fscience.8197455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span></div><div class="casAuthors">Darnell, James E., Jr.; Kerr, Ian M.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5164</span>),
    <span class="NLM_cas:pages">1415-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 97 refs.  Through the study of transcriptional activation in response to interferon α (IFN-α) and interferon γ (IFN-γ), a previously unrecognized direct signal transduction pathway to the nucleus has been uncovered: IFN-receptor interaction at the cell surface leads to the activation of kinases of the Jak family that then phosphorylate substrate proteins called STATs (signal transducers and activators of transcription).  The phosphorylated STAT proteins move to the nucleus, bind specific DNA elements, and direct transcription.  Recognition of the mols. involved in the IFN-α and IFN-γ pathway has led to discoveries that a no. of STAT family members exist and that other polypeptide ligands also use the Jak-STAT mols. in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64rvN_qWlmLVg90H21EOLACvtfcHk0lgbgDQsE3OZrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D&md5=f63d2c7bb3c1aeca6f36fef38aff713c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.8197455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8197455%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DJak-STAT%2520pathways%2520and%2520transcriptional%2520activation%2520in%2520response%2520to%2520IFNs%2520and%2520other%2520extracellular%2520signaling%2520proteins%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D1415%26epage%3D1421%26doi%3D10.1126%2Fscience.8197455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R. D.</span></span> <span> </span><span class="NLM_article-title">Cytokine signaling in 2002: new surprises in the Jak/Stat pathway</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">Suppl</span>),  <span class="NLM_fpage">S121</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00701-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2FS0092-8674%2802%2900701-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=11983158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1equr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=S121-31&issue=Suppl&author=J.+J.+O%E2%80%99Sheaauthor=M.+Gadinaauthor=R.+D.+Schreiber&title=Cytokine+signaling+in+2002%3A+new+surprises+in+the+Jak%2FStat+pathway&doi=10.1016%2FS0092-8674%2802%2900701-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine signaling in 2002: New surprises in the Jak/Stat pathway</span></div><div class="casAuthors">O'Shea, John J.; Gadina, Massimo; Schreiber, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Rev. Suppl.</span>),
    <span class="NLM_cas:pages">S121-S131</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The importance of Jak-Stat pathway signaling in regulating cytokine-dependent gene expression and cellular development/survival is well established.  Nevertheless, advances continue to be made in defining Jak-Stat pathway effects on different cellular processes and in different organisms.  This review focuses on recent advances in the field and highlights some of the most active areas of Jak-Stat pathway research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjCEpjQr_xWrVg90H21EOLACvtfcHk0lgbgDQsE3OZrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1equr0%253D&md5=257fe5cb5ed0070a8b05c8e5adf65ad5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900701-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900701-8%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DCytokine%2520signaling%2520in%25202002%253A%2520new%2520surprises%2520in%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DCell%26date%3D2002%26volume%3D109%26issue%3DSuppl%26spage%3DS121%26epage%3D31%26doi%3D10.1016%2FS0092-8674%2802%2900701-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK–STAT singnaling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK%E2%80%93STAT+singnaling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lj5aWIck7hhhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK%25E2%2580%2593STAT%2520singnaling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R.</span></span> <span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lj5aWIck7hhhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giliani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugazio, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candotti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sheai, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vezzoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notarangelo, L. D.</span></span> <span> </span><span class="NLM_article-title">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1038/377065a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2F377065a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=7659163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=65-68&author=P.+Macchiauthor=A.+Villaauthor=S.+Gilianiauthor=M.+G.+Saccoauthor=A.+Frattiniauthor=F.+Portaauthor=A.+G.+Ugazioauthor=J.+A.+Johnstonauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Sheaiauthor=P.+Vezzoniauthor=L.+D.+Notarangelo&title=Mutations+of+Jak-3+gene+in+patients+with+autosomal+severe+combined+immune+deficiency+%28SCID%29&doi=10.1038%2F377065a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span></div><div class="casAuthors">Macchi, Paolo; Villa, Anna; Giliani, Silvia; Sacco, Maria G.; Frattini, Annalisa; Porta, Fulvio; Ugazio, Alberto G.; Johnston, James A.; Candotti, Fabio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6544</span>),
    <span class="NLM_cas:pages">65-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Severe combined immune deficiency (SCID) represents a heterogeneous group of hereditary diseases.  Mutations in the common γ-chain (γc), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID, which is usually assocd. with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID).  The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown.  The Jak-3 protein kinase has been found to assoc. with the γc-chain-contg. cytokine receptors.  Therefore Jak-3 or other STAT proteins with which it interacts are candidate genes for autosomal recessive T- B+ SCID.  Here the authors investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3.  One patient carries a mutation (Tyr100→Cys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes.  The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination.  Both mutations resulted in markedly reduced levels of Jak-3.  These findings show that abnormalities in the Jak/STAT signaling pathway can account for SCID in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWFs-Wbegq7Vg90H21EOLACvtfcHk0lj5aWIck7hhhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D&md5=ac5a7064e6c3361c8906813770e1b6d9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2F377065a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377065a0%26sid%3Dliteratum%253Aachs%26aulast%3DMacchi%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DSacco%26aufirst%3DM.%2BG.%26aulast%3DFrattini%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DUgazio%26aufirst%3DA.%2BG.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Sheai%26aufirst%3DJ.%2BJ.%26aulast%3DVezzoni%26aufirst%3DP.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DMutations%2520of%2520Jak-3%2520gene%2520in%2520patients%2520with%2520autosomal%2520severe%2520combined%2520immune%2520deficiency%2520%2528SCID%2529%26jtitle%3DNature%26date%3D1995%26volume%3D377%26spage%3D65%26epage%3D68%26doi%3D10.1038%2F377065a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conklyn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koslov, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milici, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckius, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodworth, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaweco, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beals, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagouras, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magna, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltarelli, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelms, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Des Etages, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finco-Kent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paniagua, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borie, D. C.</span></span> <span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>302</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1126/science.1087061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor&doi=10.1126%2Fscience.1087061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lhroji3Csvmjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878%26doi%3D10.1126%2Fscience.1087061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lhroji3Csvmjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0ljJyAWCo59N1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0ljJyAWCo59N1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombs, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span> <span> </span><span class="NLM_article-title">The Safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis. Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+F.+Zerbiniauthor=S.+H.+Zwillich&title=The+Safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis.+Results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0ljAE-EMGxp2Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%2BF.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520Safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis.%2520Results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0ljAE-EMGxp2Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollman, P. A.</span></span> <span> </span><span class="NLM_article-title">The maximal affinity of ligands</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">9997</span>– <span class="NLM_lpage">10002</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.18.9997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1073%2Fpnas.96.18.9997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10468550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFehu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=9997-10002&author=I.+D.+Kuntzauthor=K.+Chenauthor=K.+A.+Sharpauthor=P.+A.+Kollman&title=The+maximal+affinity+of+ligands&doi=10.1073%2Fpnas.96.18.9997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The maximal affinity of ligands</span></div><div class="casAuthors">Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9997-10002</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We explore the question of what are the best ligands for macromol. targets.  A survey of exptl. data on a large no. of the strongest-binding ligands indicates that the free energy of binding increases with the no. of nonhydrogen atoms with an initial slope of ≈-1.5 kcal/mol (1 cal = 4.18 J) per atom.  For ligands that contain more than 15 nonhydrogen atoms, the free energy of binding increases very little with relative mol. mass.  This nonlinearity is largely ascribed to nonthermodynamic factors.  An anal. of the dominant interactions suggests that van der Waals interactions and hydrophobic effects provide a reasonable basis for understanding binding affinities across the entire set of ligands.  Interesting outliers that bind unusually strongly on a per atom basis include metal ions, covalently attached ligands, and a few well known complexes such as biotin-avidin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0L6KZhR0TxbVg90H21EOLACvtfcHk0ljAE-EMGxp2Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFehu7s%253D&md5=46fe894b016f3041831a2f0b71f812b1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.9997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.9997%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DI.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DSharp%26aufirst%3DK.%2BA.%26aulast%3DKollman%26aufirst%3DP.%2BA.%26atitle%3DThe%2520maximal%2520affinity%2520of%2520ligands%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D9997%26epage%3D10002%26doi%3D10.1073%2Fpnas.96.18.9997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=Springthorpe%2C+B.+The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0liBHSvFYQT2bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DSpringthorpe%252C%2520B.%2520The%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abad-Zapatero, C.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency indices for effective drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1517/17460441.2.4.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1517%2F17460441.2.4.469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=23484756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=469-488&author=C.+Abad-Zapatero&title=Ligand+efficiency+indices+for+effective+drug+discovery&doi=10.1517%2F17460441.2.4.469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices for effective drug discovery</span></div><div class="casAuthors">Abad-Zapatero, Cele</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-488</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Successful drug discovery requires the optimization of a large no. of variables ranging from strictly physicochem. parameters such as mol. wt. to more complex parameters related to toxicity and bioavailability.  Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclin. characterization.  However, crit. biol. issues along the path to the market have diminished the impact and power of this methodol.  The physicochem. properties of the novel chem. entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate.  The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process.  More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context.  Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKduo41JcS7Vg90H21EOLACvtfcHk0liBHSvFYQT2bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D&md5=a1682fbc4545d8eab3a44417c0e88869</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.4.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.4.469%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26atitle%3DLigand%2520efficiency%2520indices%2520for%2520effective%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D469%26epage%3D488%26doi%3D10.1517%2F17460441.2.4.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0liBHSvFYQT2bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirrung, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halstead, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, N. J. G.</span></span> <span> </span><span class="NLM_article-title">Methyl Scanning: Total synthesis of demethylasterriquinone B1 and derivatives for identification of sites of interaction with and isolation of its receptor(s)</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">4609</span>– <span class="NLM_lpage">4624</span>, <span class="refDoi"> DOI: 10.1021/ja044325h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja044325h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Krtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=4609-4624&author=M.+C.+Pirrungauthor=Y.+Liuauthor=L.+Dengauthor=D.+K.+Halsteadauthor=Z.+Liauthor=J.+F.+Mayauthor=M.+Wedelauthor=D.+A.+Austinauthor=N.+J.+G.+Webster&title=Methyl+Scanning%3A+Total+synthesis+of+demethylasterriquinone+B1+and+derivatives+for+identification+of+sites+of+interaction+with+and+isolation+of+its+receptor%28s%29&doi=10.1021%2Fja044325h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Scanning: Total Synthesis of Demethylasterriquinone B1 and Derivatives for Identification of Sites of Interaction with and Isolation of Its Receptor(s)</span></div><div class="casAuthors">Pirrung, Michael C.; Liu, Yufa; Deng, Liu; Halstead, Diana K.; Li, Zhitao; May, John F.; Wedel, Michael; Austin, Darrell A.; Webster, Nicholas J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4609-4624</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The principle of Me scanning is proposed for detn. of the sites of interaction between biol. active small mols. and their macromol. target(s).  It involves the systematic prepn. of a family of methylated derivs. of a compd. and their biol. testing.  As a functional assay, the method can identify the regions of a mol. that are important (and unimportant) for biol. activity against even unknown targets, and thus provides an excellent complement to structural biol.  Me scanning was applied to demethylasterriquinone B1, a small-mol. mimetic of insulin.  A new, optimal total synthesis of this natural product was developed that enables the family of Me scan derivs. to be concisely prepd. for evaluation in a cellular assay.  The results of this expt. were used to design a biotin-demethylasterriquinone conjugate for use as an affinity reagent.  This compd. was prepd. in tens of milligram quantities in a four-step synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFivtvsdHSBLVg90H21EOLACvtfcHk0liBHSvFYQT2bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Krtrw%253D&md5=0556ce71c359790203c641280d133dbf</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja044325h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja044325h%26sid%3Dliteratum%253Aachs%26aulast%3DPirrung%26aufirst%3DM.%2BC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DHalstead%26aufirst%3DD.%2BK.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMay%26aufirst%3DJ.%2BF.%26aulast%3DWedel%26aufirst%3DM.%26aulast%3DAustin%26aufirst%3DD.%2BA.%26aulast%3DWebster%26aufirst%3DN.%2BJ.%2BG.%26atitle%3DMethyl%2520Scanning%253A%2520Total%2520synthesis%2520of%2520demethylasterriquinone%2520B1%2520and%2520derivatives%2520for%2520identification%2520of%2520sites%2520of%2520interaction%2520with%2520and%2520isolation%2520of%2520its%2520receptor%2528s%2529%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D4609%26epage%3D4624%26doi%3D10.1021%2Fja044325h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="note"><p class="first last">These Fsp<sup>3</sup> values were calculated as part of our post analysis of our work on the JAK inhibition project.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="note"><p class="first last">On the basis of the structure of <i>ent</i>-<b>60</b> (JTE-052) inferred from the X-ray cocrystal analysis (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), <i>ent</i>-<b>60</b> (JTE-052) was synthesized according to <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>. The JAK3 inhibitory activity of provided compound accorded with those of <i>ent</i>-<b>60</b>. The absolute stereochemistry of <i>ent</i>-<b>60</b> (JTE-052) was afterward confirmed by its X-ray crystallographic analysis. The detailed data was described in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last">The detailed kinase panel results are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebens, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3149</span>– <span class="NLM_lpage">3153</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.bmcl.2013.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=23623490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Oisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3149-3153&author=X.+Wangauthor=S.+Magnusonauthor=R.+Pastorauthor=E.+Fanauthor=H.+Huauthor=V.+Tsuiauthor=W.+Dengauthor=J.+Murrayauthor=M.+Steffekauthor=H.+Wallweberauthor=J.+Moffatauthor=J.+Drummondauthor=G.+Chanauthor=E.+Harstadauthor=A.+J.+Ebens&title=Discovery+of+novel+pyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+pan-Pim+inhibitors+by+structure-+and+property-based+drug+design&doi=10.1016%2Fj.bmcl.2013.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design</span></div><div class="casAuthors">Wang, Xiaojing; Magnuson, Steven; Pastor, Rich; Fan, Eric; Hu, Huiyong; Tsui, Vickie; Deng, Wei; Murray, Jeremy; Steffek, Micah; Wallweber, Heidi; Moffat, John; Drummond, Jason; Chan, Grace; Harstad, Eric; Ebens, Allen J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3149-3153</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pim kinases are promising targets for the development of cancer therapeutics.  Among the three Pim isoforms, Pim-2 is particularly important in multiple myeloma, yet is the most difficult to inhibit due to its high affinity for ATP.  We identified compd. 1 via high throughput screening.  Using property-based drug design and co-crystal structures with Pim-1 kinase to guide analog design, we were able to improve potency against all three Pim isoforms including a significant 10,000-fold gain against Pim-2.  Compd. 17 is a novel lead with low picomolar potency on all three Pim kinase isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonWvohEjJoarVg90H21EOLACvtfcHk0lj43KaajJk-iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Oisbg%253D&md5=9129c2f2897d536317c3243220b37251</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DPastor%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DE.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DEbens%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520novel%2520pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520pan-Pim%2520inhibitors%2520by%2520structure-%2520and%2520property-based%2520drug%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3149%26epage%3D3153%26doi%3D10.1016%2Fj.bmcl.2013.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span> <span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0lj43KaajJk-iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5Bmethyl%287H-pyrrolo%5B2%2C3-d%5D-pyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+a+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lhjGv6cxI1O2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255Bmethyl%25287H-pyrrolo%255B2%252C3-d%255D-pyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520a%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, J. C.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span> <span> </span><span class="NLM_article-title">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1136/ard.2007.076430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1136%2Fard.2007.076430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=18055474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=1505-1515&author=M.+Hegenauthor=J.+C.+Keithauthor=M.+Collinsauthor=C.+L.+Nickerson-Nutter&title=Utility+of+animal+models+for+identification+of+potential+therapeutics+for+rheumatoid+arthritis&doi=10.1136%2Fard.2007.076430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Hegen, M.; Keith, J. C., Jr.; Collins, M.; Nickerson-Nutter, C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1505-1515</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA.  However, the question of which animal model is most predictive of therapeutic efficacy in human RA commonly arises in data evaluation.  A retrospective review of the animal models used to evaluate approved, pending RA therapies, and compds. that were discontinued during phase II or III clin. trials found that the three most commonly used models were adjuvant-induced arthritis (AIA) in rats and collagen-induced arthritis (CIA) in rats and mice.  Limited data were found for more recently developed genetically modified animal models.  Examn. of the efficacy of various compds. in these animal models revealed that a compd.'s therapeutic efficacy, rather than prophylactic efficacy, in AIA and CIA models was more predictive of clin. efficacy in human RA than data from either model alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruwo5lHLFB3bVg90H21EOLACvtfcHk0lhjGv6cxI1O2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP&md5=417b41682141901273229dacb8f63283</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1136%2Fard.2007.076430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2007.076430%26sid%3Dliteratum%253Aachs%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DKeith%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26atitle%3DUtility%2520of%2520animal%2520models%2520for%2520identification%2520of%2520potential%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26spage%3D1505%26epage%3D1515%26doi%3D10.1136%2Fard.2007.076430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span> <span> </span><span class="NLM_article-title">Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis</span>. <i>BMC Musculoskeletal Disord.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">339</span>, <span class="refDoi"> DOI: 10.1186/s12891-015-0802-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1186%2Fs12891-015-0802-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=26546348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2qsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=339&author=A.+Tanimotoauthor=Y.+Shinozakiauthor=K.+Nozawaauthor=Y.+Kimotoauthor=W.+Amanoauthor=A.+Matsuoauthor=T.+Yamaguchiauthor=M.+Matsushita&title=Improvement+of+spontaneous+locomotor+activity+with+JAK+inhibition+by+JTE-052+in+rat+adjuvant-induced+arthritis&doi=10.1186%2Fs12891-015-0802-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Tanimoto, Atsuo; Shinozaki, Yuichi; Nozawa, Keisuke; Kimoto, Yukari; Amano, Wataru; Matsuo, Akira; Yamaguchi, Takayuki; Matsushita, Mutsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">BMC Musculoskeletal Disorders</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339/1-339/8</span>CODEN:
                <span class="NLM_cas:coden">BMDMCE</span>;
        ISSN:<span class="NLM_cas:issn">1471-2474</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction, disability, and decreased quality of life (QOL).  Inhibition of Janus kinase (JAK) signaling ameliorates articular inflammation and joint destruction in animal models of RA, but its effects on behaviors indicating well-being are poorly understood.  In this study, we evaluated the effect of JAK inhibition on spontaneous locomotor activity in rats with adjuvant-induced arthritis, a rodent model of RA.  Methods: Arthritis was induced in male Lewis rats by a single s.c. injection of Freund's complete adjuvant.  The novel JAK inhibitor JTE-052 was orally administered for 7 days after the onset of arthritis.  Results: Induction of arthritis suppressed the spontaneous locomotor activity of the rats.  Administration of JTE-052 completely improved the spontaneous locomotor activity, with partial redns. in articular inflammation and joint destruction.  Hyperalgesia and motor functions were also improved, but the efficacy was not complete.  However, serum interleukin (IL)-6 levels were completely decreased at 4 h after administration of the first dose of JTE-052.  Conclusions: This study demonstrated that JAK inhibition improved the spontaneous locomotor activity of rats with adjuvant-induced arthritis, in assocn. with amelioration of pain and phys. dysfunction as a consequence of suppression of joint inflammation.  Moreover, although further studies are needed, there was possible participation of IL-6 downregulation in the improvement of locomotor activity by JAK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LG2OzBnyYbVg90H21EOLACvtfcHk0lhjGv6cxI1O2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2qsrzF&md5=bfb8da317cf3b6508b042353b679ba7f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2Fs12891-015-0802-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12891-015-0802-0%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DShinozaki%26aufirst%3DY.%26aulast%3DNozawa%26aufirst%3DK.%26aulast%3DKimoto%26aufirst%3DY.%26aulast%3DAmano%26aufirst%3DW.%26aulast%3DMatsuo%26aufirst%3DA.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DMatsushita%26aufirst%3DM.%26atitle%3DImprovement%2520of%2520spontaneous%2520locomotor%2520activity%2520with%2520JAK%2520inhibition%2520by%2520JTE-052%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DBMC%2520Musculoskeletal%2520Disord.%26date%3D2015%26volume%3D16%26spage%3D339%26doi%3D10.1186%2Fs12891-015-0802-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengoku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakura, S.</span></span> <span> </span><span class="NLM_article-title">Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats</span>. <i>Skin Pharmacol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1159/000235551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1159%2F000235551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=19690449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1WmsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=240-247&author=Y.+Fujiiauthor=H.+Takeuchiauthor=S.+Sakumaauthor=T.+Sengokuauthor=S.+Takakura&title=Characterization+of+a+2%2C4-dinitrochlorobenzene-induced+chronic+dermatitis+model+in+rats&doi=10.1159%2F000235551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a 2,4-Dinitrochlorobenzene-Induced Chronic Dermatitis Model in Rats</span></div><div class="casAuthors">Fujii, Y.; Takeuchi, H.; Sakuma, S.; Sengoku, T.; Takakura, S.</div><div class="citationInfo"><span class="NLM_cas:title">Skin Pharmacology and Physiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">240-247</span>CODEN:
                <span class="NLM_cas:coden">SPPKE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-5527</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Although many mouse models of atopic dermatitis have been reported, few rat models have been studied.  In this study, a rat chronic allergic dermatitis model was developed and evaluated as a pharmacol. model of atopic dermatitis.  Prominent ear thickening and scratching were induced after the application of 2,4-dinitrochlorobenzene to the right ear of Brown Norway rats 3 times per wk for 3 wk.  Histopathol., infiltration of T cells in the ear was obsd. on day 7, and eosinophils and mast cells were found in addn. to T cells on day 21.  The expression of interferon-γ and interleukin-4 was increased on day 7 when compared with normal rats.  However, interferon-γ expression had disappeared by day 21.  Tacrolimus ointment applied after ear tissue thickening fully developed, suppressed chronic dermatitis in a dose-dependent manner.  This model has some symptomatic and histopathol. similarities to atopic dermatitis and might be useful in pharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMri4SQblO7Vg90H21EOLACvtfcHk0lip5Axdt5J4NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1WmsrzN&md5=f024274b151f1d07296d58b4fa02a5f7</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1159%2F000235551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000235551%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DSakuma%26aufirst%3DS.%26aulast%3DSengoku%26aufirst%3DT.%26aulast%3DTakakura%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520a%25202%252C4-dinitrochlorobenzene-induced%2520chronic%2520dermatitis%2520model%2520in%2520rats%26jtitle%3DSkin%2520Pharmacol.%2520Physiol.%26date%3D2009%26volume%3D22%26spage%3D240%26epage%3D247%26doi%3D10.1159%2F000235551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniai-Riya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span> <span> </span><span class="NLM_article-title">A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents</span>. <i>Exp Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1111/exd.13370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fexd.13370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=28423239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=22-29&author=A.+Tanimotoauthor=Y.+Shinozakiauthor=Y.+Yamamotoauthor=Y.+Katsudaauthor=E.+Taniai-Riyaauthor=K.+Toyodaauthor=K.+Kakimotoauthor=Y.+Kimotoauthor=W.+Amanoauthor=N.+Konishiauthor=M.+Hayashi&title=A+novel+JAK+inhibitor+JTE-052+reduces+skin+inflammation+and+ameliorates+chronic+dermatitis+in+rodent+models%3A+comparison+with+conventional+therapeutic+agents&doi=10.1111%2Fexd.13370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents</span></div><div class="casAuthors">Tanimoto, Atsuo; Shinozaki, Yuichi; Yamamoto, Yasuo; Katsuda, Yoshiaki; Taniai-Riya, Eriko; Toyoda, Kaoru; Kakimoto, Kochi; Kimoto, Yukari; Amano, Wataru; Konishi, Noriko; Hayashi, Mikio</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-29</span>CODEN:
                <span class="NLM_cas:coden">EXDEEY</span>;
        ISSN:<span class="NLM_cas:issn">1600-0625</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are required for several inflammatory cytokine signalling pathways and are implicated in the pathogenesis of chronic dermatitis, including atopic dermatitis and psoriasis.  JAK inhibitors are therefore promising therapeutic candidates for chronic dermatitis.  In this study, we evaluated the effects of the novel JAK inhibitor JTE-052 on inflammatory responses assocd. with chronic dermatitis, and compared its profile with those of conventional therapeutic agents in rodent models of chronic dermatitis.  JTE-052 inhibited the Th1-, Th2- and Th17-type inflammatory responses of human T cells and mast cells in vitro.  Oral administration of JTE-052 inhibited skin inflammation in hapten-induced chronic dermatitis in mice, assocd. with reduced levels of inflammatory cytokines in the skin and Ig (Ig) E in serum.  In contrast, although ciclosporin partly inhibited skin inflammation, it did not reduce interleukin (IL)-4 prodn. in skin, and enhanced IgE prodn. in serum.  Oral administration of JTE-052 also inhibited skin inflammation in mouse models of atopic dermatitis and psoriasis induced by a mite ext., thymic stromal lymphopoietin or IL-23.  The maximal efficacy of JTE-052 in these dermatitis models was superior to the conventional therapeutic agents, ciclosporin and methotrexate.  Topical application of JTE-052 ointment ameliorated hapten-induced chronic dermatitis in rats more effectively than tacrolimus ointment.  Furthermore, JTE-052 ointment did not cause the thinning of normal skin assocd. with topical corticosteroids.  These results indicate that JTE-052 is a promising candidate as an anti-inflammatory drug for various types of chronic dermatitis, with a distinctly different profile from conventional therapy following either oral or topical application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Iu1ITQQgm7Vg90H21EOLACvtfcHk0lip5Axdt5J4NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFyjtQ%253D%253D&md5=6097721ece490e0aa83a2c31b0898e8c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fexd.13370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.13370%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DShinozaki%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKatsuda%26aufirst%3DY.%26aulast%3DTaniai-Riya%26aufirst%3DE.%26aulast%3DToyoda%26aufirst%3DK.%26aulast%3DKakimoto%26aufirst%3DK.%26aulast%3DKimoto%26aufirst%3DY.%26aulast%3DAmano%26aufirst%3DW.%26aulast%3DKonishi%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DM.%26atitle%3DA%2520novel%2520JAK%2520inhibitor%2520JTE-052%2520reduces%2520skin%2520inflammation%2520and%2520ameliorates%2520chronic%2520dermatitis%2520in%2520rodent%2520models%253A%2520comparison%2520with%2520conventional%2520therapeutic%2520agents%26jtitle%3DExp%2520Dermatol.%26date%3D2018%26volume%3D27%26spage%3D22%26epage%3D29%26doi%3D10.1111%2Fexd.13370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of model compound containing an indole spiro-β-lactam moiety with vinylchloride in chartellines</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">440</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1246/cl.2004.440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1246%2Fcl.2004.440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFKhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=440-441&author=T.+Nishikawaauthor=S.+Kajiiauthor=M.+Isobe&title=Synthesis+of+model+compound+containing+an+indole+spiro-%CE%B2-lactam+moiety+with+vinylchloride+in+chartellines&doi=10.1246%2Fcl.2004.440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of model compound containing an indole spiro-β-lactam moiety with vinylchloride in chartellines</span></div><div class="casAuthors">Nishikawa, Toshio; Kajii, Shigeo; Isobe, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">440-441</span>CODEN:
                <span class="NLM_cas:coden">CMLTAG</span>;
        ISSN:<span class="NLM_cas:issn">0366-7022</span>.
    
            (<span class="NLM_cas:orgname">Chemical Society of Japan</span>)
        </div><div class="casAbstract">The synthesis of I, a chartelline model compd. contg. an indole β-lactam moiety bearing a vinylchloride, is reported.  A Mannich reaction of isatin imine II with 1-ethoxy-1-(trimethylsilyloxy)ethene gave β-amino ester III, which was converted to β-amino acid IV.  β-Lactam formation of IV followed by copper(I)-mediated coupling with (E)-α-chloro-β-iodostyrene afforded I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq6mQmvJMlu7Vg90H21EOLACvtfcHk0lip5Axdt5J4NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFKhtbg%253D&md5=3e8f26052b21e06ad3204ef180c71857</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1246%2Fcl.2004.440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.2004.440%26sid%3Dliteratum%253Aachs%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DKajii%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520model%2520compound%2520containing%2520an%2520indole%2520spiro-%25CE%25B2-lactam%2520moiety%2520with%2520vinylchloride%2520in%2520chartellines%26jtitle%3DChem.%2520Lett.%26date%3D2004%26volume%3D33%26spage%3D440%26epage%3D441%26doi%3D10.1246%2Fcl.2004.440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couty, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, K. R.</span></span> <span> </span><span class="NLM_article-title">Stereocontrolled synthesis of 3-substituted azetidinic amino acids</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1055/s-2006-933125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1055%2Fs-2006-933125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=781-785&author=M.+Sivaprakasamauthor=F.+Coutyauthor=G.+Evanoauthor=B.+Srinivasauthor=R.+Sridharauthor=K.+R.+Rao&title=Stereocontrolled+synthesis+of+3-substituted+azetidinic+amino+acids&doi=10.1055%2Fs-2006-933125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-933125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-933125%26sid%3Dliteratum%253Aachs%26aulast%3DSivaprakasam%26aufirst%3DM.%26aulast%3DCouty%26aufirst%3DF.%26aulast%3DEvano%26aufirst%3DG.%26aulast%3DSrinivas%26aufirst%3DB.%26aulast%3DSridhar%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DK.%2BR.%26atitle%3DStereocontrolled%2520synthesis%2520of%25203-substituted%2520azetidinic%2520amino%2520acids%26jtitle%3DSynlett%26date%3D2006%26volume%3D5%26spage%3D781%26epage%3D785%26doi%3D10.1055%2Fs-2006-933125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lig4e9iml1Kbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&author=F.+Lovering&title=Escape+from+flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lig4e9iml1Kbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Méndez-Lucio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">The many roles of molecular complexity in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.drudis.2016.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=27575998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVelsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=120-126&author=O.+M%C3%A9ndez-Lucioauthor=J.+L.+Medina-Franco&title=The+many+roles+of+molecular+complexity+in+drug+discovery&doi=10.1016%2Fj.drudis.2016.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of molecular complexity in drug discovery</span></div><div class="casAuthors">Mendez-Lucio, Oscar; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-126</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mol. complexity is becoming a crucial concept in drug discovery.  It has been assocd. with target selectivity, success in progressing into clin. development and compd. safety, among other factors.  Multiple metrics have been developed to quantify mol. complexity and explore complexity-property relationships.  However, there is no general agreement regarding how to measure this mol. feature.  Herein, we have surveyed the many roles of mol. complexity in drug discovery discussing in a crit. manner different quantification methods.  Through the anal. of various ref. compd. databases, common pitfalls and workarounds of the quantification of mol. complexity are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyZIwgtqVak7Vg90H21EOLACvtfcHk0lig4e9iml1Kbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVelsL7P&md5=f731baf9298ee3b0f0c341970a990841</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9ndez-Lucio%26aufirst%3DO.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520many%2520roles%2520of%2520molecular%2520complexity%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D120%26epage%3D126%26doi%3D10.1016%2Fj.drudis.2016.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprecher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsborough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld-Franklin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bort, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuijper, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukowski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCiel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waggie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topouzis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuestner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish-Novak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. A.</span></span> <span> </span><span class="NLM_article-title">Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1038/ni1084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fni1084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=15184896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1WmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=752-760&author=S.+R.+Dillonauthor=C.+Sprecherauthor=A.+Hammondauthor=J.+Bilsboroughauthor=M.+Rosenfeld-Franklinauthor=S.+R.+Presnellauthor=H.+S.+Haugenauthor=M.+Maurerauthor=B.+Harderauthor=J.+Johnstonauthor=S.+Bortauthor=S.+Mudriauthor=J.+L.+Kuijperauthor=T.+Bukowskiauthor=P.+Sheaauthor=D.+L.+Dongauthor=M.+Dasovichauthor=F.+J.+Grantauthor=L.+Lockwoodauthor=S.+D.+Levinauthor=C.+LeCielauthor=K.+Waggieauthor=H.+Dayauthor=S.+Topouzisauthor=J.+Kramerauthor=R.+Kuestnerauthor=Z.+Chenauthor=D.+Fosterauthor=J.+Parrish-Novakauthor=J.+A.+Gross&title=Interleukin+31%2C+a+cytokine+produced+by+activated+T+cells%2C+induces+dermatitis+in+mice&doi=10.1038%2Fni1084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice</span></div><div class="casAuthors">Dillon, Stacey R.; Sprecher, Cindy; Hammond, Angela; Bilsborough, Janine; Rosenfeld-Franklin, Maryland; Presnell, Scott R.; Haugen, Harald S.; Maurer, Mark; Harder, Brandon; Johnston, Janet; Bort, Susan; Mudri, Sherri; Kuijper, Joseph L.; Bukowski, Tom; Shea, Pamela; Dong, Dennis L.; Dasovich, Maria; Grant, Francis J.; Lockwood, Luann; Levin, Steven D.; LeCiel, Cosette; Waggie, Kim; Day, Heather; Topouzis, Stavros; Kramer, Janet; Kuestner, Rolf; Chen, Zhi; Foster, Don; Parrish-Novak, Julia; Gross, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">752-760</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">T cell-derived cytokines are important in the development of an effective immune response, but when dysregulated they can promote disease.  Here we identify a four-helix bundle cytokine we have called interleukin 31 (IL-31), which is preferentially produced by T helper type 2 cells.  IL-31 signals through a receptor composed of IL-31 receptor A and oncostatin M receptor.  Expression of IL-31 receptor A and oncostatin M receptor mRNA was induced in activated monocytes, whereas epithelial cells expressed both mRNAs constitutively.  Transgenic mice overexpressing IL-31 developed severe pruritis, alopecia and skin lesions.  Furthermore, IL-31 receptor expression was increased in diseased tissues derived from an animal model of airway hypersensitivity.  These data indicate that IL-31 may be involved in promoting the dermatitis and epithelial responses that characterize allergic and non-allergic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp48HWTuQd9ybVg90H21EOLACvtfcHk0lhMQfWasO8h9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1WmurY%253D&md5=d7dd4dc7e218b814451b231b578b278b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fni1084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1084%26sid%3Dliteratum%253Aachs%26aulast%3DDillon%26aufirst%3DS.%2BR.%26aulast%3DSprecher%26aufirst%3DC.%26aulast%3DHammond%26aufirst%3DA.%26aulast%3DBilsborough%26aufirst%3DJ.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DPresnell%26aufirst%3DS.%2BR.%26aulast%3DHaugen%26aufirst%3DH.%2BS.%26aulast%3DMaurer%26aufirst%3DM.%26aulast%3DHarder%26aufirst%3DB.%26aulast%3DJohnston%26aufirst%3DJ.%26aulast%3DBort%26aufirst%3DS.%26aulast%3DMudri%26aufirst%3DS.%26aulast%3DKuijper%26aufirst%3DJ.%2BL.%26aulast%3DBukowski%26aufirst%3DT.%26aulast%3DShea%26aufirst%3DP.%26aulast%3DDong%26aufirst%3DD.%2BL.%26aulast%3DDasovich%26aufirst%3DM.%26aulast%3DGrant%26aufirst%3DF.%2BJ.%26aulast%3DLockwood%26aufirst%3DL.%26aulast%3DLevin%26aufirst%3DS.%2BD.%26aulast%3DLeCiel%26aufirst%3DC.%26aulast%3DWaggie%26aufirst%3DK.%26aulast%3DDay%26aufirst%3DH.%26aulast%3DTopouzis%26aufirst%3DS.%26aulast%3DKramer%26aufirst%3DJ.%26aulast%3DKuestner%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFoster%26aufirst%3DD.%26aulast%3DParrish-Novak%26aufirst%3DJ.%26aulast%3DGross%26aufirst%3DJ.%2BA.%26atitle%3DInterleukin%252031%252C%2520a%2520cytokine%2520produced%2520by%2520activated%2520T%2520cells%252C%2520induces%2520dermatitis%2520in%2520mice%26jtitle%3DNat.%2520Immunol.%26date%3D2004%26volume%3D5%26spage%3D752%26epage%3D760%26doi%3D10.1038%2Fni1084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüscher-Firzlaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüscher, B.</span></span> <span> </span><span class="NLM_article-title">Signaling by IL-31 and functional consequences</span>. <i>Eur. J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1016/j.ejcb.2011.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.ejcb.2011.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=21982586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFyqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=552-566&author=C.+Cornelissenauthor=J.+L%C3%BCscher-Firzlaffauthor=J.+M.+Baronauthor=B.+L%C3%BCscher&title=Signaling+by+IL-31+and+functional+consequences&doi=10.1016%2Fj.ejcb.2011.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-31 and functional consequences</span></div><div class="casAuthors">Cornelissen, Christian; Luescher-Firzlaff, Juliane; Baron, Jens Malte; Luescher, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">552-566</span>CODEN:
                <span class="NLM_cas:coden">EJCBDN</span>;
        ISSN:<span class="NLM_cas:issn">0171-9335</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">A review.  Cytokines are key to control cellular communication.  Interleukin-31 (IL-31) was recently discovered as a new member of the IL-6 family of cytokines.  IL-31 signals through a heterodimeric receptor composed of OSMR and IL-31RA, a complex that stimulates the JAK-STAT, the RAS/ERK and the PI3K/AKT signal transduction pathways.  The available data suggests that IL-31 is important for both innate and adaptive immunity in tissues that are in close contact with the environment, i.e. the skin, the airways and the lung, and the lining of the intestine.  Enhanced expression of IL-31 is assocd. with a no. of diseases, including pruritic diseases such as atopic dermatitis, but also in allergy and inflammatory bowel disease.  In these tissues IL-31 coordinates the interaction of different immune cells, including T-cells, mast cells, and eosinophils, with epithelial cells.  In this review we have summarized the available data on IL-31 and its receptor, their expression pattern and how they are regulated.  We describe the current state of knowledge of the involvement of IL-31 in diseases, both in humans and in mouse models.  From these studies it is becoming clear that IL-31 plays an important role in the proper functioning of the skin and of airway and intestinal epithelia.  The findings available suggest that IL-31 might be an interesting target for directed drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL6-csNS7AfLVg90H21EOLACvtfcHk0lhMQfWasO8h9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFyqs7c%253D&md5=bab940bd616cab7bf4de94cf4f317bac</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejcb.2011.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejcb.2011.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DCornelissen%26aufirst%3DC.%26aulast%3DL%25C3%25BCscher-Firzlaff%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DJ.%2BM.%26aulast%3DL%25C3%25BCscher%26aufirst%3DB.%26atitle%3DSignaling%2520by%2520IL-31%2520and%2520functional%2520consequences%26jtitle%3DEur.%2520J.%2520Cell%2520Biol.%26date%3D2012%26volume%3D91%26spage%3D552%26epage%3D566%26doi%3D10.1016%2Fj.ejcb.2011.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L. S.</span></span> <span> </span><span class="NLM_article-title">The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis</span>. <i>JAKSTAT</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e24137</span>, <span class="refDoi"> DOI: 10.4161/jkst.24137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.4161%2Fjkst.24137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=24069552" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e24137&issue=3&author=L.+Baoauthor=H.+Zhangauthor=L.+S.+Chan&title=The+involvement+of+the+JAK-STAT+signaling+pathway+in+chronic+inflammatory+skin+disease+atopic+dermatitis&doi=10.4161%2Fjkst.24137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4161%2Fjkst.24137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.24137%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DL.%2BS.%26atitle%3DThe%2520involvement%2520of%2520the%2520JAK-STAT%2520signaling%2520pathway%2520in%2520chronic%2520inflammatory%2520skin%2520disease%2520atopic%2520dermatitis%26jtitle%3DJAKSTAT%26date%3D2013%26volume%3D2%26issue%3D3%26spage%3De24137%26doi%3D10.4161%2Fjkst.24137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danso, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Drongelen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Esch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Smeden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Ghalbzouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwstra, J. A.</span></span> <span> </span><span class="NLM_article-title">TNF-α and Th2 cytokines induce atopic dermatitis like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1941</span>– <span class="NLM_lpage">1950</span>, <span class="refDoi"> DOI: 10.1038/jid.2014.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fjid.2014.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=24518171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvF2msLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=1941-1950&author=M.+O.+Dansoauthor=V.+Van+Drongelenauthor=A.+Mulderauthor=J.+Van+Eschauthor=H.+Scottauthor=J.+Van+Smedenauthor=A.+El+Ghalbzouriauthor=J.+A.+Bouwstra&title=TNF-%CE%B1+and+Th2+cytokines+induce+atopic+dermatitis+like+features+on+epidermal+differentiation+proteins+and+stratum+corneum+lipids+in+human+skin+equivalents&doi=10.1038%2Fjid.2014.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">TNF-α and Th2 Cytokines Induce Atopic Dermatitis-Like Features on Epidermal Differentiation Proteins and Stratum Corneum Lipids in Human Skin Equivalents</span></div><div class="casAuthors">Danso, Mogbekeloluwa O.; van Drongelen, Vincent; Mulder, Aat; van Esch, Jeltje; Scott, Hannah; van Smeden, Jeroen; El Ghalbzouri, Abdoelwaheb; Bouwstra, Joke A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1941-1950</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Atopic dermatitis (AD) is a chronic inflammatory skin disease in which the skin barrier function is disrupted.  In this inflammatory AD environment, cytokines are upregulated, but the cytokine effect on the AD skin barrier is not fully understood.  We aimed to investigate the influence of Th2 (IL-4, IL-13, IL-31) and pro-inflammatory (tumor necrosis factor alpha (TNF-α)) cytokines on epidermal morphogenesis, proliferation, differentiation, and stratum corneum lipid properties.  For this purpose, we used the Leiden epidermal model (LEM) in which the medium was supplemented with these cytokines.  Our results show that IL-4, IL-13, IL-31, and TNF-α induce spongiosis, augment TSLP secretion by keratinocytes, and alter early and terminal differentiation-protein expression in LEMs.  TNF-α alone or in combination with Th2 cytokines decreases the level of long chain free fatty acids (FFAs) and ester linked ω-hydroxy (EO) ceramides, consequently affecting the lipid organization.  IL-31 increases long chain FFAs in LEMs but decreases relative abundance of EO ceramides.  These findings clearly show that supplementation with TNF-α and Th2 cytokines influence epidermal morphogenesis and barrier function.  As a result, these LEMs show similar characteristics as found in AD skin and can be used as an excellent tool for screening formulations and drugs for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLxQx1bHSlO7Vg90H21EOLACvtfcHk0lioAqwquzNeHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvF2msLw%253D&md5=0c64f286ae3a2ae2e78da5d67d190f3b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fjid.2014.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2014.83%26sid%3Dliteratum%253Aachs%26aulast%3DDanso%26aufirst%3DM.%2BO.%26aulast%3DVan%2BDrongelen%26aufirst%3DV.%26aulast%3DMulder%26aufirst%3DA.%26aulast%3DVan%2BEsch%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DH.%26aulast%3DVan%2BSmeden%26aufirst%3DJ.%26aulast%3DEl%2BGhalbzouri%26aufirst%3DA.%26aulast%3DBouwstra%26aufirst%3DJ.%2BA.%26atitle%3DTNF-%25CE%25B1%2520and%2520Th2%2520cytokines%2520induce%2520atopic%2520dermatitis%2520like%2520features%2520on%2520epidermal%2520differentiation%2520proteins%2520and%2520stratum%2520corneum%2520lipids%2520in%2520human%2520skin%2520equivalents%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2014%26volume%3D134%26spage%3D1941%26epage%3D1950%26doi%3D10.1038%2Fjid.2014.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Numata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span> <span> </span><span class="NLM_article-title">The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2015.03.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaci.2015.03.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=26115905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2lsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=667-677&author=W.+Amanoauthor=S.+Nakajimaauthor=H.+Kunugiauthor=Y.+Numataauthor=A.+Kitohauthor=G.+Egawaauthor=T.+Dainichiauthor=T.+Hondaauthor=A.+Otsukaauthor=Y.+Kimotoauthor=Y.+Yamamotoauthor=A.+Tanimotoauthor=M.+Matsushitaauthor=Y.+Miyachiauthor=K.+Kabashima&title=The+Janus+kinase+inhibitor+JTE-052+improves+skin+barrier+function+through+suppressing+signal+transducer+and+activator+of+transcription+3+signaling&doi=10.1016%2Fj.jaci.2015.03.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling</span></div><div class="casAuthors">Amano, Wataru; Nakajima, Saeko; Kunugi, Hayato; Numata, Yasuharu; Kitoh, Akihiko; Egawa, Gyohei; Dainichi, Teruki; Honda, Tetsuya; Otsuka, Atsushi; Kimoto, Yukari; Yamamoto, Yasuo; Tanimoto, Atsuo; Matsushita, Mutsuyoshi; Miyachi, Yoshiki; Kabashima, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">667-677.e7</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Barrier disruption and the resulting continuous exposure to allergens are presumed to be responsible for the development of atopic dermatitis (AD).  However, the mechanism through which skin barrier function is disrupted in patients with AD remains unclear.  Taking into account the fact that the TH2 milieu impairs keratinocyte terminal differentiation, we sought to clarify our hypothesis that the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a crit. role in skin barrier function and can be a therapeutic target for AD.  We analyzed the mechanism of keratinocyte differentiation using a microarray and small interfering RNA targeting STATs.  We studied the effect of the JAK inhibitor JTE-052 on keratinocyte differentiation using the human skin equiv. model and normal human epidermal keratinocytes.  We applied topical JAK inhibitor onto NC/Nga mice, dry skin model mice, and human skin grafted to immunocompromised mice.  IL-4 and IL-13 downregulated genes involved in keratinocyte differentiation.  STAT3 and STAT6 are involved in keratinocyte differentiation and chemokine prodn. by keratinocytes, resp.  Topical application of the JAK inhibitor suppressed STAT3 activation and improved skin barrier function, permitting increases in levels of terminal differentiation proteins, such as filaggrin, and natural moisturizing factors in models of AD and dry skin and in human skin.  STAT3 signaling is a key element that regulates keratinocyte differentiation.  The JAK inhibitor can be a new therapeutic tool for the treatment of disrupted barrier function in patients with AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9EisMWkNHW7Vg90H21EOLACvtfcHk0lioAqwquzNeHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2lsL%252FE&md5=b56ee7a724ce3eb91286f3ab80f3ebe5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2015.03.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2015.03.051%26sid%3Dliteratum%253Aachs%26aulast%3DAmano%26aufirst%3DW.%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DKunugi%26aufirst%3DH.%26aulast%3DNumata%26aufirst%3DY.%26aulast%3DKitoh%26aufirst%3DA.%26aulast%3DEgawa%26aufirst%3DG.%26aulast%3DDainichi%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DOtsuka%26aufirst%3DA.%26aulast%3DKimoto%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DMiyachi%26aufirst%3DY.%26aulast%3DKabashima%26aufirst%3DK.%26atitle%3DThe%2520Janus%2520kinase%2520inhibitor%2520JTE-052%2520improves%2520skin%2520barrier%2520function%2520through%2520suppressing%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520signaling%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D136%26spage%3D667%26epage%3D677%26doi%3D10.1016%2Fj.jaci.2015.03.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model</span>. <i>J. Dermatol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.jdermsci.2019.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jdermsci.2019.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=31924380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslaiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2020&pages=161-164&author=Y.+Yamamotoauthor=A.+Otsukaauthor=C.+Nakashimaauthor=Y.+Ishidaauthor=T.+Hondaauthor=G.+Egawaauthor=W.+Amanoauthor=K.+Usuiauthor=Y.+Hamadaauthor=M.+Wadaauthor=A.+Tanimotoauthor=N.+Konishiauthor=M.+Hayashiauthor=M.+Matsushitaauthor=K.+Kabashima&title=Janus+kinase+inhibitor+delgocitinib+suppresses+pruritus+and+nerve+elongation+in+an+atopic+dermatitis+murine+model&doi=10.1016%2Fj.jdermsci.2019.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model</span></div><div class="casAuthors">Yamamoto, Yasuo; Otsuka, Atsushi; Nakashima, Chisa; Ishida, Yoshihiro; Honda, Tetsuya; Egawa, Gyohei; Amano, Wataru; Usui, Kenji; Hamada, Yuji; Wada, Masashi; Tanimoto, Atsuo; Konishi, Noriko; Hayashi, Mikio; Matsushita, Mutsuyoshi; Kabashima, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatological Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-164</span>CODEN:
                <span class="NLM_cas:coden">JDSCEI</span>;
        ISSN:<span class="NLM_cas:issn">0923-1811</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">This article discussed about janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.  In this study, we found that the JAK inhibitor delgocitinib inhibited pruritus in vivo using an AD-like mouse model and an IL-31-injection mouse model.  We examd. whether delgocitinib acts directly on nerves to suppress scratching behavior by using IL-31.  First, we performed intradermal IL-31 injection into the cheek area of C57BL/6 mice and evaluated scratching behavior after topical administration of delgocitinib or control soln.  Delgocitinib significantly reduced scratching behavior caused by IL-31 in a dose-dependent manner.  Next, we examd. whether the JAK pathway is involved in the IL-31-induced nerve elongation.  To investigate direct influence on neural morphol., Dorsal root ganglion (DRG) neurons were isolated from mice and were stimulated with IL-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7JfpiE8w38rVg90H21EOLACvtfcHk0lioAqwquzNeHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslaiuw%253D%253D&md5=65be7fd8e2a547dbe8956e277f81599a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.jdermsci.2019.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdermsci.2019.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DOtsuka%26aufirst%3DA.%26aulast%3DNakashima%26aufirst%3DC.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DEgawa%26aufirst%3DG.%26aulast%3DAmano%26aufirst%3DW.%26aulast%3DUsui%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DM.%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DKonishi%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DKabashima%26aufirst%3DK.%26atitle%3DJanus%2520kinase%2520inhibitor%2520delgocitinib%2520suppresses%2520pruritus%2520and%2520nerve%2520elongation%2520in%2520an%2520atopic%2520dermatitis%2520murine%2520model%26jtitle%3DJ.%2520Dermatol.%2520Sci.%26date%3D2020%26volume%3D97%26spage%3D161%26epage%3D164%26doi%3D10.1016%2Fj.jdermsci.2019.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissonnette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallbris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papacharalambous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ports, W. C.</span></span> <span> </span><span class="NLM_article-title">Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">902</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1111/bjd.14871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fbjd.14871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=27423107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGhu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2016&pages=902-911&author=R.+Bissonnetteauthor=K.+A.+Pappauthor=Y.+Poulinauthor=M.+Gooderhamauthor=M.+Ramanauthor=L.+Mallbrisauthor=C.+Wangauthor=V.+Purohitauthor=C.+Mamoloauthor=J.+Papacharalambousauthor=W.+C.+Ports&title=Topical+tofacitinib+for+atopic+dermatitis%3A+a+phase+IIa+randomized+trial&doi=10.1111%2Fbjd.14871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial</span></div><div class="casAuthors">Bissonnette, R.; Papp, K. A.; Poulin, Y.; Gooderham, M.; Raman, M.; Mallbris, L.; Wang, C.; Purohit, V.; Mamolo, C.; Papacharalambous, J.; Ports, W. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">902-911</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved.  Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown.  Objectives : Tofacitinib, a small-mol. JAK inhibitor, was investigated for the topical treatment of AD.  Methods : In this 4-wk, phase IIa, randomized, double-blind, vehicle-controlled study (NCT02001181), 69 adults with mild-to-moderate AD were randomized 1:1 to 2% tofacitinib or vehicle ointment twice daily.  Percentage change from baseline (CFB) in Eczema Area and Severity Index (EASI) score at week 4 was the primary end point.  Secondary efficacy end points included percentage CFB in body surface area (BSA), CFB in EASI Clin. Signs Severity Sum Score, proportion of patients with Physician's Global Assessment (PGA) response and CFB in patient-reported pruritus.  Safety, local tolerability and pharmacokinetics were monitored.  Results : The mean percentage CFB at week 4 in EASI score was significantly greater (P < 0·001) for tofacitinib (-81·7%) vs. vehicle (-29·9%).  Patients treated with tofacitinib showed significant (P < 0·001) improvements vs. vehicle across all prespecified efficacy end points and for pruritus at week 4.  Significant improvements in EASI, PGA and BSA were obsd. by week 1 and improvements in pruritus were obsd. by day 2.  Safety/local tolerability were generally similar for both treatments, although more adverse events were obsd. for vehicle vs. tofacitinib.  Conclusions : Tofacitinib ointment showed significantly greater efficacy vs. vehicle across end points, with early onset of effect and comparable safety/local tolerability to vehicle.  JAK inhibition through topical delivery is potentially a promising therapeutic target for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS0IFqnWN1v7Vg90H21EOLACvtfcHk0lgUcDc_U2TjGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGhu77O&md5=a14f37aab18bd596279da0dc2a842291</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14871%26sid%3Dliteratum%253Aachs%26aulast%3DBissonnette%26aufirst%3DR.%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DPoulin%26aufirst%3DY.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DRaman%26aufirst%3DM.%26aulast%3DMallbris%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPurohit%26aufirst%3DV.%26aulast%3DMamolo%26aufirst%3DC.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DPorts%26aufirst%3DW.%2BC.%26atitle%3DTopical%2520tofacitinib%2520for%2520atopic%2520dermatitis%253A%2520a%2520phase%2520IIa%2520randomized%2520trial%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D175%26spage%3D902%26epage%3D911%26doi%3D10.1111%2Fbjd.14871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, A. D.</span></span> <span> </span><span class="NLM_article-title">Atopic dermatitis</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1038/s41572-018-0001-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fs41572-018-0001-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=29930242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FgsFylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=1&author=S.+Weidingerauthor=L.+A.+Beckauthor=T.+Bieberauthor=K.+Kabashimaauthor=A.+D.+Irvine&title=Atopic+dermatitis&doi=10.1038%2Fs41572-018-0001-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic dermatitis</span></div><div class="casAuthors">Weidinger Stephan; Beck Lisa A; Bieber Thomas; Bieber Thomas; Kabashima Kenji; Irvine Alan D; Irvine Alan D; Irvine Alan D</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, with a lifetime prevalence of up to 20% and substantial effects on quality of life.  AD is characterized by intense itch, recurrent eczematous lesions and a fluctuating course.  AD has a strong heritability component and is closely related to and commonly co-occurs with other atopic diseases (such as asthma and allergic rhinitis).  Several pathophysiological mechanisms contribute to AD aetiology and clinical manifestations.  Impairment of epidermal barrier function, for example, owing to deficiency in the structural protein filaggrin, can promote inflammation and T cell infiltration.  The immune response in AD is skewed towards T helper 2 cell-mediated pathways and can in turn favour epidermal barrier disruption.  Other contributing factors to AD onset include dysbiosis of the skin microbiota (in particular overgrowth of Staphylococcus aureus), systemic immune responses (including immunoglobulin E (IgE)-mediated sensitization) and neuroinflammation, which is involved in itch.  Current treatments for AD include topical moisturizers and anti-inflammatory agents (such as corticosteroids, calcineurin inhibitors and cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4) inhibitors), phototherapy and systemic immunosuppressants.  Translational research has fostered the development of targeted small molecules and biologic therapies, especially for moderate-to-severe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRD30bRGadyc-xsqfvU0ziafW6udTcc2eZkGwTREktOXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FgsFylsQ%253D%253D&md5=8b21bcac0a6919a47c8af6690725394d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fs41572-018-0001-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41572-018-0001-z%26sid%3Dliteratum%253Aachs%26aulast%3DWeidinger%26aufirst%3DS.%26aulast%3DBeck%26aufirst%3DL.%2BA.%26aulast%3DBieber%26aufirst%3DT.%26aulast%3DKabashima%26aufirst%3DK.%26aulast%3DIrvine%26aufirst%3DA.%2BD.%26atitle%3DAtopic%2520dermatitis%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2018%26volume%3D4%26spage%3D1%26doi%3D10.1038%2Fs41572-018-0001-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors for atopic dermatitis: an update</span>. <i>Am. J. Clin. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s40257-018-0413-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1007%2Fs40257-018-0413-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=30536048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BB3cngs1Gnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=181-192&author=H.+Heauthor=E.+Guttman-Yassky&title=JAK+inhibitors+for+atopic+dermatitis%3A+an+update&doi=10.1007%2Fs40257-018-0413-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">JAK Inhibitors for Atopic Dermatitis: An Update</span></div><div class="casAuthors">He Helen; Guttman-Yassky Emma; Guttman-Yassky Emma</div><div class="citationInfo"><span class="NLM_cas:title">American journal of clinical dermatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-192</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is one of the most common inflammatory skin diseases.  AD is driven by barrier dysfunction and abnormal immune activation of T helper (Th) 2, Th22, and varying degrees of Th1 and Th17 among various subtypes.  The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and spleen tyrosine kinase (SYK) pathways are involved in signaling of several AD-related cytokines, such as IFN-γ, IL-4, IL-13, IL-31, IL-33, IL-23, IL-22, and IL-17, mediating downstream inflammation and barrier alterations.  While AD is primarily Th2-driven, the clinical and molecular heterogeneity of AD endotypes highlights the unmet need for effective therapeutic options that target more than one immune axis and are safe for long-term use.  The JAK inhibitors, which target different combinations of kinases, have overlapping but distinct mechanisms of action and safety profiles.  Several topical and oral JAK inhibitors have been shown to decrease AD severity and symptoms.  A review of the JAK and SYK inhibitors that are currently undergoing evaluation for efficacy and safety in the treatment of AD summarizes available data on a promising area of therapeutics and further elucidates the complex molecular interactions that drive AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAPBlCneYGgjQLBVDQn4bCfW6udTcc2eZkGwTREktOXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cngs1Gnug%253D%253D&md5=64df553216e84950efc632ee5060353f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs40257-018-0413-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40257-018-0413-2%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26atitle%3DJAK%2520inhibitors%2520for%2520atopic%2520dermatitis%253A%2520an%2520update%26jtitle%3DAm.%2520J.%2520Clin.%2520Dermatol.%26date%3D2019%26volume%3D20%26spage%3D181%26epage%3D192%26doi%3D10.1007%2Fs40257-018-0413-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemoto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, T.</span></span> <span> </span><span class="NLM_article-title">Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">831</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2019.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaad.2019.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=32029304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFOisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2020&pages=823-831&author=H.+Nakagawaauthor=O.+Nemotoauthor=A.+Igarashiauthor=H.+Saekiauthor=H.+Kainoauthor=T.+Nagata&title=Delgocitinib+ointment%2C+a+topical+Janus+kinase+inhibitor%2C+in+adult+patients+with+moderate+to+severe+atopic+dermatitis%3A+a+phase+3%2C+randomized%2C+double-blind%2C+vehicle-controlled+study+and+an+open-label%2C+long-term+extension+study&doi=10.1016%2Fj.jaad.2019.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study</span></div><div class="casAuthors">Nakagawa, Hidemi; Nemoto, Osamu; Igarashi, Atsuyuki; Saeki, Hidehisa; Kaino, Hironobu; Nagata, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">823-831</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Previous studies showed the potential effectiveness of delgocitinib ointment, a novel topical Janus kinase inhibitor, in atopic dermatitis (AD).  This study aimed to evaluate the efficacy and safety of delgocitinib 0.5% ointment.  In part 1, a 4-wk double-blind period, Japanese patients aged 16 years or older with moderate or severe AD were randomly assigned in a 2:1 ratio to delgocitinib 0.5% ointment or vehicle ointment.  Eligible patients entered part 2, a 24-wk extension period, to receive delgocitinib 0.5% ointment.  At the end of treatment in part 1, the least-squares mean percent changes from baseline in the modified Eczema Area and Severity Index score, the primary efficacy endpoint, were significantly greater in the delgocitinib group than in the vehicle group (-44.3% vs 1.7%, P < .001).  The improvement in modified Eczema Area and Severity Index score was maintained in part 2.  Most adverse events were mild and unrelated to delgocitinib across the study periods.  Only Japanese patients were included.  The vehicle-controlled period lasted only 4 wk.  In part 2, topical corticosteroids were allowed for the treatment of worsening of AD.  Delgocitinib ointment was effective and well tolerated in Japanese adult patients with moderate to severe AD for up to 28 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwjl1ABzs3rbVg90H21EOLACvtfcHk0li7GYrrcox89Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFOisLw%253D&md5=b716fad55ea63896fcab14cf039315be</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2019.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2019.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DNemoto%26aufirst%3DO.%26aulast%3DIgarashi%26aufirst%3DA.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DKaino%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DT.%26atitle%3DDelgocitinib%2520ointment%252C%2520a%2520topical%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520adult%2520patients%2520with%2520moderate%2520to%2520severe%2520atopic%2520dermatitis%253A%2520a%2520phase%25203%252C%2520randomized%252C%2520double-blind%252C%2520vehicle-controlled%2520study%2520and%2520an%2520open-label%252C%2520long-term%2520extension%2520study%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2020%26volume%3D82%26spage%3D823%26epage%3D831%26doi%3D10.1016%2Fj.jaad.2019.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemoto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, T.</span></span> <span> </span><span class="NLM_article-title">Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis</span>. <i>J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1111/1346-8138.15173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2F1346-8138.15173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=31820485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFKnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2020&pages=114-120&author=H.+Nakagawaauthor=O.+Nemotoauthor=A.+Igarashiauthor=H.+Saekiauthor=R.+Murataauthor=H.+Kainoauthor=T.+Nagata&title=Long-term+safety+and+efficacy+of+delgocitinib+ointment%2C+a+topical+Janus+kinase+inhibitor%2C+in+adult+patients+with+atopic+dermatitis&doi=10.1111%2F1346-8138.15173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis</span></div><div class="casAuthors">Nakagawa, Hidemi; Nemoto, Osamu; Igarashi, Atsuyuki; Saeki, Hidehisa; Murata, Ryusei; Kaino, Hironobu; Nagata, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-120</span>CODEN:
                <span class="NLM_cas:coden">JDMYAG</span>;
        ISSN:<span class="NLM_cas:issn">0385-2407</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Previous studies demonstrated that delgocitinib ointment, a novel topical Janus kinase inhibitor, rapidly improved clin. signs and symptoms of atopic dermatitis (AD) in Japanese adult patients.  We sought to evaluate the long-term safety and efficacy of delgocitinib 0.5% ointment in a 52-wk study (QBA4-2).  Japanese patients aged 16 years or older with AD received delgocitinib 0.5% ointment b.i.d. for up to 52 wk.  Topical corticosteroids for the treatment of worsening of AD could be used at the investigators discretion during the treatment period.  Safety end-points included the incidence and severity of adverse events (AEs).  Pooled safety analyses included the data from the other long-term study (QBA4-1).  Efficacy end-points included the percentage change from baseline in the modified Eczema Area and Severity Index (mEASI).  A total of 506 patients were included in the pooled safety population.  Overall, AEs were reported in 69.0% of patients; most AEs were mild and unrelated to delgocitinib ointment.  The most common AE was nasopharyngitis, followed by contact dermatitis, acne, and application site folliculitis.  No skin atrophy or telangiectasia was found at the application sites of delgocitinib ointment.  Application site irritation symptoms were infrequent (<2%) and mild.  The incidence of AEs did not increase over time, except for seasonal diseases.  The improvement effects on AD as assessed by mEASI were maintained throughout the treatment period.  Delgocitinib 0.5% ointment was well tolerated and effective when administrated to Japanese adult patients with AD for up to 52 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9y9USmzk0crVg90H21EOLACvtfcHk0li7GYrrcox89Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFKnsrs%253D&md5=114fb26bf87b5a9d6d0a468c7e8766e0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2F1346-8138.15173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1346-8138.15173%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DNemoto%26aufirst%3DO.%26aulast%3DIgarashi%26aufirst%3DA.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DMurata%26aufirst%3DR.%26aulast%3DKaino%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DT.%26atitle%3DLong-term%2520safety%2520and%2520efficacy%2520of%2520delgocitinib%2520ointment%252C%2520a%2520topical%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520adult%2520patients%2520with%2520atopic%2520dermatitis%26jtitle%3DJ.%2520Dermatol.%26date%3D2020%26volume%3D47%26spage%3D114%26epage%3D120%26doi%3D10.1111%2F1346-8138.15173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit53"><span> <i>JT Files New Drug Application of JTE-052 Ointment,
JAK inhibitor,
for the Treatment of Atopic Dermatitis in Japan</i>; <span class="NLM_publisher-name">Japan Tobacco Inc.</span>, <span class="NLM_year">2019</span>; <a href="https://www.jt.com/media/news/2019/pdf/20190131_E01.pdf" class="extLink">https://www.jt.com/media/news/2019/pdf/20190131_E01.pdf</a> (accessed 2020-01-20).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+JT+Files+New+Drug+Application+of+JTE-052+Ointment%2C%0AJAK+inhibitor%2C%0Afor+the+Treatment+of+Atopic+Dermatitis+in+Japan%3B+Japan+Tobacco+Inc.%2C+2019%3B+https%3A%2F%2Fwww.jt.com%2Fmedia%2Fnews%2F2019%2Fpdf%2F20190131_E01.pdf+%28accessed+2020-01-20%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DJT%2520Files%2520New%2520Drug%2520Application%2520of%2520JTE-052%2520Ointment%252C%250AJAK%2520inhibitor%252C%250Afor%2520the%2520Treatment%2520of%2520Atopic%2520Dermatitis%2520in%2520Japan%26pub%3DJapan%2520Tobacco%2520Inc%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit54"><span> <i>JT Receives Manufacturing
and Marketing Approval of CORECTIM Ointment
0.5% for the Treatment of Atopic Dermatitis in Japan</i>; <span class="NLM_publisher-name">Japan Tobacco Inc.</span>, <span class="NLM_year">2020</span>; <a href="https://www.jt.com/media/news/2020/pdf/20200123_E01.pdf" class="extLink">https://www.jt.com/media/news/2020/pdf/20200123_E01.pdf</a> (accessed 2020-01-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+JT+Receives+Manufacturing%0Aand+Marketing+Approval+of+CORECTIM+Ointment%0A0.5%25+for+the+Treatment+of+Atopic+Dermatitis+in+Japan%3B+Japan+Tobacco+Inc.%2C+2020%3B+https%3A%2F%2Fwww.jt.com%2Fmedia%2Fnews%2F2020%2Fpdf%2F20200123_E01.pdf+%28accessed+2020-01-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DJT%2520Receives%2520Manufacturing%250Aand%2520Marketing%2520Approval%2520of%2520CORECTIM%2520Ointment%250A0.5%2525%2520for%2520the%2520Treatment%2520of%2520Atopic%2520Dermatitis%2520in%2520Japan%26pub%3DJapan%2520Tobacco%2520Inc%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':[],'ref29':[],'ref30':[],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref55':['cit55'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Manfred Manßen, Danfeng Deng, Cameron H. M. Zheng, Rebecca C. DiPucchio, Dafa Chen, <span class="NLM_string-name hlFld-ContribAuthor">Laurel L. Schafer</span>. </span><span class="cited-content_cbyCitation_article-title">Ureate Titanium Catalysts for Hydroaminoalkylation: Using Ligand Design to Increase Reactivity and Utility. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2021,</strong> <em>11 </em>
                                    (8)
                                     , 4550-4560. <a href="https://doi.org/10.1021/acscatal.1c00014" title="DOI URL">https://doi.org/10.1021/acscatal.1c00014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.1c00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.1c00014%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DUreate%252BTitanium%252BCatalysts%252Bfor%252BHydroaminoalkylation%25253A%252BUsing%252BLigand%252BDesign%252Bto%252BIncrease%252BReactivity%252Band%252BUtility%26aulast%3DMan%25C3%259Fen%26aufirst%3DManfred%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D02012021%26date%3D27022021%26date%3D30032021%26volume%3D11%26issue%3D8%26spage%3D4550%26epage%3D4560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hiromu Takiguchi, Akinobu Higashi, Takashi Watanabe, Tsubasa Takeichi, Takahisa Shimazaki, <span class="NLM_string-name hlFld-ContribAuthor">Takashi Inaba</span>. </span><span class="cited-content_cbyCitation_article-title">Stereocontrolled Synthesis of Delgocitinib, a JAK Inhibitor for the Treatment of Atopic Dermatitis. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (2)
                                     , 342-348. <a href="https://doi.org/10.1021/acs.oprd.1c00031" title="DOI URL">https://doi.org/10.1021/acs.oprd.1c00031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.1c00031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.1c00031%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DStereocontrolled%252BSynthesis%252Bof%252BDelgocitinib%25252C%252Ba%252BJAK%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAtopic%252BDermatitis%26aulast%3DTakiguchi%26aufirst%3DHiromu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D26012021%26date%3D09022021%26volume%3D25%26issue%3D2%26spage%3D342%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eunsun Park, Sun Joo Lee, Heegyum Moon, Jongmi Park, Hyeonho Jeon, Ji Sun Hwang, Hayoung Hwang, Ki Bum Hong, Seung-Hee Han, Sun Choi, <span class="NLM_string-name hlFld-ContribAuthor">Soosung Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 958-979. <a href="https://doi.org/10.1021/acs.jmedchem.0c01026" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252BEvaluation%252Bof%252BN-Methyl-pyrrolo%25255B2%25252C3-b%25255Dpyridine-5-carboxamide%252BDerivatives%252Bas%252BJAK1-Selective%252BInhibitors%26aulast%3DPark%26aufirst%3DEunsun%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D16062020%26date%3D11012021%26volume%3D64%26issue%3D2%26spage%3D958%26epage%3D979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julie J.  Hong</span>, <span class="hlFld-ContribAuthor ">Megan L.  Mosca</span>, <span class="hlFld-ContribAuthor ">Edward K.  Hadeler</span>, <span class="hlFld-ContribAuthor ">Nicholas D.  Brownstone</span>, <span class="hlFld-ContribAuthor ">Tina  Bhutani</span>, <span class="hlFld-ContribAuthor ">Wilson J.  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. </span><span class="cited-content_cbyCitation_journal-name">Dermatology and Therapy</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     , 833-844. <a href="https://doi.org/10.1007/s13555-021-00536-6" title="DOI URL">https://doi.org/10.1007/s13555-021-00536-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13555-021-00536-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13555-021-00536-6%26sid%3Dliteratum%253Aachs%26jtitle%3DDermatology%2520and%2520Therapy%26atitle%3DGenital%252Band%252BInverse%25252FIntertriginous%252BPsoriasis%25253A%252BAn%252BUpdated%252BReview%252Bof%252BTherapies%252Band%252BRecommendations%252Bfor%252BPractical%252BManagement%26aulast%3DHong%26aufirst%3DJulie%2BJ.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D3%26spage%3D833%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahboobeh  Salehpour</span>, <span class="hlFld-ContribAuthor ">Javad  Azizian</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of interaction behavior between spiro[indene-2,2'-[1,3,5]oxathiazine]-1,3-diones and DNA with the help of DFT, molecular docking, and MD simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>8 </em>, 1-21. <a href="https://doi.org/10.1080/07391102.2021.1924266" title="DOI URL">https://doi.org/10.1080/07391102.2021.1924266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1924266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1924266%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DExploration%252Bof%252Binteraction%252Bbehavior%252Bbetween%252Bspiro%25255Bindene-2%25252C2%252527-%25255B1%25252C3%25252C5%25255Doxathiazine%25255D-1%25252C3-diones%252Band%252BDNA%252Bwith%252Bthe%252Bhelp%252Bof%252BDFT%25252C%252Bmolecular%252Bdocking%25252C%252Band%252BMD%252Bsimulations%26aulast%3DSalehpour%26aufirst%3DMahboobeh%26date%3D2021%26date%3D2021%26volume%3D8%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anastasiya V.  Agafonova</span>, <span class="hlFld-ContribAuthor ">Liya D.  Funt</span>, <span class="hlFld-ContribAuthor ">Mikhail S.  Novikov</span>, <span class="hlFld-ContribAuthor ">Alexander F.  Khlebnikov</span>. </span><span class="cited-content_cbyCitation_article-title">An isoxazole strategy for the synthesis of alkyl 5-amino-4-cyano-1
              H
              -pyrrole-2-carboxylates – versatile building blocks for assembling pyrrolo-fused heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (9)
                                     , 1976-1984. <a href="https://doi.org/10.1039/D1OB00053E" title="DOI URL">https://doi.org/10.1039/D1OB00053E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00053E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00053E%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DAn%252Bisoxazole%252Bstrategy%252Bfor%252Bthe%252Bsynthesis%252Bof%252Balkyl%252B5-amino-4-cyano-1%252BH%252B-pyrrole-2-carboxylates%252B%2525E2%252580%252593%252Bversatile%252Bbuilding%252Bblocks%252Bfor%252Bassembling%252Bpyrrolo-fused%252Bheterocycles%26aulast%3DAgafonova%26aufirst%3DAnastasiya%2BV.%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D9%26spage%3D1976%26epage%3D1984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kris  Meier</span>, <span class="hlFld-ContribAuthor ">Josep  Arús‐Pous</span>, <span class="hlFld-ContribAuthor ">Jean‐Louis  Reymond</span>. </span><span class="cited-content_cbyCitation_article-title">A Potent and Selective Janus Kinase Inhibitor with a Chiral 3D‐Shaped Triquinazine Ring System from Chemical Space. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (4)
                                     , 2102-2105. <a href="https://doi.org/10.1002/ange.202012049" title="DOI URL">https://doi.org/10.1002/ange.202012049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202012049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202012049%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DA%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252BInhibitor%252Bwith%252Ba%252BChiral%252B3D%2525E2%252580%252590Shaped%252BTriquinazine%252BRing%252BSystem%252Bfrom%252BChemical%252BSpace%26aulast%3DMeier%26aufirst%3DKris%26date%3D2021%26date%3D2020%26volume%3D133%26issue%3D4%26spage%3D2102%26epage%3D2105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kris  Meier</span>, <span class="hlFld-ContribAuthor ">Josep  Arús‐Pous</span>, <span class="hlFld-ContribAuthor ">Jean‐Louis  Reymond</span>. </span><span class="cited-content_cbyCitation_article-title">A Potent and Selective Janus Kinase Inhibitor with a Chiral 3D‐Shaped Triquinazine Ring System from Chemical Space. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (4)
                                     , 2074-2077. <a href="https://doi.org/10.1002/anie.202012049" title="DOI URL">https://doi.org/10.1002/anie.202012049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202012049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202012049%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DA%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252BInhibitor%252Bwith%252Ba%252BChiral%252B3D%2525E2%252580%252590Shaped%252BTriquinazine%252BRing%252BSystem%252Bfrom%252BChemical%252BSpace%26aulast%3DMeier%26aufirst%3DKris%26date%3D2021%26date%3D2020%26volume%3D60%26issue%3D4%26spage%3D2074%26epage%3D2077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Delgocitinib. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2020,</strong>,, 1016. <a href="https://doi.org/10.1055/s-0040-1705874" title="DOI URL">https://doi.org/10.1055/s-0040-1705874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1705874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1705874%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DSynthesis%252Bof%252BDelgocitinib%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D09%26spage%3D1016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of CP-690,550 (tofacitinib).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0002.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystallographic structure of JAK3 (human) in complex with JTE-052 focusing on binding site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C3N">7C3N</a>). Hydrogen bonds are depicted as dashed lines (yellow). Surfaces are shown around JTE-052 as meshed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0003.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vivo potency of JTE-052. (a) Effect of JTE-052 at 30, 3, and 0.3 mg/kg by po administration on the hind paw volume in a rat adjuvant-induced arthritis (AIA) model. The results are expressed as mean ± SD (<i>n</i> = 4). †, ‡: <i>p</i> < 0.05, <i>p</i> < 0.01 vs vehicle group by Dunnett’s test. (b) Effect of JTE-052 at 10 and 1 mg/kg by po administration on the ear thickness in a rat DNCB-induced chronic dermatitis model. The results are expressed as mean ± SD (<i>n</i> = 3–4). †, ‡: <i>p</i> < 0.05, <i>p</i> < 0.01 vs vehicle group by Dunnett’s test. §: <i>p</i> < 0.05 vs vehicle group by Steel test. (c) Effect of JTE-052 ointment at once a daily and three times a day on the ear thickness in a rat DNCB-induced chronic dermatitis model. The results are expressed as mean ± SD (<i>n</i> = 3–4). ‡: <i>p</i> < 0.01 vs vehicle group by Dunnett’s test. §, §§: <i>p</i> < 0.05, <i>p</i> < 0.01 vs vehicle group by Steel test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0005.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of JAK Inhibitors Composed of Various Hinge Binders (<b>3</b>–<b>13</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) for <b>3</b>, 4-chloroquinazoline, <i>i</i>-Pr<sub>2</sub>NEt, THF, microwave, 80 °C; for <b>4</b>, (i) 4-chloroquinoline, Pd<sub>2</sub>(dba)<sub>3</sub>, DAVEPHOS, NaO<i>t</i>-Bu, 1,4-dioxane, 80 °C, (ii) 4 N HCl in EtOAc; for <b>7</b> and <b>8</b>, corresponding heteroaryl chloride, <i>n</i>-BuOH, 145 °C; (b) <i>N</i>-methylcyclohexylamine, EtOH, 80 °C; (c) (i)TFA, anisole, 70 °C, (ii) 4 N NaOH, EtOH, 120 °C, (iii) SOCl<sub>2</sub>, toluene, 60 °C, (iv) 28% NH<sub>3</sub> aq, THF, rt; (d) (i) AcCl, Et<sub>3</sub>N, DMAP, CHCl<sub>3</sub>, 0 °C, (ii) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O; (e) for <b>9</b>, 2-aminopyridine, Pd(OAc)<sub>2</sub>, DPEphos, K<sub>2</sub>CO<sub>3</sub>, THF, 80 °C; for <b>10</b>, ethyl 4-aminobenzoate, Pd(OAc)<sub>2</sub>, DPEphos, K<sub>2</sub>CO<sub>3</sub>, THF, 80 °C; (f) (i) for <b>11</b> and <b>12</b>, corresponding amino lactam, NaBH(OAc)<sub>3</sub>, AcOH, CHCl<sub>3</sub>, rt, (ii) HCHO, NaBH(OAc)<sub>3</sub>, AcOH, CHCl<sub>3</sub>, rt; for <b>13</b>, (i) <i>N</i>-methylcyclohexylamine, TsOH, toluene, 90 °C then NaBH<sub>4</sub>, EtOH, rt, (ii) 4 N HCl in EtOAc, rt.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0006.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of JAK Inhibitors Listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> (<b>14</b>–<b>20</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl 4-aminobenzoate, Pd(OAc)<sub>2</sub>, DPEphos, K<sub>2</sub>CO<sub>3</sub>, THF, 80 °C; (b) LiAlH<sub>4</sub>, THF, rt; (c) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O, 50 °C; (d) NH<sub>4</sub>Cl or NHMe<sub>2</sub>, <i>i</i>-Pr<sub>2</sub>NEt, WSC·HCl, HOBt·H<sub>2</sub>O, DMF, rt.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0007.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Biaryl Amine-Based JAK Inhibitors Listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> (<b>21</b>–<b>25</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-aminobenzamide, <i>i</i>-Pr<sub>2</sub>NEt, THF, rt; (b) corresponding amine, <i>i</i>-Pr<sub>2</sub>NEt, DMA, 80 °C.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0008.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of JAK Inhibitors Bearing a Pyrrolopyrimidine (<b>26</b>–<b>29</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-(1-cyclohexylvinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, Pd(PPh<sub>3</sub>)<sub>4</sub>, 2 N Na<sub>2</sub>CO<sub>3</sub>, DME, microwave, 150 °C; (b) (i) cyclohexanol, NaH, THF, 80 °C, (ii) 4 N HCl in EtOAc, rt; (c) (i) H<sub>2</sub> (1 atm), Pd/C, EtOAc, rt, (ii) 4 N HCl in EtOAc, rt; (d) (i) cyclohexanecarbonyl chloride, <i>i</i>-PrMgCl, bis[2-<i>N</i>,<i>N</i>-dimethylaminoethyl]ether, THF, 0 °C, (ii) 2 N NaOH, THF, MeOH, rt.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0009.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of JAK Inhibitors Bearing a Pyrrolopyrimidine (<b>30</b>–<b>53</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) corresponding cyclic amine, <i>t</i>-BuOH, microwave, 100 °C; (b) correponding cyclic amime, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 100 °C; (c) 4 N HCl in EtOAc rt; (d) for <b>38</b>–<b>49</b>, 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile, <i>i</i>-Pr<sub>2</sub>NEt, 1,4-dioxane, 80 °C; for <b>50</b>, AcCl, Et<sub>3</sub>N, CHCl<sub>3</sub>, 0 °C; for <b>51</b>, (i) acetoxyacetyl chloride, Et<sub>3</sub>N, CHCl<sub>3</sub>, 0 °C, (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; for <b>52</b>, 2-methoxyacetyl chloride, Et<sub>3</sub>N, CHCl<sub>3</sub>, 0 °C; for <b>53</b>, 4-nitrophenyl (cyanomethyl)carbamate, <i>i</i>-Pr<sub>2</sub>NEt, DMA, rt.</p></p></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0004.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Synthetic strategy for a diazaspiroalkane containing an azetidine ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0010.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Route Scouting Based on Path A from Compound <b>77</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, 0.5 N NaOH, 1,4-dioxane, 0 °C to rt (62%); (b) CDI, NH<sub>4</sub>Cl, Et<sub>3</sub>N, THF, 0 °C to rt (quant); (c) TFAA, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt (45%); (d) KHMDS, 1-bromo-3-chloropropane, THF, −78 °C to rt (17%); (e) H<sub>2</sub> (4 atm), Raney Ni, 28% NH<sub>3</sub> aq MeOH, rt.</p></p></figure><figure data-id="sch7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0011.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Route Scouting Based on Path A from Compound <b>83</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, EtI, DMF, rt, (97%); (b) LiHMDS, allyl bromide, THF, −78 °C (88%); (c) BH<sub>3</sub>, THF, rt then 4 N NaOH, H<sub>2</sub>O<sub>2</sub>, 0 °C, (29%); (d) CBr<sub>4</sub>, PPh<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt (62%); (e) BnNH<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 120 °C (trace); (f) DMP CH<sub>2</sub>Cl<sub>2</sub>, rt (75%).</p></p></figure><figure data-id="sch8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0012.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Route Scouting Based on Path B from Compound <b>90</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ph<sub>3</sub>P<sup>+</sup>MeBr<sup>–</sup>, KO<i>t</i>-Bu, THF, rt, (85%); (b) ClSO<sub>2</sub>NCO, Et<sub>2</sub>O, rt.</p></p></figure><figure data-id="sch9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0013.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of JAK Inhibitor Bearing a Spirocycle (<b>54</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (EtO)<sub>2</sub>POCH<sub>2</sub>CO<sub>2</sub>Et, NaH, THF, 0 °C to rt; (b) NH<sub>3</sub> in MeOH, 80 °C; (c) 2 N NaOH, MeOH, rt; (d) tris(2-oxo-3-benzoxazolinnyl phosphine oxide, Et<sub>3</sub>N, CH<sub>3</sub>CN, 100 °C; (e) BnBr, NaH, DMF, rt; (f) 4 N HCl in EtOAc, rt then satd NaHCO<sub>3</sub>; (g) LiAlH<sub>4</sub>, H<sub>2</sub>SO<sub>4</sub>, THF, 0 °C; (h) (i) <b>73</b>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 100 °C, (ii) Pd/C, H<sub>2</sub> (4 atm), MeOH, rt, (iii) 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile, <i>i</i>-Pr<sub>2</sub>NEt, 1,4-dioxane, 100 °C.</p></p></figure><figure data-id="sch10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0014.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of JAK Inhibitors Bearing Various Spirocycles (<b>55</b>–<b>61</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BrCH<sub>2</sub>CH═CR<sup>2</sup>R<sup>3</sup>, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (b) LiHMDS, THF, −78 °C to rt then TMSCl, −78 °C to rt; (c) (i) DPPA, Et<sub>3</sub>N, toluene, 100 °C, then BnOH, DMAP, 100 °C; (d) O<sub>3</sub>, CHCl<sub>3</sub>, MeOH, −78 °C then NaBH<sub>4</sub>, −78 °C to rt; (e) (i) H<sub>2</sub> (1 atm), Pd/C, THF, rt, (ii) Et<sub>3</sub>N, Ph<sub>3</sub>P, CBr<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, (iii) <i>i</i>-Pr<sub>2</sub>NEt, CbzCl, 0 °C; (f) 4 N HCl in 1,4-dioxane, CHCl<sub>3</sub>, rt; (g) (i) <b>73</b>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 100 °C, (ii) Pd/C, H<sub>2</sub> (4 atm), THF, MeOH, rt; (h) 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile, <i>i</i>-Pr<sub>2</sub>NEt, 1,4-dioxane, 80 °C.</p></p></figure><figure data-id="sch11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/medium/jm0c00450_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0015.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Stereoselective Synthesis of JTE-052<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00450/20200701/images/large/jm0c00450_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00450&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BrCH<sub>2</sub>CO<sub>2</sub><i>t</i>-Bu, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C; (b) SOCl<sub>2</sub>, DMF, 60 °C; (c) LiHMDS, HMPA, THF, −78 to 0 °C; (d) H<sub>2</sub> (4 atm) Pd(OH)<sub>2</sub>/C, (BOC)<sub>2</sub>O, THF, MeOH, rt; (e) BrCH<sub>2</sub>CH═CMe<sub>2</sub>, LiHMDS, THF, −78 °C to −20 °C; (f) O<sub>3</sub>, PPh<sub>3</sub>, CHCl<sub>3</sub>, MeOH, −78 °C; (g) BnNH<sub>2</sub>, NaBH(OAc)<sub>3</sub>, THF, rt; (h) 4 N HCl in 1,4-dioxane, H<sub>2</sub>O; (i) HATU, <i>I</i>-Pr<sub>2</sub>NEt, DMF, rt; (j) LiAlH<sub>4</sub>, H<sub>2</sub>SO<sub>4</sub>, THF, 0 °C then (BOC)<sub>2</sub>O, rt; (k) H<sub>2</sub> (4 atm) Pd(OH)<sub>2</sub>/C, MeOH, rt; (l)<b>73</b>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, 100 °C; (m) 4 N HCl in 1,4-dioxane, CHCl<sub>3</sub>, MeOH, 60 °C; (n) 3-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-3-oxopropanenitrile, <i>i</i>-Pr<sub>2</sub>NEt, 1,4-dioxane, 100 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i107">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eyerich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyerich, S.</span></span> <span> </span><span class="NLM_article-title">Immune response patterns in non-communicable inflammatory skin diseases</span>. <i>J. Eur. Acad. Dermatol. Venereol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">692</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1111/jdv.14673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fjdv.14673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=29114938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ovFCiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=692-703&author=K.+Eyerichauthor=S.+Eyerich&title=Immune+response+patterns+in+non-communicable+inflammatory+skin+diseases&doi=10.1111%2Fjdv.14673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Immune response patterns in non-communicable inflammatory skin diseases</span></div><div class="casAuthors">Eyerich K; Eyerich S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the European Academy of Dermatology and Venereology : JEADV</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">692-703</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-communicable inflammatory skin diseases (ncISD) such as psoriasis or atopic eczema are a major cause of global disease burden.  Due to their impact and complexity, ncISD represent a major challenge of modern medicine.  Dermatology textbooks describe more than 100 different ncISD based on clinical phenotype and histological architecture.  In the last decades, this historical description was complemented by increasing molecular knowledge - and this knowledge is now being translated into specific therapeutics.  Combining the enormous advances made in lymphocyte immunology and molecular genetics with clinical and histological phenotyping reveals six immune response patterns of the skin - type I immune cells cause the lichenoid pattern characterized by immune-mediated cell death of keratinocytes; type II immune cells underlie the eczematous pattern with impaired epidermal barrier, infection and eosinophils as well as the bullous pattern with loss of epithelial integrity; Th17 cells and ILC3 mediate the psoriatic pattern characterized by acanthosis, high metabolic activity and neutrophils; dysbalance of regulatory T cells causes either the fibrogenic pattern with rarefication of cells and dermal thickening or the granulomatous pattern defined by formation of granulomas.  With more and more specific therapeutic agents approved, classifying ncISD also according to their immune response pattern will become highly relevant.  This review defines the six immune response patterns of ncISD and highlights therapeutic strategies targeting key lymphocyte mediators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLKUvEbSnBDpSWdIdmEou5fW6udTcc2ebkChpsXr80hLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ovFCiuw%253D%253D&md5=c77cce34f1f25f922e4cc176dded5944</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fjdv.14673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjdv.14673%26sid%3Dliteratum%253Aachs%26aulast%3DEyerich%26aufirst%3DK.%26aulast%3DEyerich%26aufirst%3DS.%26atitle%3DImmune%2520response%2520patterns%2520in%2520non-communicable%2520inflammatory%2520skin%2520diseases%26jtitle%3DJ.%2520Eur.%2520Acad.%2520Dermatol.%2520Venereol.%26date%3D2018%26volume%3D32%26spage%3D692%26epage%3D703%26doi%3D10.1111%2Fjdv.14673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, S. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resneck, J. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognia, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrer, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Beek, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sober, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerenz, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith Begolka, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyano, J. V.</span></span> <span> </span><span class="NLM_article-title">The burden of skin disease in the United States</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">958</span>– <span class="NLM_lpage">972</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2016.12.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaad.2016.12.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=28259441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BC1czivVSiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=958-972&author=H.+W.+Limauthor=S.+A.+B.+Collinsauthor=J.+J.+S.+Resneckauthor=J.+L.+Bologniaauthor=J.+A.+Hodgeauthor=T.+A.+Rohrerauthor=M.+J.+Van+Beekauthor=D.+J.+Margolisauthor=A.+J.+Soberauthor=M.+A.+Weinstockauthor=D.+R.+Nerenzauthor=W.+Smith+Begolkaauthor=J.+V.+Moyano&title=The+burden+of+skin+disease+in+the+United+States&doi=10.1016%2Fj.jaad.2016.12.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The burden of skin disease in the United States</span></div><div class="casAuthors">Lim Henry W; Collins Scott A B; Resneck Jack S Jr; Bolognia Jean L; Hodge Julie A; Rohrer Thomas A; Van Beek Marta J; Margolis David J; Sober Arthur J; Weinstock Martin A; Nerenz David R; Smith Begolka Wendy; Moyano Jose V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">958-972.e2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the publication of the last US national burden of skin disease report in 2006, there have been substantial changes in the practice of dermatology and the US health care system.  These include the development of new treatment modalities, marked increases in the cost of medications, increasingly complex payer rules and regulations, and an aging of the US population.  Recognizing the need for up-to-date data to inform researchers, policy makers, public stakeholders, and health care providers about the impact of skin disease on patients and US society, the American Academy of Dermatology produced a new national burden of skin disease report.  Using 2013 claims data from private and governmental insurance providers, this report analyzed the prevalence, cost, and mortality attributable to 24 skin disease categories in the US population.  In this first of 3 articles, the presented data demonstrate that nearly 85 million Americans were seen by a physician for at least 1 skin disease in 2013.  This led to an estimated direct health care cost of $75 billion and an indirect lost opportunity cost of $11 billion.  Further, mortality was noted in half of the 24 skin disease categories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrK0VuDKPusWHOrQ6qeX-mfW6udTcc2eZ7T95dVOfFnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czivVSiuw%253D%253D&md5=6885422c743b0171162dcfed2b5ff3dd</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2016.12.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2016.12.043%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DH.%2BW.%26aulast%3DCollins%26aufirst%3DS.%2BA.%2BB.%26aulast%3DResneck%26aufirst%3DJ.%2BJ.%2BS.%26aulast%3DBolognia%26aufirst%3DJ.%2BL.%26aulast%3DHodge%26aufirst%3DJ.%2BA.%26aulast%3DRohrer%26aufirst%3DT.%2BA.%26aulast%3DVan%2BBeek%26aufirst%3DM.%2BJ.%26aulast%3DMargolis%26aufirst%3DD.%2BJ.%26aulast%3DSober%26aufirst%3DA.%2BJ.%26aulast%3DWeinstock%26aufirst%3DM.%2BA.%26aulast%3DNerenz%26aufirst%3DD.%2BR.%26aulast%3DSmith%2BBegolka%26aufirst%3DW.%26aulast%3DMoyano%26aufirst%3DJ.%2BV.%26atitle%3DThe%2520burden%2520of%2520skin%2520disease%2520in%2520the%2520United%2520States%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2017%26volume%3D76%26spage%3D958%26epage%3D972%26doi%3D10.1016%2Fj.jaad.2016.12.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span> <span> </span><span class="NLM_article-title">The translational revolution and use of biologics in patients with inflammatory skin diseases</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2014.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaci.2014.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=25541257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1ersbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=324-336&author=S.+Nodaauthor=J.+G.+Kruegerauthor=E.+Guttman-Yassky&title=The+translational+revolution+and+use+of+biologics+in+patients+with+inflammatory+skin+diseases&doi=10.1016%2Fj.jaci.2014.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The translational revolution and use of biologics in patients with inflammatory skin diseases</span></div><div class="casAuthors">Noda, Shinji; Krueger, James G.; Guttman-Yassky, Emma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-336</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation.  Although T-cell infiltration characterizes both diseases, T-cell polarization differs.  Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/TH17 polarized.  In patients with AD, although therapeutic development is approx. a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (TH2, TH22, and IL-23/TH17).  These clin. trials and subsequent mol. analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZC48i_pyLyLVg90H21EOLACvtfcHk0lh3oBRSnwhSnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1ersbw%253D&md5=8dc31b8b2cc1a0bab77b543818c1dcff</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2014.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2014.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DNoda%26aufirst%3DS.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26atitle%3DThe%2520translational%2520revolution%2520and%2520use%2520of%2520biologics%2520in%2520patients%2520with%2520inflammatory%2520skin%2520diseases%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D135%26spage%3D324%26epage%3D336%26doi%3D10.1016%2Fj.jaci.2014.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasparakis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haase, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestle, F. O.</span></span> <span> </span><span class="NLM_article-title">Mechanisms regulating skin immunity and inflammation</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1038/nri3646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnri3646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=24722477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlajtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=289-301&author=M.+Pasparakisauthor=I.+Haaseauthor=F.+O.+Nestle&title=Mechanisms+regulating+skin+immunity+and+inflammation&doi=10.1038%2Fnri3646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms regulating skin immunity and inflammation</span></div><div class="casAuthors">Pasparakis, Manolis; Haase, Ingo; Nestle, Frank O.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">289-301</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immune responses in the skin are important for host defense against pathogenic microorganisms.  However, dysregulated immune reactions can cause chronic inflammatory skin diseases.  Extensive crosstalk between the different cellular and microbial components of the skin regulates local immune responses to ensure efficient host defense, to maintain and restore homeostasis, and to prevent chronic disease.  In this Review, we discuss recent findings that highlight the complex regulatory networks that control skin immunity, and we provide new paradigms for the mechanisms that regulate skin immune responses in host defense and in chronic inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6YV0xbMejgLVg90H21EOLACvtfcHk0lh3oBRSnwhSnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlajtrk%253D&md5=383246bd46717d6695fc4b6bcd363d49</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnri3646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3646%26sid%3Dliteratum%253Aachs%26aulast%3DPasparakis%26aufirst%3DM.%26aulast%3DHaase%26aufirst%3DI.%26aulast%3DNestle%26aufirst%3DF.%2BO.%26atitle%3DMechanisms%2520regulating%2520skin%2520immunity%2520and%2520inflammation%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D14%26spage%3D289%26epage%3D301%26doi%3D10.1038%2Fnri3646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, N.</span></span> <span> </span><span class="NLM_article-title">Atopic dermatitis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1122</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)00149-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2FS0140-6736%2815%2900149-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=26377142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BC283jtVShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=1109-1122&author=S.+Weidingerauthor=N.+Novak&title=Atopic+dermatitis&doi=10.1016%2FS0140-6736%2815%2900149-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic dermatitis</span></div><div class="casAuthors">Weidinger Stephan; Novak Natalija</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10023</span>),
    <span class="NLM_cas:pages">1109-1122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (also known as atopic eczema) is a chronic inflammatory skin disease that is characterised by intense itching and recurrent eczematous lesions.  Although it most often starts in infancy and affects two of ten children, it is also highly prevalent in adults.  It is the leading non-fatal health burden attributable to skin diseases, inflicts a substantial psychosocial burden on patients and their relatives, and increases the risk of food allergy, asthma, allergic rhinitis, other immune-mediated inflammatory diseases, and mental health disorders.  Originally regarded as a childhood disorder mediated by an imbalance towards a T-helper-2 response and exaggerated IgE responses to allergens, it is now recognised as a lifelong disposition with variable clinical manifestations and expressivity, in which defects of the epidermal barrier are central.  Present prevention and treatment focus on restoration of epidermal barrier function, which is best achieved through the use of emollients.  Topical corticosteroids are still the first-line therapy for acute flares, but they are also used proactively along with topical calcineurin inhibitors to maintain remission.  Non-specific immunosuppressive drugs are used in severe refractory cases, but targeted disease-modifying drugs are being developed.  We need to improve understanding of the heterogeneity of the disease and its subtypes, the role of atopy and autoimmunity, the mechanisms behind disease-associated itch, and the comparative effectiveness and safety of therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCv4mFAtl09MrRqEXsZufAfW6udTcc2eZ7T95dVOfFnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283jtVShsQ%253D%253D&md5=02bc2d67207d07d0a6b24f1da996792e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2900149-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252900149-X%26sid%3Dliteratum%253Aachs%26aulast%3DWeidinger%26aufirst%3DS.%26aulast%3DNovak%26aufirst%3DN.%26atitle%3DAtopic%2520dermatitis%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26spage%3D1109%26epage%3D1122%26doi%3D10.1016%2FS0140-6736%2815%2900149-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boehncke, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, M. P.</span></span> <span> </span><span class="NLM_article-title">Psoriasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)61909-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2FS0140-6736%2814%2961909-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=26025581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpt1Sht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=983-994&author=W.+H.+Boehnckeauthor=M.+P.+Schon&title=Psoriasis&doi=10.1016%2FS0140-6736%2814%2961909-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Psoriasis</span></div><div class="casAuthors">Boehncke, Wolf-Henning; Schon, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9997</span>),
    <span class="NLM_cas:pages">983-994</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Psoriasis is an immune-mediated, genetic disease manifesting in the skin or joints or both.  A diverse team of clinicians with a range of expertise is often needed to treat the disease.  Psoriasis provides many challenges including high prevalence, chronicity, disfiguration, disability, and assocd. comorbidity.  Understanding the role of immune function in psoriasis and the interplay between the innate and adaptive immune system has helped to manage this complex disease, which affects patients far beyond the skin.  In this Seminar, we highlight the clin. diversity of psoriasis and assocd. comorbid diseases.  We describe recent developments in psoriasis epidemiol., pathogenesis, and genetics to better understand present trends in psoriasis management.  Our key objective is to raise awareness of the complexity of this multifaceted disease, the potential of state-of-the-art therapeutic approaches, and the need for early diagnosis and comprehensive management of patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB2TaF6yGN8bVg90H21EOLACvtfcHk0lhVHe1O0U1m4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpt1Sht7s%253D&md5=616839f94122d1c1d167b9bd068283bd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2961909-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252961909-7%26sid%3Dliteratum%253Aachs%26aulast%3DBoehncke%26aufirst%3DW.%2BH.%26aulast%3DSchon%26aufirst%3DM.%2BP.%26atitle%3DPsoriasis%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D983%26epage%3D994%26doi%3D10.1016%2FS0140-6736%2814%2961909-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bewley, A.</span></span> <span> </span><span class="NLM_article-title">Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">920</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2133.2008.08479.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fj.1365-2133.2008.08479.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=18294314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ksFansQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2008&pages=917-920&author=A.+Bewley&title=Expert+consensus%3A+time+for+a+change+in+the+way+we+advise+our+patients+to+use+topical+corticosteroids&doi=10.1111%2Fj.1365-2133.2008.08479.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids</span></div><div class="casAuthors">Bewley A</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of dermatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">917-20</span>
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    </div><div class="casAbstract">Topical corticosteroids form the mainstay of treatment for many skin conditions.  If used appropriately, they are safe and effective, and side-effects are generally uncommon.  Current advice to patients to apply topical corticosteroid preparations 'sparingly' or 'thinly' contributes to 'steroid phobia', increasing the risk of poor clinical response and treatment failure.  Such cautionary advice also overlooks the fact that the vast majority of patients are prescribed topical corticosteroids of mild potency for which the evidence suggests that the risk of harm is minimal.  In the patient's mind, the current advice groups all steroids together regardless of their potential for adverse effects.  The advice also tends to reinforce an erroneous concern that the risks from topical corticosteroids may be similar to those from systemic corticosteroids.  We propose a change to make the pharmacy labelling of topical corticosteroids more accurately reflect the low risk of harm from corticosteroids of low to moderate potency and the importance of applying sufficient medication to achieve a satisfactory clinical response.  This change could provide the focus for updated, evidence-based education for healthcare professionals in prescribing of topical corticosteroids and help in the provision of more appropriate advice to patients.  We recommend that patients are informed that treatment should not exceed prescribed quantities, and continuing treatment should be under careful medical supervision.  We also recommend that topical corticosteroid products include clear 'fingertip unit' instructions, preferably with images of a 'fingertip unit' and a chart to show the number of units required for specific areas of the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnM1hKrqgj0vSAs_PE1QvifW6udTcc2eYznVbg6uY7yrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ksFansQ%253D%253D&md5=1dcea70b7d942fe4065227d50436431c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.2008.08479.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.2008.08479.x%26sid%3Dliteratum%253Aachs%26aulast%3DBewley%26aufirst%3DA.%26atitle%3DExpert%2520consensus%253A%2520time%2520for%2520a%2520change%2520in%2520the%2520way%2520we%2520advise%2520our%2520patients%2520to%2520use%2520topical%2520corticosteroids%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2008%26volume%3D158%26spage%3D917%26epage%3D920%26doi%3D10.1111%2Fj.1365-2133.2008.08479.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ring, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alomar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deleuran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink-Wagner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gieler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipozencic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oranje, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwennesen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidenari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stingl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szalai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szepietowski, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taieb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werfel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darsow, U.</span></span> <span> </span><span class="NLM_article-title">Guidelines for treatment of atopic eczema (atopic dermatitis) part I</span>. <i>J. Eur. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1060</span>, <span class="refDoi"> DOI: 10.1111/j.1468-3083.2012.04635.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fj.1468-3083.2012.04635.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=22805051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKjtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1045-1060&author=J.+Ringauthor=A.+Alomarauthor=T.+Bieberauthor=M.+Deleuranauthor=A.+Fink-Wagnerauthor=C.+Gelmettiauthor=U.+Gielerauthor=J.+Lipozencicauthor=T.+Lugerauthor=A.+P.+Oranjeauthor=T.+Schaferauthor=T.+Schwennesenauthor=S.+Seidenariauthor=D.+Simonauthor=S.+Standerauthor=G.+Stinglauthor=S.+Szalaiauthor=J.+C.+Szepietowskiauthor=A.+Taiebauthor=T.+Werfelauthor=A.+Wollenbergauthor=U.+Darsow&title=Guidelines+for+treatment+of+atopic+eczema+%28atopic+dermatitis%29+part+I&doi=10.1111%2Fj.1468-3083.2012.04635.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines for treatment of atopic eczema (atopic dermatitis) Part I</span></div><div class="casAuthors">Ring, J.; Alomar, A.; Bieber, T.; Deleuran, M.; Fink-Wagner, A.; Gelmetti, C.; Gieler, U.; Lipozencic, J.; Luger, T.; Oranje, A. P.; Schaefer, T.; Schwennesen, T.; Seidenari, S.; Simon, D.; Staender, S.; Stingl, G.; Szalai, S.; Szepietowski, J. C.; Taieb, A.; Werfel, T.; Wollenberg, A.; Darsow, U.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the European Academy of Dermatology and Venereology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1045-1060</span>CODEN:
                <span class="NLM_cas:coden">JEAVEQ</span>;
        ISSN:<span class="NLM_cas:issn">1468-3083</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national std. Appraisal of Guidelines Research and Evaluation.  The consensus process consisted of a nominal group process and a DELPHI procedure.  Management of AE must consider the individual symptomatic variability of the disease.  Basic therapy is focused on hydrating topical treatment, and avoidance of specific and unspecific provocation factors.  Anti-inflammatory treatment based on topical glucocorticosteroids and topical calcineurin inhibitors (TCI) is used for exacerbation management and more recently for proactive therapy in selected cases.  Topical corticosteroids remain the mainstay of therapy, but the TCI tacrolimus and pimecrolimus are preferred in certain locations.  Systemic immune-suppressive treatment is an option for severe refractory cases.  Microbial colonization and superinfection may induce disease exacerbation and can justify addnl. antimicrobial treatment.  Adjuvant therapy includes UV irradn. preferably with UVA1 wavelength or UVB 311 nm.  Dietary recommendations should be specific and given only in diagnosed individual food allergy.  Allergen-specific immunotherapy to aeroallergens may be useful in selected cases.  Stress-induced exacerbations may make psychosomatic counselling recommendable.  "Eczema school" educational programs have been proven to be helpful.  Pruritus is targeted with the majority of the recommended therapies, but some patients need addnl. antipruritic therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDDo36QS4CF7Vg90H21EOLACvtfcHk0lhVHe1O0U1m4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKjtbrP&md5=2222a565d3ef4eb2c7118cfa00316c4a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-3083.2012.04635.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-3083.2012.04635.x%26sid%3Dliteratum%253Aachs%26aulast%3DRing%26aufirst%3DJ.%26aulast%3DAlomar%26aufirst%3DA.%26aulast%3DBieber%26aufirst%3DT.%26aulast%3DDeleuran%26aufirst%3DM.%26aulast%3DFink-Wagner%26aufirst%3DA.%26aulast%3DGelmetti%26aufirst%3DC.%26aulast%3DGieler%26aufirst%3DU.%26aulast%3DLipozencic%26aufirst%3DJ.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DOranje%26aufirst%3DA.%2BP.%26aulast%3DSchafer%26aufirst%3DT.%26aulast%3DSchwennesen%26aufirst%3DT.%26aulast%3DSeidenari%26aufirst%3DS.%26aulast%3DSimon%26aufirst%3DD.%26aulast%3DStander%26aufirst%3DS.%26aulast%3DStingl%26aufirst%3DG.%26aulast%3DSzalai%26aufirst%3DS.%26aulast%3DSzepietowski%26aufirst%3DJ.%2BC.%26aulast%3DTaieb%26aufirst%3DA.%26aulast%3DWerfel%26aufirst%3DT.%26aulast%3DWollenberg%26aufirst%3DA.%26aulast%3DDarsow%26aufirst%3DU.%26atitle%3DGuidelines%2520for%2520treatment%2520of%2520atopic%2520eczema%2520%2528atopic%2520dermatitis%2529%2520part%2520I%26jtitle%3DJ.%2520Eur.%2520Acad.%2520Dermatol.%26date%3D2012%26volume%3D26%26spage%3D1045%26epage%3D1060%26doi%3D10.1111%2Fj.1468-3083.2012.04635.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmets, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfand, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo, J. Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Voorhees, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutner, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, R.</span></span> <span> </span><span class="NLM_article-title">Guidelines of care for the management of psoriasis and psoriatic arthritis section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2008.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaad.2008.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=19217694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BD1M3hsVWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=643-659&author=A.+Menterauthor=N.+J.+Kormanauthor=C.+A.+Elmetsauthor=S.+R.+Feldmanauthor=J.+M.+Gelfandauthor=K.+B.+Gordonauthor=A.+Gottliebauthor=J.+Y.+M.+Kooauthor=M.+Lebwohlauthor=H.+W.+Limauthor=A.+S.+Van+Voorheesauthor=K.+R.+Beutnerauthor=R.+Bhushan&title=Guidelines+of+care+for+the+management+of+psoriasis+and+psoriatic+arthritis+section+3.+Guidelines+of+care+for+the+management+and+treatment+of+psoriasis+with+topical+therapies&doi=10.1016%2Fj.jaad.2008.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</span></div><div class="casAuthors">Menter Alan; Korman Neil J; Elmets Craig A; Feldman Steven R; Gelfand Joel M; Gordon Kenneth B; Gottlieb Alice; Koo John Y M; Lebwohl Mark; Lim Henry W; Van Voorhees Abby S; Beutner Karl R; Bhushan Reva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">643-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Psoriasis is a common, chronic, inflammatory, multi-system disease with predominantly skin and joint manifestations affecting approximately 2% of the population.  In this third of 6 sections of the guidelines of care for psoriasis, we discuss the use of topical medications for the treatment of psoriasis.  The majority of patients with psoriasis have limited disease (<5% body surface area involvement) and can be treated with topical agents, which generally provide a high efficacy-to-safety ratio.  Topical agents may also be used adjunctively for patients with more extensive psoriasis undergoing therapy with either ultraviolet light, systemic or biologic medications.  However, the use of topical agents as monotherapy in the setting of extensive disease or in the setting of limited, but recalcitrant, disease is not routinely recommended.  Treatment should be tailored to meet individual patients' needs.  We will discuss the efficacy and safety of as well as offer recommendations for the use of topical corticosteroids, vitamin D analogues, tazarotene, tacrolimus, pimecrolimus, emollients, salicylic acid, anthralin, coal tar, as well as combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNrA_ozK6QJHy-c-E1v-fmfW6udTcc2eZkFrBkkdlI57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3hsVWnug%253D%253D&md5=c4975aee4050bd186fb5ff428a8f23bd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2008.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2008.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DMenter%26aufirst%3DA.%26aulast%3DKorman%26aufirst%3DN.%2BJ.%26aulast%3DElmets%26aufirst%3DC.%2BA.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGelfand%26aufirst%3DJ.%2BM.%26aulast%3DGordon%26aufirst%3DK.%2BB.%26aulast%3DGottlieb%26aufirst%3DA.%26aulast%3DKoo%26aufirst%3DJ.%2BY.%2BM.%26aulast%3DLebwohl%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DH.%2BW.%26aulast%3DVan%2BVoorhees%26aufirst%3DA.%2BS.%26aulast%3DBeutner%26aufirst%3DK.%2BR.%26aulast%3DBhushan%26aufirst%3DR.%26atitle%3DGuidelines%2520of%2520care%2520for%2520the%2520management%2520of%2520psoriasis%2520and%2520psoriatic%2520arthritis%2520section%25203.%2520Guidelines%2520of%2520care%2520for%2520the%2520management%2520and%2520treatment%2520of%2520psoriasis%2520with%2520topical%2520therapies%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2009%26volume%3D60%26spage%3D643%26epage%3D659%26doi%3D10.1016%2Fj.jaad.2008.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paller, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span> <span> </span><span class="NLM_article-title">Therapeutic pipeline for atopic dermatitis: end of the drought?</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">633</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2017.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaci.2017.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=28887947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BC1cbmtlSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=633-643&author=A.+S.+Pallerauthor=K.+Kabashimaauthor=T.+Bieber&title=Therapeutic+pipeline+for+atopic+dermatitis%3A+end+of+the+drought%3F&doi=10.1016%2Fj.jaci.2017.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic pipeline for atopic dermatitis: End of the drought?</span></div><div class="casAuthors">Paller Amy S; Kabashima Kenji; Bieber Thomas</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">633-643</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Until the past year, our therapeutic armamentarium for treating atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, systemic immunosuppressants.  The pipeline of more targeted topical and systemic therapies is expanding based on our growing understanding of the mechanism for AD and is particularly focused on suppressing the skewed immune activation.  Most agents are in phase 2 clinical trials.  Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available in late 2016 in the United States for mild-to-moderate AD, with other PDE4 inhibitors, an agonist of the aryl hydrocarbon receptor, Janus kinase inhibitors, and commensal organisms also in trials for topical application.  The first highly effective mAb for AD, dupilumab, targets the IL-4/IL-13 receptor and was approved in early 2017 in the United States for moderate-to-severe adult AD.  Other biologics similarly inhibit TH2 cytokines (thymic stromal lymphopoietin, IL-4, IL-5, IL-13, and the itch-specific cytokine IL-31 and their receptors) or TH22/TH17 cytokines, levels of which are increased in lesional skin.  Orally administered small-molecule inhibitors that suppress inflammation (targeting chemoattractant receptor-homologous molecules expressed on TH2 lymphocytes, PDE4, the histamine 4 receptor, and Janus kinase) or specifically itching (eg, NK1R inhibitors) are also being studied.  Comparing biomarkers with individual responses to experimental agents will help to determine subphenotypes within AD that predict prognosis and treatment responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWd6Thbey6Prt7lRqEFUJVfW6udTcc2eZkFrBkkdlI57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbmtlSrsQ%253D%253D&md5=66000cb56b3e306b9d09a2bba7cb9135</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2017.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2017.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DPaller%26aufirst%3DA.%2BS.%26aulast%3DKabashima%26aufirst%3DK.%26aulast%3DBieber%26aufirst%3DT.%26atitle%3DTherapeutic%2520pipeline%2520for%2520atopic%2520dermatitis%253A%2520end%2520of%2520the%2520drought%253F%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2017%26volume%3D140%26spage%3D633%26epage%3D643%26doi%3D10.1016%2Fj.jaci.2017.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hengge, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzicka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cork, M. J.</span></span> <span> </span><span class="NLM_article-title">Adverse effects of topical glucocorticosteroids</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2005.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaad.2005.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=16384751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BD2MnpsF2isw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=1-15&author=U.+R.+Henggeauthor=T.+Ruzickaauthor=R.+A.+Schwartzauthor=M.+J.+Cork&title=Adverse+effects+of+topical+glucocorticosteroids&doi=10.1016%2Fj.jaad.2005.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of topical glucocorticosteroids</span></div><div class="casAuthors">Hengge Ulrich R; Ruzicka Thomas; Schwartz Robert A; Cork Michael J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-15; quiz 16-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Topical corticosteroids were introduced into medicine about 50 years ago.  They represent a significant milestone in dermatologic therapy.  Despite encouragement to report observed adverse drug reactions, the clinical practice of reporting is poor and incomplete.  Likewise, adverse effects and safety of topical corticosteroids are neglected in the medical literature.  The authors provide an updated review of their adverse-effect profile.  Children are more prone to the development of systemic reactions to topically applied medication because of their higher ratio of total body surface area to body weight.  Cutaneous adverse effects occur regularly with prolonged treatment and are dependent on the chemical nature of the drug, the vehicle, and the location of its application.  The most frequent adverse effects include atrophy, striae, rosacea, perioral dermatitis, acne, and purpura.  Those that occur with lower frequency include hypertrichosis, pigmentation alterations, delayed wound healing, and exacerbation of skin infections.  Of particular interest is the rate of contact sensitization against corticosteroids, which is considerably higher than generally believed.  Systemic reactions such as hyperglycemia, glaucoma, and adrenal insufficiency have also been reported to follow topical application.  The authors provide an updated review of local and systemic adverse effects upon administration of topical corticosteroids, including the latest FDA report on the safety of such steroids in children.  LEARNING OBJECTIVE:  At the completion of this learning activity, participants should be familiar with topical corticosteroids and their proper use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrXh2cb8QSTLqxQ2mb9Pu8fW6udTcc2eZkFrBkkdlI57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnpsF2isw%253D%253D&md5=08f66f7a68bc5d643bd4198f22a7fb53</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2005.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2005.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DHengge%26aufirst%3DU.%2BR.%26aulast%3DRuzicka%26aufirst%3DT.%26aulast%3DSchwartz%26aufirst%3DR.%2BA.%26aulast%3DCork%26aufirst%3DM.%2BJ.%26atitle%3DAdverse%2520effects%2520of%2520topical%2520glucocorticosteroids%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2006%26volume%3D54%26spage%3D1%26epage%3D15%26doi%3D10.1016%2Fj.jaad.2005.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darnell, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, G. R.</span></span> <span> </span><span class="NLM_article-title">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>264</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1421</span>, <span class="refDoi"> DOI: 10.1126/science.8197455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1126%2Fscience.8197455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=8197455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=1415-1421&author=J.+E.+J.+Darnellauthor=I.+M.+Kerrauthor=G.+R.+Stark&title=Jak-STAT+pathways+and+transcriptional+activation+in+response+to+IFNs+and+other+extracellular+signaling+proteins&doi=10.1126%2Fscience.8197455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span></div><div class="casAuthors">Darnell, James E., Jr.; Kerr, Ian M.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5164</span>),
    <span class="NLM_cas:pages">1415-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 97 refs.  Through the study of transcriptional activation in response to interferon α (IFN-α) and interferon γ (IFN-γ), a previously unrecognized direct signal transduction pathway to the nucleus has been uncovered: IFN-receptor interaction at the cell surface leads to the activation of kinases of the Jak family that then phosphorylate substrate proteins called STATs (signal transducers and activators of transcription).  The phosphorylated STAT proteins move to the nucleus, bind specific DNA elements, and direct transcription.  Recognition of the mols. involved in the IFN-α and IFN-γ pathway has led to discoveries that a no. of STAT family members exist and that other polypeptide ligands also use the Jak-STAT mols. in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64rvN_qWlmLVg90H21EOLACvtfcHk0lgiLG4NaDjl0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D&md5=f63d2c7bb3c1aeca6f36fef38aff713c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.8197455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8197455%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DJak-STAT%2520pathways%2520and%2520transcriptional%2520activation%2520in%2520response%2520to%2520IFNs%2520and%2520other%2520extracellular%2520signaling%2520proteins%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D1415%26epage%3D1421%26doi%3D10.1126%2Fscience.8197455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R. D.</span></span> <span> </span><span class="NLM_article-title">Cytokine signaling in 2002: new surprises in the Jak/Stat pathway</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">Suppl</span>),  <span class="NLM_fpage">S121</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(02)00701-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2FS0092-8674%2802%2900701-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=11983158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1equr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=S121-31&issue=Suppl&author=J.+J.+O%E2%80%99Sheaauthor=M.+Gadinaauthor=R.+D.+Schreiber&title=Cytokine+signaling+in+2002%3A+new+surprises+in+the+Jak%2FStat+pathway&doi=10.1016%2FS0092-8674%2802%2900701-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine signaling in 2002: New surprises in the Jak/Stat pathway</span></div><div class="casAuthors">O'Shea, John J.; Gadina, Massimo; Schreiber, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Rev. Suppl.</span>),
    <span class="NLM_cas:pages">S121-S131</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The importance of Jak-Stat pathway signaling in regulating cytokine-dependent gene expression and cellular development/survival is well established.  Nevertheless, advances continue to be made in defining Jak-Stat pathway effects on different cellular processes and in different organisms.  This review focuses on recent advances in the field and highlights some of the most active areas of Jak-Stat pathway research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjCEpjQr_xWrVg90H21EOLACvtfcHk0lgiLG4NaDjl0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1equr0%253D&md5=257fe5cb5ed0070a8b05c8e5adf65ad5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900701-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900701-8%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DCytokine%2520signaling%2520in%25202002%253A%2520new%2520surprises%2520in%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DCell%26date%3D2002%26volume%3D109%26issue%3DSuppl%26spage%3DS121%26epage%3D31%26doi%3D10.1016%2FS0092-8674%2802%2900701-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">Regulation of JAK–STAT singnaling in the immune system</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-911&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK%E2%80%93STAT+singnaling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lgiLG4NaDjl0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK%25E2%2580%2593STAT%2520singnaling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D911%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenge, R.</span></span> <span> </span><span class="NLM_article-title">JAK and STAT signaling molecules in immunoregulation and immune-mediated disease</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2012.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.immuni.2012.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=22520847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=542-550&author=J.+J.+O%E2%80%99Sheaauthor=R.+Plenge&title=JAK+and+STAT+signaling+molecules+in+immunoregulation+and+immune-mediated+disease&doi=10.1016%2Fj.immuni.2012.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease</span></div><div class="casAuthors">O'Shea, John J.; Plenge, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">542-550</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The discovery of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway, a landmark in cell biol., provided a simple mechanism for gene regulation that dramatically advanced our understanding of the action of hormones, interferons, colony-stimulating factors, and interleukins.  As we learn more about the complexities of immune responses, new insights into the functions of this pathway continue to be revealed, aided by technol. that permits genome-wide views.  As we celebrate the 20th anniversary of the discovery of this paradigm in cell signaling, it is particularly edifying to see how this knowledge has rapidly been translated to human immune disease.  Not only have genome-wide assocn. studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc6dj5Zf9fdLVg90H21EOLACvtfcHk0lgOjzwEcdsPOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFWqt7g%253D&md5=de187a0555549f9f00f5a41052c05352</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2012.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2012.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPlenge%26aufirst%3DR.%26atitle%3DJAK%2520and%2520STAT%2520signaling%2520molecules%2520in%2520immunoregulation%2520and%2520immune-mediated%2520disease%26jtitle%3DImmunity%26date%3D2012%26volume%3D36%26spage%3D542%26epage%3D550%26doi%3D10.1016%2Fj.immuni.2012.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giliani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugazio, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candotti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sheai, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vezzoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notarangelo, L. D.</span></span> <span> </span><span class="NLM_article-title">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1038/377065a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2F377065a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=7659163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1995&pages=65-68&author=P.+Macchiauthor=A.+Villaauthor=S.+Gilianiauthor=M.+G.+Saccoauthor=A.+Frattiniauthor=F.+Portaauthor=A.+G.+Ugazioauthor=J.+A.+Johnstonauthor=F.+Candottiauthor=J.+J.+O%E2%80%99Sheaiauthor=P.+Vezzoniauthor=L.+D.+Notarangelo&title=Mutations+of+Jak-3+gene+in+patients+with+autosomal+severe+combined+immune+deficiency+%28SCID%29&doi=10.1038%2F377065a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</span></div><div class="casAuthors">Macchi, Paolo; Villa, Anna; Giliani, Silvia; Sacco, Maria G.; Frattini, Annalisa; Porta, Fulvio; Ugazio, Alberto G.; Johnston, James A.; Candotti, Fabio; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">6544</span>),
    <span class="NLM_cas:pages">65-8</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Severe combined immune deficiency (SCID) represents a heterogeneous group of hereditary diseases.  Mutations in the common γ-chain (γc), which is part of several cytokine receptors including those for interleukin (IL)-2, IL-4, IL-7, IL-9 and IL-15, are responsible for X-linked SCID, which is usually assocd. with a lack of circulating T cells and the presence of B lymphocytes (T- B+ SCID).  The gene(s) responsible for autosomal recessive T- B+ SCID is still unknown.  The Jak-3 protein kinase has been found to assoc. with the γc-chain-contg. cytokine receptors.  Therefore Jak-3 or other STAT proteins with which it interacts are candidate genes for autosomal recessive T- B+ SCID.  Here the authors investigate two unrelated T- B+ SCID patients (both from consanguineous parents) who have homozygous mutations in the gene for Jak-3.  One patient carries a mutation (Tyr100→Cys) in a conserved tyrosine residue in the JH7 domain of Jak-3 which is absent in more than 150 investigated chromosomes.  The other patient carries a homozygous 151-base-pair deletion in the kinase-like domain, leading to a frameshift and premature termination.  Both mutations resulted in markedly reduced levels of Jak-3.  These findings show that abnormalities in the Jak/STAT signaling pathway can account for SCID in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJWFs-Wbegq7Vg90H21EOLACvtfcHk0lgOjzwEcdsPOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvFektb4%253D&md5=ac5a7064e6c3361c8906813770e1b6d9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2F377065a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F377065a0%26sid%3Dliteratum%253Aachs%26aulast%3DMacchi%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DA.%26aulast%3DGiliani%26aufirst%3DS.%26aulast%3DSacco%26aufirst%3DM.%2BG.%26aulast%3DFrattini%26aufirst%3DA.%26aulast%3DPorta%26aufirst%3DF.%26aulast%3DUgazio%26aufirst%3DA.%2BG.%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DCandotti%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Sheai%26aufirst%3DJ.%2BJ.%26aulast%3DVezzoni%26aufirst%3DP.%26aulast%3DNotarangelo%26aufirst%3DL.%2BD.%26atitle%3DMutations%2520of%2520Jak-3%2520gene%2520in%2520patients%2520with%2520autosomal%2520severe%2520combined%2520immune%2520deficiency%2520%2528SCID%2529%26jtitle%3DNature%26date%3D1995%26volume%3D377%26spage%3D65%26epage%3D68%26doi%3D10.1038%2F377065a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conklyn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koslov, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milici, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckius, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodworth, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaweco, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beals, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littman, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagouras, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magna, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltarelli, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelms, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Des Etages, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finco-Kent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paniagua, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borie, D. C.</span></span> <span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>302</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">878</span>, <span class="refDoi"> DOI: 10.1126/science.1087061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor&doi=10.1126%2Fscience.1087061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lgOjzwEcdsPOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878%26doi%3D10.1126%2Fscience.1087061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0ljC67ns4i-2tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+development+of+Janus+kinase+%28JAK%29+inhibitors+for+inflammatory+diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0lgyHCaY_Q6Epw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520for%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnrd.2017.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=29104284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=843-862&author=D.+M.+Schwartzauthor=Y.+Kannoauthor=A.+Villarinoauthor=M.+Wardauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=JAK+inhibition+as+a+therapeutic+strategy+for+immune+and+inflammatory+diseases&doi=10.1038%2Fnrd.2017.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">JAK inhibition as a therapeutic strategy for immune and inflammatory diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Kanno, Yuka; Villarino, Alejandro; Ward, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">843-862</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts to target their assocd. signalling pathways.  Janus kinases (JAKs) are essential signalling mediators downstream of many pro-inflammatory cytokines, and small-mol. inhibitors of JAKs (jakinibs) have gained traction as safe and efficacious options for the treatment of inflammation-driven pathologies such as rheumatoid arthritis, psoriasis and inflammatory bowel disease.  Building on the clin. success of first-generation jakinibs, second-generation compds. that claim to be more selective are currently undergoing development and proceeding to clin. trials.  However, important questions remain about the advantages and limitations of improved JAK selectivity, optimal routes and dosing regimens and how best to identify patients who will benefit from jakinibs.  This Review discusses the biol. of jakinibs from a translational perspective, focusing on recent insights from clin. trials, the development of novel agents and the use of jakinibs in a spectrum of immune and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9TNpGT01l8rVg90H21EOLACvtfcHk0lgyHCaY_Q6Epw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGqsLnO&md5=4607422f83f94c0c7194935d6d460c31</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.201%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DKanno%26aufirst%3DY.%26aulast%3DVillarino%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520therapeutic%2520strategy%2520for%2520immune%2520and%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D843%26epage%3D862%26doi%3D10.1038%2Fnrd.2017.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombs, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos-Vargas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span> <span> </span><span class="NLM_article-title">The Safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis. Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1905</span>, <span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+F.+Zerbiniauthor=S.+H.+Zwillich&title=The+Safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis.+Results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lgyHCaY_Q6Epw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%2BF.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520Safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis.%2520Results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korniski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gormley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leone, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommers, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenbrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasselli, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, T. E.</span></span> <span> </span><span class="NLM_article-title">Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>400</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2010.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jmb.2010.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=20478313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=2010&pages=413-433&author=J.+E.+Chrencikauthor=A.+Patnyauthor=I.+K.+Leungauthor=B.+Korniskiauthor=T.+L.+Emmonsauthor=T.+Hallauthor=R.+A.+Weinbergauthor=J.+A.+Gormleyauthor=J.+M.+Williamsauthor=J.+E.+Dayauthor=J.+L.+Hirschauthor=J.+R.+Kieferauthor=J.+W.+Leoneauthor=H.+D.+Fischerauthor=C.+D.+Sommersauthor=H.-C.+Huangauthor=E.+J.+Jacobsenauthor=R.+E.+Tenbrinkauthor=A.+G.+Tomasselliauthor=T.+E.+Benson&title=Structural+and+thermodynamic+characterization+of+the+TYK2+and+JAK3+kinase+domains+in+complex+with+CP-690550+and+CMP-6&doi=10.1016%2Fj.jmb.2010.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6</span></div><div class="casAuthors">Chrencik, Jill E.; Patny, Akshay; Leung, Iris K.; Korniski, Brian; Emmons, Thomas L.; Hall, Troii; Weinberg, Robin A.; Gormley, Jennifer A.; Williams, Jennifer M.; Day, Jacqueline E.; Hirsch, Jeffrey L.; Kiefer, James R.; Leone, Joseph W.; Fischer, H. David; Sommers, Cynthia D.; Huang, Horng-Chih; Jacobsen, E. J.; Tenbrink, Ruth E.; Tomasselli, Alfredo G.; Benson, Timothy E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">400</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-433</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are crit. regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases.  Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clin. compd. CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.  Here, we report the crystal structures of TYK2, a first in class structure, and JAK3 in complex with PAN-JAK inhibitors CP-690550 ((3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile) and CMP-6 (tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one), both of which bind in the ATP-binding cavities of both JAK isoenzymes in orientations similar to that obsd. in crystal structures of JAK1 and JAK2.  Addnl., a complete thermodn. characterization of JAK/CP-690550 complex formation was completed by isothermal titrn. calorimetry, indicating the crit. role of the nitrile group from the CP-690550 compd.  Finally, computational anal. using WaterMap further highlights the crit. positioning of the CP-690550 nitrile group in the displacement of an unfavorable water mol. beneath the glycine-rich loop.  Taken together, the data emphasize the outstanding properties of the kinome-selective JAK inhibitor CP-690550, as well as the challenges in obtaining JAK isoenzyme-selective inhibitors due to the overall structural and sequence similarities between the TYK2, JAK1, JAK2 and JAK3 isoenzymes.  Nevertheless, subtle amino acid variations of residues lining the ligand-binding cavity of the JAK enzymes, as well as the global positioning of the glycine-rich loop, might provide the initial clues to obtaining JAK-isoenzyme selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dnGkvq0jPbVg90H21EOLACvtfcHk0lhdee1-N2fk2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ylt7g%253D&md5=1b1efc3d6f913143dc9113e4ac1c4c60</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2010.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2010.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DChrencik%26aufirst%3DJ.%2BE.%26aulast%3DPatny%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DI.%2BK.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DEmmons%26aufirst%3DT.%2BL.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26aulast%3DGormley%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DDay%26aufirst%3DJ.%2BE.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DKiefer%26aufirst%3DJ.%2BR.%26aulast%3DLeone%26aufirst%3DJ.%2BW.%26aulast%3DFischer%26aufirst%3DH.%2BD.%26aulast%3DSommers%26aufirst%3DC.%2BD.%26aulast%3DHuang%26aufirst%3DH.-C.%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DTenbrink%26aufirst%3DR.%2BE.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DBenson%26aufirst%3DT.%2BE.%26atitle%3DStructural%2520and%2520thermodynamic%2520characterization%2520of%2520the%2520TYK2%2520and%2520JAK3%2520kinase%2520domains%2520in%2520complex%2520with%2520CP-690550%2520and%2520CMP-6%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2010%26volume%3D400%26spage%3D413%26epage%3D433%26doi%3D10.1016%2Fj.jmb.2010.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuntz, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollman, P. A.</span></span> <span> </span><span class="NLM_article-title">The maximal affinity of ligands</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">9997</span>– <span class="NLM_lpage">10002</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.18.9997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1073%2Fpnas.96.18.9997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10468550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFehu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=9997-10002&author=I.+D.+Kuntzauthor=K.+Chenauthor=K.+A.+Sharpauthor=P.+A.+Kollman&title=The+maximal+affinity+of+ligands&doi=10.1073%2Fpnas.96.18.9997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The maximal affinity of ligands</span></div><div class="casAuthors">Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9997-10002</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We explore the question of what are the best ligands for macromol. targets.  A survey of exptl. data on a large no. of the strongest-binding ligands indicates that the free energy of binding increases with the no. of nonhydrogen atoms with an initial slope of ≈-1.5 kcal/mol (1 cal = 4.18 J) per atom.  For ligands that contain more than 15 nonhydrogen atoms, the free energy of binding increases very little with relative mol. mass.  This nonlinearity is largely ascribed to nonthermodynamic factors.  An anal. of the dominant interactions suggests that van der Waals interactions and hydrophobic effects provide a reasonable basis for understanding binding affinities across the entire set of ligands.  Interesting outliers that bind unusually strongly on a per atom basis include metal ions, covalently attached ligands, and a few well known complexes such as biotin-avidin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0L6KZhR0TxbVg90H21EOLACvtfcHk0lhdee1-N2fk2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFehu7s%253D&md5=46fe894b016f3041831a2f0b71f812b1</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.18.9997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.18.9997%26sid%3Dliteratum%253Aachs%26aulast%3DKuntz%26aufirst%3DI.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DSharp%26aufirst%3DK.%2BA.%26aulast%3DKollman%26aufirst%3DP.%2BA.%26atitle%3DThe%2520maximal%2520affinity%2520of%2520ligands%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D9997%26epage%3D10002%26doi%3D10.1073%2Fpnas.96.18.9997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=Springthorpe%2C+B.+The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lhdee1-N2fk2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DSpringthorpe%252C%2520B.%2520The%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abad-Zapatero, C.</span></span> <span> </span><span class="NLM_article-title">Ligand efficiency indices for effective drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1517/17460441.2.4.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1517%2F17460441.2.4.469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=23484756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=469-488&author=C.+Abad-Zapatero&title=Ligand+efficiency+indices+for+effective+drug+discovery&doi=10.1517%2F17460441.2.4.469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices for effective drug discovery</span></div><div class="casAuthors">Abad-Zapatero, Cele</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-488</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Successful drug discovery requires the optimization of a large no. of variables ranging from strictly physicochem. parameters such as mol. wt. to more complex parameters related to toxicity and bioavailability.  Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclin. characterization.  However, crit. biol. issues along the path to the market have diminished the impact and power of this methodol.  The physicochem. properties of the novel chem. entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate.  The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process.  More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context.  Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKduo41JcS7Vg90H21EOLACvtfcHk0lgA1VN7r1OZLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D&md5=a1682fbc4545d8eab3a44417c0e88869</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.4.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.4.469%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26atitle%3DLigand%2520efficiency%2520indices%2520for%2520effective%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D469%26epage%3D488%26doi%3D10.1517%2F17460441.2.4.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keserü, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. H.</span></span> <span> </span><span class="NLM_article-title">The role of ligand efficiency metrics in drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1038/nrd4163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fnrd4163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=24481311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=105-121&author=A.+L.+Hopkinsauthor=G.+M.+Keser%C3%BCauthor=P.+D.+Leesonauthor=D.+C.+Reesauthor=C.+H.+Reynolds&title=The+role+of+ligand+efficiency+metrics+in+drug+discovery&doi=10.1038%2Fnrd4163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The role of ligand efficiency metrics in drug discovery</span></div><div class="casAuthors">Hopkins, Andrew L.; Keserue, Gyoergy M.; Leeson, Paul D.; Rees, David C.; Reynolds, Charles H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-121</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The judicious application of ligand or binding efficiency metrics, which quantify the mol. properties required to obtain binding affinity for a drug target, is gaining traction in the selection and optimization of fragments, hits and leads.  Retrospective anal. of recently marketed oral drugs shows that they frequently have highly optimized ligand efficiency values for their targets.  Optimizing ligand efficiency metrics based on both mol. mass and lipophilicity, when set in the context of the specific target, has the potential to ameliorate the inflation of these properties that has been obsd. in current medicinal chem. practice, and to increase the quality of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq96uhvE1OZ5LVg90H21EOLACvtfcHk0lgA1VN7r1OZLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SmtLk%253D&md5=344030e59f499180f79d311302a27532</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrd4163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4163%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DKeser%25C3%25BC%26aufirst%3DG.%2BM.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReynolds%26aufirst%3DC.%2BH.%26atitle%3DThe%2520role%2520of%2520ligand%2520efficiency%2520metrics%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D105%26epage%3D121%26doi%3D10.1038%2Fnrd4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pirrung, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halstead, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, N. J. G.</span></span> <span> </span><span class="NLM_article-title">Methyl Scanning: Total synthesis of demethylasterriquinone B1 and derivatives for identification of sites of interaction with and isolation of its receptor(s)</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">4609</span>– <span class="NLM_lpage">4624</span>, <span class="refDoi"> DOI: 10.1021/ja044325h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja044325h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Krtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=4609-4624&author=M.+C.+Pirrungauthor=Y.+Liuauthor=L.+Dengauthor=D.+K.+Halsteadauthor=Z.+Liauthor=J.+F.+Mayauthor=M.+Wedelauthor=D.+A.+Austinauthor=N.+J.+G.+Webster&title=Methyl+Scanning%3A+Total+synthesis+of+demethylasterriquinone+B1+and+derivatives+for+identification+of+sites+of+interaction+with+and+isolation+of+its+receptor%28s%29&doi=10.1021%2Fja044325h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Scanning: Total Synthesis of Demethylasterriquinone B1 and Derivatives for Identification of Sites of Interaction with and Isolation of Its Receptor(s)</span></div><div class="casAuthors">Pirrung, Michael C.; Liu, Yufa; Deng, Liu; Halstead, Diana K.; Li, Zhitao; May, John F.; Wedel, Michael; Austin, Darrell A.; Webster, Nicholas J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4609-4624</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The principle of Me scanning is proposed for detn. of the sites of interaction between biol. active small mols. and their macromol. target(s).  It involves the systematic prepn. of a family of methylated derivs. of a compd. and their biol. testing.  As a functional assay, the method can identify the regions of a mol. that are important (and unimportant) for biol. activity against even unknown targets, and thus provides an excellent complement to structural biol.  Me scanning was applied to demethylasterriquinone B1, a small-mol. mimetic of insulin.  A new, optimal total synthesis of this natural product was developed that enables the family of Me scan derivs. to be concisely prepd. for evaluation in a cellular assay.  The results of this expt. were used to design a biotin-demethylasterriquinone conjugate for use as an affinity reagent.  This compd. was prepd. in tens of milligram quantities in a four-step synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFivtvsdHSBLVg90H21EOLACvtfcHk0lgA1VN7r1OZLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Krtrw%253D&md5=0556ce71c359790203c641280d133dbf</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja044325h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja044325h%26sid%3Dliteratum%253Aachs%26aulast%3DPirrung%26aufirst%3DM.%2BC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DHalstead%26aufirst%3DD.%2BK.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMay%26aufirst%3DJ.%2BF.%26aulast%3DWedel%26aufirst%3DM.%26aulast%3DAustin%26aufirst%3DD.%2BA.%26aulast%3DWebster%26aufirst%3DN.%2BJ.%2BG.%26atitle%3DMethyl%2520Scanning%253A%2520Total%2520synthesis%2520of%2520demethylasterriquinone%2520B1%2520and%2520derivatives%2520for%2520identification%2520of%2520sites%2520of%2520interaction%2520with%2520and%2520isolation%2520of%2520its%2520receptor%2528s%2529%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D4609%26epage%3D4624%26doi%3D10.1021%2Fja044325h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="note"><p class="first last">These Fsp<sup>3</sup> values were calculated as part of our post analysis of our work on the JAK inhibition project.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="note"><p class="first last">On the basis of the structure of <i>ent</i>-<b>60</b> (JTE-052) inferred from the X-ray cocrystal analysis (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), <i>ent</i>-<b>60</b> (JTE-052) was synthesized according to <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>. The JAK3 inhibitory activity of provided compound accorded with those of <i>ent</i>-<b>60</b>. The absolute stereochemistry of <i>ent</i>-<b>60</b> (JTE-052) was afterward confirmed by its X-ray crystallographic analysis. The detailed data was described in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last">The detailed kinase panel results are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harstad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebens, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3149</span>– <span class="NLM_lpage">3153</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.04.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.bmcl.2013.04.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=23623490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Oisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3149-3153&author=X.+Wangauthor=S.+Magnusonauthor=R.+Pastorauthor=E.+Fanauthor=H.+Huauthor=V.+Tsuiauthor=W.+Dengauthor=J.+Murrayauthor=M.+Steffekauthor=H.+Wallweberauthor=J.+Moffatauthor=J.+Drummondauthor=G.+Chanauthor=E.+Harstadauthor=A.+J.+Ebens&title=Discovery+of+novel+pyrazolo%5B1%2C5-a%5Dpyrimidines+as+potent+pan-Pim+inhibitors+by+structure-+and+property-based+drug+design&doi=10.1016%2Fj.bmcl.2013.04.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design</span></div><div class="casAuthors">Wang, Xiaojing; Magnuson, Steven; Pastor, Rich; Fan, Eric; Hu, Huiyong; Tsui, Vickie; Deng, Wei; Murray, Jeremy; Steffek, Micah; Wallweber, Heidi; Moffat, John; Drummond, Jason; Chan, Grace; Harstad, Eric; Ebens, Allen J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3149-3153</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pim kinases are promising targets for the development of cancer therapeutics.  Among the three Pim isoforms, Pim-2 is particularly important in multiple myeloma, yet is the most difficult to inhibit due to its high affinity for ATP.  We identified compd. 1 via high throughput screening.  Using property-based drug design and co-crystal structures with Pim-1 kinase to guide analog design, we were able to improve potency against all three Pim isoforms including a significant 10,000-fold gain against Pim-2.  Compd. 17 is a novel lead with low picomolar potency on all three Pim kinase isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonWvohEjJoarVg90H21EOLACvtfcHk0liepxkx9vziZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Oisbg%253D&md5=9129c2f2897d536317c3243220b37251</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.020%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMagnuson%26aufirst%3DS.%26aulast%3DPastor%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DE.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DEbens%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520novel%2520pyrazolo%255B1%252C5-a%255Dpyrimidines%2520as%2520potent%2520pan-Pim%2520inhibitors%2520by%2520structure-%2520and%2520property-based%2520drug%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3149%26epage%3D3153%26doi%3D10.1016%2Fj.bmcl.2013.04.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juba, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span> <span> </span><span class="NLM_article-title">ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1021/cb5002125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5002125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1552-1558&author=A.+Thorarensenauthor=M.+E.+Bankerauthor=A.+Fensomeauthor=J.-B.+Telliezauthor=B.+Jubaauthor=F.+Vincentauthor=R.+M.+Czerwinskiauthor=A.+Casimiro-Garcia&title=ATP-mediated+kinome+selectivity%3A+the+missing+link+in+understanding+the+contribution+of+individual+JAK+kinase+isoforms+to+cellular+signaling&doi=10.1021%2Fcb5002125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling</span></div><div class="casAuthors">Thorarensen, Atli; Banker, Mary Ellen; Fensome, Andrew; Telliez, Jean-Baptiste; Juba, Brian; Vincent, Fabien; Czerwinski, Robert M.; Casimiro-Garcia, Agustin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1552-1558</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases constitute an important class of therapeutic targets being explored both by academia and the pharmaceutical industry.  The major focus of this effort was directed toward the identification of ATP competitive inhibitors.  Although it has long been recognized that the intracellular concn. of ATP is very different from the concns. utilized in biochem. enzyme assays, little thought has been devoted to incorporating this discrepancy into our understanding of translation from enzyme inhibition to cellular function.  Significant work has been dedicated to the discovery of JAK kinase inhibitors; however, a disconnect between enzyme and cellular function is prominently displayed in the literature for this class of inhibitors.  Herein, we demonstrate utilizing the four JAK family members (JAK1, JAK2, JAK3, and TYK2) that the difference in the ATP Km of each individual kinase has a significant impact on the enzyme to cell inhibition translation.  We evaluated a large no. of JAK inhibitors in enzymic assays utilizing either 1 mM ATP or Km ATP for the four isoforms as well as in primary cell assays.  This data set provided the opportunity to examine individual kinase contributions to the heterodimeric kinase complexes mediating cellular signaling.  In contrast to a recent study, we demonstrate that for IL-15 cytokine signaling it is sufficient to inhibit either JAK1 or JAK3 to fully inhibit downstream STAT5 phosphorylation.  This addnl. data thus provides a crit. piece of information explaining why JAK1 has incorrectly been thought to have a dominant role over JAK3.  Beyond enabling a deeper understanding of JAK signaling, conducting similar analyses for other kinases by taking into account potency at high ATP rather than Km ATP may provide crucial insights into a compd.'s activity and selectivity in cellular contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYiMVl7OpPFLVg90H21EOLACvtfcHk0liepxkx9vziZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnslart7s%253D&md5=c87874cb1748e13eef2aa241ecef3e79</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5002125%26sid%3Dliteratum%253Aachs%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DJuba%26aufirst%3DB.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26atitle%3DATP-mediated%2520kinome%2520selectivity%253A%2520the%2520missing%2520link%2520in%2520understanding%2520the%2520contribution%2520of%2520individual%2520JAK%2520kinase%2520isoforms%2520to%2520cellular%2520signaling%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1552%26epage%3D1558%26doi%3D10.1021%2Fcb5002125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5Bmethyl%287H-pyrrolo%5B2%2C3-d%5D-pyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+a+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0liepxkx9vziZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255Bmethyl%25287H-pyrrolo%255B2%252C3-d%255D-pyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520a%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, J. C.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span> <span> </span><span class="NLM_article-title">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1136/ard.2007.076430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1136%2Fard.2007.076430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=18055474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=1505-1515&author=M.+Hegenauthor=J.+C.+Keithauthor=M.+Collinsauthor=C.+L.+Nickerson-Nutter&title=Utility+of+animal+models+for+identification+of+potential+therapeutics+for+rheumatoid+arthritis&doi=10.1136%2Fard.2007.076430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of animal models for identification of potential therapeutics for rheumatoid arthritis</span></div><div class="casAuthors">Hegen, M.; Keith, J. C., Jr.; Collins, M.; Nickerson-Nutter, C. L.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1505-1515</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Animal models of rheumatoid arthritis (RA) are widely used for testing potential new therapies for RA.  However, the question of which animal model is most predictive of therapeutic efficacy in human RA commonly arises in data evaluation.  A retrospective review of the animal models used to evaluate approved, pending RA therapies, and compds. that were discontinued during phase II or III clin. trials found that the three most commonly used models were adjuvant-induced arthritis (AIA) in rats and collagen-induced arthritis (CIA) in rats and mice.  Limited data were found for more recently developed genetically modified animal models.  Examn. of the efficacy of various compds. in these animal models revealed that a compd.'s therapeutic efficacy, rather than prophylactic efficacy, in AIA and CIA models was more predictive of clin. efficacy in human RA than data from either model alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruwo5lHLFB3bVg90H21EOLACvtfcHk0lj_PZQO3JTRzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2gsbbP&md5=417b41682141901273229dacb8f63283</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1136%2Fard.2007.076430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2007.076430%26sid%3Dliteratum%253Aachs%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DKeith%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26atitle%3DUtility%2520of%2520animal%2520models%2520for%2520identification%2520of%2520potential%2520therapeutics%2520for%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26spage%3D1505%26epage%3D1515%26doi%3D10.1136%2Fard.2007.076430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span> <span> </span><span class="NLM_article-title">Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis</span>. <i>BMC Musculoskeletal Disord.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">339</span>, <span class="refDoi"> DOI: 10.1186/s12891-015-0802-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1186%2Fs12891-015-0802-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=26546348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2qsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=339&author=A.+Tanimotoauthor=Y.+Shinozakiauthor=K.+Nozawaauthor=Y.+Kimotoauthor=W.+Amanoauthor=A.+Matsuoauthor=T.+Yamaguchiauthor=M.+Matsushita&title=Improvement+of+spontaneous+locomotor+activity+with+JAK+inhibition+by+JTE-052+in+rat+adjuvant-induced+arthritis&doi=10.1186%2Fs12891-015-0802-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Tanimoto, Atsuo; Shinozaki, Yuichi; Nozawa, Keisuke; Kimoto, Yukari; Amano, Wataru; Matsuo, Akira; Yamaguchi, Takayuki; Matsushita, Mutsuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">BMC Musculoskeletal Disorders</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339/1-339/8</span>CODEN:
                <span class="NLM_cas:coden">BMDMCE</span>;
        ISSN:<span class="NLM_cas:issn">1471-2474</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to joint destruction, disability, and decreased quality of life (QOL).  Inhibition of Janus kinase (JAK) signaling ameliorates articular inflammation and joint destruction in animal models of RA, but its effects on behaviors indicating well-being are poorly understood.  In this study, we evaluated the effect of JAK inhibition on spontaneous locomotor activity in rats with adjuvant-induced arthritis, a rodent model of RA.  Methods: Arthritis was induced in male Lewis rats by a single s.c. injection of Freund's complete adjuvant.  The novel JAK inhibitor JTE-052 was orally administered for 7 days after the onset of arthritis.  Results: Induction of arthritis suppressed the spontaneous locomotor activity of the rats.  Administration of JTE-052 completely improved the spontaneous locomotor activity, with partial redns. in articular inflammation and joint destruction.  Hyperalgesia and motor functions were also improved, but the efficacy was not complete.  However, serum interleukin (IL)-6 levels were completely decreased at 4 h after administration of the first dose of JTE-052.  Conclusions: This study demonstrated that JAK inhibition improved the spontaneous locomotor activity of rats with adjuvant-induced arthritis, in assocn. with amelioration of pain and phys. dysfunction as a consequence of suppression of joint inflammation.  Moreover, although further studies are needed, there was possible participation of IL-6 downregulation in the improvement of locomotor activity by JAK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7LG2OzBnyYbVg90H21EOLACvtfcHk0lj_PZQO3JTRzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2qsrzF&md5=bfb8da317cf3b6508b042353b679ba7f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2Fs12891-015-0802-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12891-015-0802-0%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DShinozaki%26aufirst%3DY.%26aulast%3DNozawa%26aufirst%3DK.%26aulast%3DKimoto%26aufirst%3DY.%26aulast%3DAmano%26aufirst%3DW.%26aulast%3DMatsuo%26aufirst%3DA.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DMatsushita%26aufirst%3DM.%26atitle%3DImprovement%2520of%2520spontaneous%2520locomotor%2520activity%2520with%2520JAK%2520inhibition%2520by%2520JTE-052%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DBMC%2520Musculoskeletal%2520Disord.%26date%3D2015%26volume%3D16%26spage%3D339%26doi%3D10.1186%2Fs12891-015-0802-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengoku, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakura, S.</span></span> <span> </span><span class="NLM_article-title">Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats</span>. <i>Skin Pharmacol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1159/000235551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1159%2F000235551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=19690449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1WmsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=240-247&author=Y.+Fujiiauthor=H.+Takeuchiauthor=S.+Sakumaauthor=T.+Sengokuauthor=S.+Takakura&title=Characterization+of+a+2%2C4-dinitrochlorobenzene-induced+chronic+dermatitis+model+in+rats&doi=10.1159%2F000235551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a 2,4-Dinitrochlorobenzene-Induced Chronic Dermatitis Model in Rats</span></div><div class="casAuthors">Fujii, Y.; Takeuchi, H.; Sakuma, S.; Sengoku, T.; Takakura, S.</div><div class="citationInfo"><span class="NLM_cas:title">Skin Pharmacology and Physiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">240-247</span>CODEN:
                <span class="NLM_cas:coden">SPPKE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-5527</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Although many mouse models of atopic dermatitis have been reported, few rat models have been studied.  In this study, a rat chronic allergic dermatitis model was developed and evaluated as a pharmacol. model of atopic dermatitis.  Prominent ear thickening and scratching were induced after the application of 2,4-dinitrochlorobenzene to the right ear of Brown Norway rats 3 times per wk for 3 wk.  Histopathol., infiltration of T cells in the ear was obsd. on day 7, and eosinophils and mast cells were found in addn. to T cells on day 21.  The expression of interferon-γ and interleukin-4 was increased on day 7 when compared with normal rats.  However, interferon-γ expression had disappeared by day 21.  Tacrolimus ointment applied after ear tissue thickening fully developed, suppressed chronic dermatitis in a dose-dependent manner.  This model has some symptomatic and histopathol. similarities to atopic dermatitis and might be useful in pharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppMri4SQblO7Vg90H21EOLACvtfcHk0lj_PZQO3JTRzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1WmsrzN&md5=f024274b151f1d07296d58b4fa02a5f7</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1159%2F000235551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000235551%26sid%3Dliteratum%253Aachs%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DSakuma%26aufirst%3DS.%26aulast%3DSengoku%26aufirst%3DT.%26aulast%3DTakakura%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520a%25202%252C4-dinitrochlorobenzene-induced%2520chronic%2520dermatitis%2520model%2520in%2520rats%26jtitle%3DSkin%2520Pharmacol.%2520Physiol.%26date%3D2009%26volume%3D22%26spage%3D240%26epage%3D247%26doi%3D10.1159%2F000235551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinozaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniai-Riya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span> <span> </span><span class="NLM_article-title">A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents</span>. <i>Exp Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1111/exd.13370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fexd.13370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=28423239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFyjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=22-29&author=A.+Tanimotoauthor=Y.+Shinozakiauthor=Y.+Yamamotoauthor=Y.+Katsudaauthor=E.+Taniai-Riyaauthor=K.+Toyodaauthor=K.+Kakimotoauthor=Y.+Kimotoauthor=W.+Amanoauthor=N.+Konishiauthor=M.+Hayashi&title=A+novel+JAK+inhibitor+JTE-052+reduces+skin+inflammation+and+ameliorates+chronic+dermatitis+in+rodent+models%3A+comparison+with+conventional+therapeutic+agents&doi=10.1111%2Fexd.13370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents</span></div><div class="casAuthors">Tanimoto, Atsuo; Shinozaki, Yuichi; Yamamoto, Yasuo; Katsuda, Yoshiaki; Taniai-Riya, Eriko; Toyoda, Kaoru; Kakimoto, Kochi; Kimoto, Yukari; Amano, Wataru; Konishi, Noriko; Hayashi, Mikio</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-29</span>CODEN:
                <span class="NLM_cas:coden">EXDEEY</span>;
        ISSN:<span class="NLM_cas:issn">1600-0625</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are required for several inflammatory cytokine signalling pathways and are implicated in the pathogenesis of chronic dermatitis, including atopic dermatitis and psoriasis.  JAK inhibitors are therefore promising therapeutic candidates for chronic dermatitis.  In this study, we evaluated the effects of the novel JAK inhibitor JTE-052 on inflammatory responses assocd. with chronic dermatitis, and compared its profile with those of conventional therapeutic agents in rodent models of chronic dermatitis.  JTE-052 inhibited the Th1-, Th2- and Th17-type inflammatory responses of human T cells and mast cells in vitro.  Oral administration of JTE-052 inhibited skin inflammation in hapten-induced chronic dermatitis in mice, assocd. with reduced levels of inflammatory cytokines in the skin and Ig (Ig) E in serum.  In contrast, although ciclosporin partly inhibited skin inflammation, it did not reduce interleukin (IL)-4 prodn. in skin, and enhanced IgE prodn. in serum.  Oral administration of JTE-052 also inhibited skin inflammation in mouse models of atopic dermatitis and psoriasis induced by a mite ext., thymic stromal lymphopoietin or IL-23.  The maximal efficacy of JTE-052 in these dermatitis models was superior to the conventional therapeutic agents, ciclosporin and methotrexate.  Topical application of JTE-052 ointment ameliorated hapten-induced chronic dermatitis in rats more effectively than tacrolimus ointment.  Furthermore, JTE-052 ointment did not cause the thinning of normal skin assocd. with topical corticosteroids.  These results indicate that JTE-052 is a promising candidate as an anti-inflammatory drug for various types of chronic dermatitis, with a distinctly different profile from conventional therapy following either oral or topical application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3Iu1ITQQgm7Vg90H21EOLACvtfcHk0ljO5lECe4gwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFyjtQ%253D%253D&md5=6097721ece490e0aa83a2c31b0898e8c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1111%2Fexd.13370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fexd.13370%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DShinozaki%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKatsuda%26aufirst%3DY.%26aulast%3DTaniai-Riya%26aufirst%3DE.%26aulast%3DToyoda%26aufirst%3DK.%26aulast%3DKakimoto%26aufirst%3DK.%26aulast%3DKimoto%26aufirst%3DY.%26aulast%3DAmano%26aufirst%3DW.%26aulast%3DKonishi%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DM.%26atitle%3DA%2520novel%2520JAK%2520inhibitor%2520JTE-052%2520reduces%2520skin%2520inflammation%2520and%2520ameliorates%2520chronic%2520dermatitis%2520in%2520rodent%2520models%253A%2520comparison%2520with%2520conventional%2520therapeutic%2520agents%26jtitle%3DExp%2520Dermatol.%26date%3D2018%26volume%3D27%26spage%3D22%26epage%3D29%26doi%3D10.1111%2Fexd.13370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of model compound containing an indole spiro-β-lactam moiety with vinylchloride in chartellines</span>. <i>Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">440</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1246/cl.2004.440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1246%2Fcl.2004.440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFKhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=440-441&author=T.+Nishikawaauthor=S.+Kajiiauthor=M.+Isobe&title=Synthesis+of+model+compound+containing+an+indole+spiro-%CE%B2-lactam+moiety+with+vinylchloride+in+chartellines&doi=10.1246%2Fcl.2004.440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of model compound containing an indole spiro-β-lactam moiety with vinylchloride in chartellines</span></div><div class="casAuthors">Nishikawa, Toshio; Kajii, Shigeo; Isobe, Minoru</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">440-441</span>CODEN:
                <span class="NLM_cas:coden">CMLTAG</span>;
        ISSN:<span class="NLM_cas:issn">0366-7022</span>.
    
            (<span class="NLM_cas:orgname">Chemical Society of Japan</span>)
        </div><div class="casAbstract">The synthesis of I, a chartelline model compd. contg. an indole β-lactam moiety bearing a vinylchloride, is reported.  A Mannich reaction of isatin imine II with 1-ethoxy-1-(trimethylsilyloxy)ethene gave β-amino ester III, which was converted to β-amino acid IV.  β-Lactam formation of IV followed by copper(I)-mediated coupling with (E)-α-chloro-β-iodostyrene afforded I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq6mQmvJMlu7Vg90H21EOLACvtfcHk0ljO5lECe4gwzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFKhtbg%253D&md5=3e8f26052b21e06ad3204ef180c71857</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1246%2Fcl.2004.440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fcl.2004.440%26sid%3Dliteratum%253Aachs%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DKajii%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520model%2520compound%2520containing%2520an%2520indole%2520spiro-%25CE%25B2-lactam%2520moiety%2520with%2520vinylchloride%2520in%2520chartellines%26jtitle%3DChem.%2520Lett.%26date%3D2004%26volume%3D33%26spage%3D440%26epage%3D441%26doi%3D10.1246%2Fcl.2004.440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivaprakasam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couty, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, K. R.</span></span> <span> </span><span class="NLM_article-title">Stereocontrolled synthesis of 3-substituted azetidinic amino acids</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1055/s-2006-933125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1055%2Fs-2006-933125" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=781-785&author=M.+Sivaprakasamauthor=F.+Coutyauthor=G.+Evanoauthor=B.+Srinivasauthor=R.+Sridharauthor=K.+R.+Rao&title=Stereocontrolled+synthesis+of+3-substituted+azetidinic+amino+acids&doi=10.1055%2Fs-2006-933125"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-933125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-933125%26sid%3Dliteratum%253Aachs%26aulast%3DSivaprakasam%26aufirst%3DM.%26aulast%3DCouty%26aufirst%3DF.%26aulast%3DEvano%26aufirst%3DG.%26aulast%3DSrinivas%26aufirst%3DB.%26aulast%3DSridhar%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DK.%2BR.%26atitle%3DStereocontrolled%2520synthesis%2520of%25203-substituted%2520azetidinic%2520amino%2520acids%26jtitle%3DSynlett%26date%3D2006%26volume%3D5%26spage%3D781%26epage%3D785%26doi%3D10.1055%2Fs-2006-933125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljAaocTwgFIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&author=F.+Lovering&title=Escape+from+flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0ljAaocTwgFIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Méndez-Lucio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">The many roles of molecular complexity in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.drudis.2016.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=27575998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVelsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=120-126&author=O.+M%C3%A9ndez-Lucioauthor=J.+L.+Medina-Franco&title=The+many+roles+of+molecular+complexity+in+drug+discovery&doi=10.1016%2Fj.drudis.2016.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The many roles of molecular complexity in drug discovery</span></div><div class="casAuthors">Mendez-Lucio, Oscar; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-126</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mol. complexity is becoming a crucial concept in drug discovery.  It has been assocd. with target selectivity, success in progressing into clin. development and compd. safety, among other factors.  Multiple metrics have been developed to quantify mol. complexity and explore complexity-property relationships.  However, there is no general agreement regarding how to measure this mol. feature.  Herein, we have surveyed the many roles of mol. complexity in drug discovery discussing in a crit. manner different quantification methods.  Through the anal. of various ref. compd. databases, common pitfalls and workarounds of the quantification of mol. complexity are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyZIwgtqVak7Vg90H21EOLACvtfcHk0ljAaocTwgFIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVelsL7P&md5=f731baf9298ee3b0f0c341970a990841</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9ndez-Lucio%26aufirst%3DO.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520many%2520roles%2520of%2520molecular%2520complexity%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D120%26epage%3D126%26doi%3D10.1016%2Fj.drudis.2016.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprecher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsborough, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld-Franklin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bort, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuijper, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukowski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeCiel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waggie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topouzis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuestner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish-Novak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. A.</span></span> <span> </span><span class="NLM_article-title">Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1038/ni1084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fni1084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=15184896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1WmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=752-760&author=S.+R.+Dillonauthor=C.+Sprecherauthor=A.+Hammondauthor=J.+Bilsboroughauthor=M.+Rosenfeld-Franklinauthor=S.+R.+Presnellauthor=H.+S.+Haugenauthor=M.+Maurerauthor=B.+Harderauthor=J.+Johnstonauthor=S.+Bortauthor=S.+Mudriauthor=J.+L.+Kuijperauthor=T.+Bukowskiauthor=P.+Sheaauthor=D.+L.+Dongauthor=M.+Dasovichauthor=F.+J.+Grantauthor=L.+Lockwoodauthor=S.+D.+Levinauthor=C.+LeCielauthor=K.+Waggieauthor=H.+Dayauthor=S.+Topouzisauthor=J.+Kramerauthor=R.+Kuestnerauthor=Z.+Chenauthor=D.+Fosterauthor=J.+Parrish-Novakauthor=J.+A.+Gross&title=Interleukin+31%2C+a+cytokine+produced+by+activated+T+cells%2C+induces+dermatitis+in+mice&doi=10.1038%2Fni1084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice</span></div><div class="casAuthors">Dillon, Stacey R.; Sprecher, Cindy; Hammond, Angela; Bilsborough, Janine; Rosenfeld-Franklin, Maryland; Presnell, Scott R.; Haugen, Harald S.; Maurer, Mark; Harder, Brandon; Johnston, Janet; Bort, Susan; Mudri, Sherri; Kuijper, Joseph L.; Bukowski, Tom; Shea, Pamela; Dong, Dennis L.; Dasovich, Maria; Grant, Francis J.; Lockwood, Luann; Levin, Steven D.; LeCiel, Cosette; Waggie, Kim; Day, Heather; Topouzis, Stavros; Kramer, Janet; Kuestner, Rolf; Chen, Zhi; Foster, Don; Parrish-Novak, Julia; Gross, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">752-760</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">T cell-derived cytokines are important in the development of an effective immune response, but when dysregulated they can promote disease.  Here we identify a four-helix bundle cytokine we have called interleukin 31 (IL-31), which is preferentially produced by T helper type 2 cells.  IL-31 signals through a receptor composed of IL-31 receptor A and oncostatin M receptor.  Expression of IL-31 receptor A and oncostatin M receptor mRNA was induced in activated monocytes, whereas epithelial cells expressed both mRNAs constitutively.  Transgenic mice overexpressing IL-31 developed severe pruritis, alopecia and skin lesions.  Furthermore, IL-31 receptor expression was increased in diseased tissues derived from an animal model of airway hypersensitivity.  These data indicate that IL-31 may be involved in promoting the dermatitis and epithelial responses that characterize allergic and non-allergic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp48HWTuQd9ybVg90H21EOLACvtfcHk0ljryami70o_oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1WmurY%253D&md5=d7dd4dc7e218b814451b231b578b278b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fni1084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1084%26sid%3Dliteratum%253Aachs%26aulast%3DDillon%26aufirst%3DS.%2BR.%26aulast%3DSprecher%26aufirst%3DC.%26aulast%3DHammond%26aufirst%3DA.%26aulast%3DBilsborough%26aufirst%3DJ.%26aulast%3DRosenfeld-Franklin%26aufirst%3DM.%26aulast%3DPresnell%26aufirst%3DS.%2BR.%26aulast%3DHaugen%26aufirst%3DH.%2BS.%26aulast%3DMaurer%26aufirst%3DM.%26aulast%3DHarder%26aufirst%3DB.%26aulast%3DJohnston%26aufirst%3DJ.%26aulast%3DBort%26aufirst%3DS.%26aulast%3DMudri%26aufirst%3DS.%26aulast%3DKuijper%26aufirst%3DJ.%2BL.%26aulast%3DBukowski%26aufirst%3DT.%26aulast%3DShea%26aufirst%3DP.%26aulast%3DDong%26aufirst%3DD.%2BL.%26aulast%3DDasovich%26aufirst%3DM.%26aulast%3DGrant%26aufirst%3DF.%2BJ.%26aulast%3DLockwood%26aufirst%3DL.%26aulast%3DLevin%26aufirst%3DS.%2BD.%26aulast%3DLeCiel%26aufirst%3DC.%26aulast%3DWaggie%26aufirst%3DK.%26aulast%3DDay%26aufirst%3DH.%26aulast%3DTopouzis%26aufirst%3DS.%26aulast%3DKramer%26aufirst%3DJ.%26aulast%3DKuestner%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DFoster%26aufirst%3DD.%26aulast%3DParrish-Novak%26aufirst%3DJ.%26aulast%3DGross%26aufirst%3DJ.%2BA.%26atitle%3DInterleukin%252031%252C%2520a%2520cytokine%2520produced%2520by%2520activated%2520T%2520cells%252C%2520induces%2520dermatitis%2520in%2520mice%26jtitle%3DNat.%2520Immunol.%26date%3D2004%26volume%3D5%26spage%3D752%26epage%3D760%26doi%3D10.1038%2Fni1084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüscher-Firzlaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lüscher, B.</span></span> <span> </span><span class="NLM_article-title">Signaling by IL-31 and functional consequences</span>. <i>Eur. J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1016/j.ejcb.2011.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.ejcb.2011.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=21982586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFyqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=552-566&author=C.+Cornelissenauthor=J.+L%C3%BCscher-Firzlaffauthor=J.+M.+Baronauthor=B.+L%C3%BCscher&title=Signaling+by+IL-31+and+functional+consequences&doi=10.1016%2Fj.ejcb.2011.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling by IL-31 and functional consequences</span></div><div class="casAuthors">Cornelissen, Christian; Luescher-Firzlaff, Juliane; Baron, Jens Malte; Luescher, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">552-566</span>CODEN:
                <span class="NLM_cas:coden">EJCBDN</span>;
        ISSN:<span class="NLM_cas:issn">0171-9335</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">A review.  Cytokines are key to control cellular communication.  Interleukin-31 (IL-31) was recently discovered as a new member of the IL-6 family of cytokines.  IL-31 signals through a heterodimeric receptor composed of OSMR and IL-31RA, a complex that stimulates the JAK-STAT, the RAS/ERK and the PI3K/AKT signal transduction pathways.  The available data suggests that IL-31 is important for both innate and adaptive immunity in tissues that are in close contact with the environment, i.e. the skin, the airways and the lung, and the lining of the intestine.  Enhanced expression of IL-31 is assocd. with a no. of diseases, including pruritic diseases such as atopic dermatitis, but also in allergy and inflammatory bowel disease.  In these tissues IL-31 coordinates the interaction of different immune cells, including T-cells, mast cells, and eosinophils, with epithelial cells.  In this review we have summarized the available data on IL-31 and its receptor, their expression pattern and how they are regulated.  We describe the current state of knowledge of the involvement of IL-31 in diseases, both in humans and in mouse models.  From these studies it is becoming clear that IL-31 plays an important role in the proper functioning of the skin and of airway and intestinal epithelia.  The findings available suggest that IL-31 might be an interesting target for directed drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL6-csNS7AfLVg90H21EOLACvtfcHk0ljryami70o_oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFyqs7c%253D&md5=bab940bd616cab7bf4de94cf4f317bac</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejcb.2011.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejcb.2011.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DCornelissen%26aufirst%3DC.%26aulast%3DL%25C3%25BCscher-Firzlaff%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DJ.%2BM.%26aulast%3DL%25C3%25BCscher%26aufirst%3DB.%26atitle%3DSignaling%2520by%2520IL-31%2520and%2520functional%2520consequences%26jtitle%3DEur.%2520J.%2520Cell%2520Biol.%26date%3D2012%26volume%3D91%26spage%3D552%26epage%3D566%26doi%3D10.1016%2Fj.ejcb.2011.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L. S.</span></span> <span> </span><span class="NLM_article-title">The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis</span>. <i>JAKSTAT</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">e24137</span>, <span class="refDoi"> DOI: 10.4161/jkst.24137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.4161%2Fjkst.24137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=24069552" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e24137&issue=3&author=L.+Baoauthor=H.+Zhangauthor=L.+S.+Chan&title=The+involvement+of+the+JAK-STAT+signaling+pathway+in+chronic+inflammatory+skin+disease+atopic+dermatitis&doi=10.4161%2Fjkst.24137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4161%2Fjkst.24137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fjkst.24137%26sid%3Dliteratum%253Aachs%26aulast%3DBao%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DL.%2BS.%26atitle%3DThe%2520involvement%2520of%2520the%2520JAK-STAT%2520signaling%2520pathway%2520in%2520chronic%2520inflammatory%2520skin%2520disease%2520atopic%2520dermatitis%26jtitle%3DJAKSTAT%26date%3D2013%26volume%3D2%26issue%3D3%26spage%3De24137%26doi%3D10.4161%2Fjkst.24137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danso, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Drongelen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Esch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Smeden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Ghalbzouri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwstra, J. A.</span></span> <span> </span><span class="NLM_article-title">TNF-α and Th2 cytokines induce atopic dermatitis like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1941</span>– <span class="NLM_lpage">1950</span>, <span class="refDoi"> DOI: 10.1038/jid.2014.83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fjid.2014.83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=24518171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvF2msLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=1941-1950&author=M.+O.+Dansoauthor=V.+Van+Drongelenauthor=A.+Mulderauthor=J.+Van+Eschauthor=H.+Scottauthor=J.+Van+Smedenauthor=A.+El+Ghalbzouriauthor=J.+A.+Bouwstra&title=TNF-%CE%B1+and+Th2+cytokines+induce+atopic+dermatitis+like+features+on+epidermal+differentiation+proteins+and+stratum+corneum+lipids+in+human+skin+equivalents&doi=10.1038%2Fjid.2014.83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">TNF-α and Th2 Cytokines Induce Atopic Dermatitis-Like Features on Epidermal Differentiation Proteins and Stratum Corneum Lipids in Human Skin Equivalents</span></div><div class="casAuthors">Danso, Mogbekeloluwa O.; van Drongelen, Vincent; Mulder, Aat; van Esch, Jeltje; Scott, Hannah; van Smeden, Jeroen; El Ghalbzouri, Abdoelwaheb; Bouwstra, Joke A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1941-1950</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Atopic dermatitis (AD) is a chronic inflammatory skin disease in which the skin barrier function is disrupted.  In this inflammatory AD environment, cytokines are upregulated, but the cytokine effect on the AD skin barrier is not fully understood.  We aimed to investigate the influence of Th2 (IL-4, IL-13, IL-31) and pro-inflammatory (tumor necrosis factor alpha (TNF-α)) cytokines on epidermal morphogenesis, proliferation, differentiation, and stratum corneum lipid properties.  For this purpose, we used the Leiden epidermal model (LEM) in which the medium was supplemented with these cytokines.  Our results show that IL-4, IL-13, IL-31, and TNF-α induce spongiosis, augment TSLP secretion by keratinocytes, and alter early and terminal differentiation-protein expression in LEMs.  TNF-α alone or in combination with Th2 cytokines decreases the level of long chain free fatty acids (FFAs) and ester linked ω-hydroxy (EO) ceramides, consequently affecting the lipid organization.  IL-31 increases long chain FFAs in LEMs but decreases relative abundance of EO ceramides.  These findings clearly show that supplementation with TNF-α and Th2 cytokines influence epidermal morphogenesis and barrier function.  As a result, these LEMs show similar characteristics as found in AD skin and can be used as an excellent tool for screening formulations and drugs for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLxQx1bHSlO7Vg90H21EOLACvtfcHk0ljryami70o_oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvF2msLw%253D&md5=0c64f286ae3a2ae2e78da5d67d190f3b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fjid.2014.83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjid.2014.83%26sid%3Dliteratum%253Aachs%26aulast%3DDanso%26aufirst%3DM.%2BO.%26aulast%3DVan%2BDrongelen%26aufirst%3DV.%26aulast%3DMulder%26aufirst%3DA.%26aulast%3DVan%2BEsch%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DH.%26aulast%3DVan%2BSmeden%26aufirst%3DJ.%26aulast%3DEl%2BGhalbzouri%26aufirst%3DA.%26aulast%3DBouwstra%26aufirst%3DJ.%2BA.%26atitle%3DTNF-%25CE%25B1%2520and%2520Th2%2520cytokines%2520induce%2520atopic%2520dermatitis%2520like%2520features%2520on%2520epidermal%2520differentiation%2520proteins%2520and%2520stratum%2520corneum%2520lipids%2520in%2520human%2520skin%2520equivalents%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2014%26volume%3D134%26spage%3D1941%26epage%3D1950%26doi%3D10.1038%2Fjid.2014.83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Numata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainichi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyachi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span> <span> </span><span class="NLM_article-title">The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2015.03.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaci.2015.03.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=26115905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2lsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=667-677&author=W.+Amanoauthor=S.+Nakajimaauthor=H.+Kunugiauthor=Y.+Numataauthor=A.+Kitohauthor=G.+Egawaauthor=T.+Dainichiauthor=T.+Hondaauthor=A.+Otsukaauthor=Y.+Kimotoauthor=Y.+Yamamotoauthor=A.+Tanimotoauthor=M.+Matsushitaauthor=Y.+Miyachiauthor=K.+Kabashima&title=The+Janus+kinase+inhibitor+JTE-052+improves+skin+barrier+function+through+suppressing+signal+transducer+and+activator+of+transcription+3+signaling&doi=10.1016%2Fj.jaci.2015.03.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling</span></div><div class="casAuthors">Amano, Wataru; Nakajima, Saeko; Kunugi, Hayato; Numata, Yasuharu; Kitoh, Akihiko; Egawa, Gyohei; Dainichi, Teruki; Honda, Tetsuya; Otsuka, Atsushi; Kimoto, Yukari; Yamamoto, Yasuo; Tanimoto, Atsuo; Matsushita, Mutsuyoshi; Miyachi, Yoshiki; Kabashima, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">667-677.e7</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Barrier disruption and the resulting continuous exposure to allergens are presumed to be responsible for the development of atopic dermatitis (AD).  However, the mechanism through which skin barrier function is disrupted in patients with AD remains unclear.  Taking into account the fact that the TH2 milieu impairs keratinocyte terminal differentiation, we sought to clarify our hypothesis that the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a crit. role in skin barrier function and can be a therapeutic target for AD.  We analyzed the mechanism of keratinocyte differentiation using a microarray and small interfering RNA targeting STATs.  We studied the effect of the JAK inhibitor JTE-052 on keratinocyte differentiation using the human skin equiv. model and normal human epidermal keratinocytes.  We applied topical JAK inhibitor onto NC/Nga mice, dry skin model mice, and human skin grafted to immunocompromised mice.  IL-4 and IL-13 downregulated genes involved in keratinocyte differentiation.  STAT3 and STAT6 are involved in keratinocyte differentiation and chemokine prodn. by keratinocytes, resp.  Topical application of the JAK inhibitor suppressed STAT3 activation and improved skin barrier function, permitting increases in levels of terminal differentiation proteins, such as filaggrin, and natural moisturizing factors in models of AD and dry skin and in human skin.  STAT3 signaling is a key element that regulates keratinocyte differentiation.  The JAK inhibitor can be a new therapeutic tool for the treatment of disrupted barrier function in patients with AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9EisMWkNHW7Vg90H21EOLACvtfcHk0lhyKCQ4w2GfSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2lsL%252FE&md5=b56ee7a724ce3eb91286f3ab80f3ebe5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2015.03.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2015.03.051%26sid%3Dliteratum%253Aachs%26aulast%3DAmano%26aufirst%3DW.%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DKunugi%26aufirst%3DH.%26aulast%3DNumata%26aufirst%3DY.%26aulast%3DKitoh%26aufirst%3DA.%26aulast%3DEgawa%26aufirst%3DG.%26aulast%3DDainichi%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DOtsuka%26aufirst%3DA.%26aulast%3DKimoto%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DMiyachi%26aufirst%3DY.%26aulast%3DKabashima%26aufirst%3DK.%26atitle%3DThe%2520Janus%2520kinase%2520inhibitor%2520JTE-052%2520improves%2520skin%2520barrier%2520function%2520through%2520suppressing%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520signaling%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D136%26spage%3D667%26epage%3D677%26doi%3D10.1016%2Fj.jaci.2015.03.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model</span>. <i>J. Dermatol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.jdermsci.2019.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jdermsci.2019.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=31924380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslaiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2020&pages=161-164&author=Y.+Yamamotoauthor=A.+Otsukaauthor=C.+Nakashimaauthor=Y.+Ishidaauthor=T.+Hondaauthor=G.+Egawaauthor=W.+Amanoauthor=K.+Usuiauthor=Y.+Hamadaauthor=M.+Wadaauthor=A.+Tanimotoauthor=N.+Konishiauthor=M.+Hayashiauthor=M.+Matsushitaauthor=K.+Kabashima&title=Janus+kinase+inhibitor+delgocitinib+suppresses+pruritus+and+nerve+elongation+in+an+atopic+dermatitis+murine+model&doi=10.1016%2Fj.jdermsci.2019.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model</span></div><div class="casAuthors">Yamamoto, Yasuo; Otsuka, Atsushi; Nakashima, Chisa; Ishida, Yoshihiro; Honda, Tetsuya; Egawa, Gyohei; Amano, Wataru; Usui, Kenji; Hamada, Yuji; Wada, Masashi; Tanimoto, Atsuo; Konishi, Noriko; Hayashi, Mikio; Matsushita, Mutsuyoshi; Kabashima, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatological Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-164</span>CODEN:
                <span class="NLM_cas:coden">JDSCEI</span>;
        ISSN:<span class="NLM_cas:issn">0923-1811</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">This article discussed about janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.  In this study, we found that the JAK inhibitor delgocitinib inhibited pruritus in vivo using an AD-like mouse model and an IL-31-injection mouse model.  We examd. whether delgocitinib acts directly on nerves to suppress scratching behavior by using IL-31.  First, we performed intradermal IL-31 injection into the cheek area of C57BL/6 mice and evaluated scratching behavior after topical administration of delgocitinib or control soln.  Delgocitinib significantly reduced scratching behavior caused by IL-31 in a dose-dependent manner.  Next, we examd. whether the JAK pathway is involved in the IL-31-induced nerve elongation.  To investigate direct influence on neural morphol., Dorsal root ganglion (DRG) neurons were isolated from mice and were stimulated with IL-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7JfpiE8w38rVg90H21EOLACvtfcHk0lhyKCQ4w2GfSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslaiuw%253D%253D&md5=65be7fd8e2a547dbe8956e277f81599a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.jdermsci.2019.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdermsci.2019.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DOtsuka%26aufirst%3DA.%26aulast%3DNakashima%26aufirst%3DC.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DEgawa%26aufirst%3DG.%26aulast%3DAmano%26aufirst%3DW.%26aulast%3DUsui%26aufirst%3DK.%26aulast%3DHamada%26aufirst%3DY.%26aulast%3DWada%26aufirst%3DM.%26aulast%3DTanimoto%26aufirst%3DA.%26aulast%3DKonishi%26aufirst%3DN.%26aulast%3DHayashi%26aufirst%3DM.%26aulast%3DMatsushita%26aufirst%3DM.%26aulast%3DKabashima%26aufirst%3DK.%26atitle%3DJanus%2520kinase%2520inhibitor%2520delgocitinib%2520suppresses%2520pruritus%2520and%2520nerve%2520elongation%2520in%2520an%2520atopic%2520dermatitis%2520murine%2520model%26jtitle%3DJ.%2520Dermatol.%2520Sci.%26date%3D2020%26volume%3D97%26spage%3D161%26epage%3D164%26doi%3D10.1016%2Fj.jdermsci.2019.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissonnette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallbris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papacharalambous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ports, W. C.</span></span> <span> </span><span class="NLM_article-title">Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">902</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1111/bjd.14871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2Fbjd.14871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=27423107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGhu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2016&pages=902-911&author=R.+Bissonnetteauthor=K.+A.+Pappauthor=Y.+Poulinauthor=M.+Gooderhamauthor=M.+Ramanauthor=L.+Mallbrisauthor=C.+Wangauthor=V.+Purohitauthor=C.+Mamoloauthor=J.+Papacharalambousauthor=W.+C.+Ports&title=Topical+tofacitinib+for+atopic+dermatitis%3A+a+phase+IIa+randomized+trial&doi=10.1111%2Fbjd.14871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial</span></div><div class="casAuthors">Bissonnette, R.; Papp, K. A.; Poulin, Y.; Gooderham, M.; Raman, M.; Mallbris, L.; Wang, C.; Purohit, V.; Mamolo, C.; Papacharalambous, J.; Ports, W. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">902-911</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved.  Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown.  Objectives : Tofacitinib, a small-mol. JAK inhibitor, was investigated for the topical treatment of AD.  Methods : In this 4-wk, phase IIa, randomized, double-blind, vehicle-controlled study (NCT02001181), 69 adults with mild-to-moderate AD were randomized 1:1 to 2% tofacitinib or vehicle ointment twice daily.  Percentage change from baseline (CFB) in Eczema Area and Severity Index (EASI) score at week 4 was the primary end point.  Secondary efficacy end points included percentage CFB in body surface area (BSA), CFB in EASI Clin. Signs Severity Sum Score, proportion of patients with Physician's Global Assessment (PGA) response and CFB in patient-reported pruritus.  Safety, local tolerability and pharmacokinetics were monitored.  Results : The mean percentage CFB at week 4 in EASI score was significantly greater (P < 0·001) for tofacitinib (-81·7%) vs. vehicle (-29·9%).  Patients treated with tofacitinib showed significant (P < 0·001) improvements vs. vehicle across all prespecified efficacy end points and for pruritus at week 4.  Significant improvements in EASI, PGA and BSA were obsd. by week 1 and improvements in pruritus were obsd. by day 2.  Safety/local tolerability were generally similar for both treatments, although more adverse events were obsd. for vehicle vs. tofacitinib.  Conclusions : Tofacitinib ointment showed significantly greater efficacy vs. vehicle across end points, with early onset of effect and comparable safety/local tolerability to vehicle.  JAK inhibition through topical delivery is potentially a promising therapeutic target for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS0IFqnWN1v7Vg90H21EOLACvtfcHk0lhyKCQ4w2GfSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGhu77O&md5=a14f37aab18bd596279da0dc2a842291</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14871%26sid%3Dliteratum%253Aachs%26aulast%3DBissonnette%26aufirst%3DR.%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DPoulin%26aufirst%3DY.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DRaman%26aufirst%3DM.%26aulast%3DMallbris%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPurohit%26aufirst%3DV.%26aulast%3DMamolo%26aufirst%3DC.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DPorts%26aufirst%3DW.%2BC.%26atitle%3DTopical%2520tofacitinib%2520for%2520atopic%2520dermatitis%253A%2520a%2520phase%2520IIa%2520randomized%2520trial%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D175%26spage%3D902%26epage%3D911%26doi%3D10.1111%2Fbjd.14871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weidinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, A. D.</span></span> <span> </span><span class="NLM_article-title">Atopic dermatitis</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>, <span class="refDoi"> DOI: 10.1038/s41572-018-0001-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1038%2Fs41572-018-0001-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=29930242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FgsFylsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=1&author=S.+Weidingerauthor=L.+A.+Beckauthor=T.+Bieberauthor=K.+Kabashimaauthor=A.+D.+Irvine&title=Atopic+dermatitis&doi=10.1038%2Fs41572-018-0001-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Atopic dermatitis</span></div><div class="casAuthors">Weidinger Stephan; Beck Lisa A; Bieber Thomas; Bieber Thomas; Kabashima Kenji; Irvine Alan D; Irvine Alan D; Irvine Alan D</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, with a lifetime prevalence of up to 20% and substantial effects on quality of life.  AD is characterized by intense itch, recurrent eczematous lesions and a fluctuating course.  AD has a strong heritability component and is closely related to and commonly co-occurs with other atopic diseases (such as asthma and allergic rhinitis).  Several pathophysiological mechanisms contribute to AD aetiology and clinical manifestations.  Impairment of epidermal barrier function, for example, owing to deficiency in the structural protein filaggrin, can promote inflammation and T cell infiltration.  The immune response in AD is skewed towards T helper 2 cell-mediated pathways and can in turn favour epidermal barrier disruption.  Other contributing factors to AD onset include dysbiosis of the skin microbiota (in particular overgrowth of Staphylococcus aureus), systemic immune responses (including immunoglobulin E (IgE)-mediated sensitization) and neuroinflammation, which is involved in itch.  Current treatments for AD include topical moisturizers and anti-inflammatory agents (such as corticosteroids, calcineurin inhibitors and cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4) inhibitors), phototherapy and systemic immunosuppressants.  Translational research has fostered the development of targeted small molecules and biologic therapies, especially for moderate-to-severe disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRD30bRGadyc-xsqfvU0ziafW6udTcc2ebjdMyDKwuzn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FgsFylsQ%253D%253D&md5=8b21bcac0a6919a47c8af6690725394d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fs41572-018-0001-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41572-018-0001-z%26sid%3Dliteratum%253Aachs%26aulast%3DWeidinger%26aufirst%3DS.%26aulast%3DBeck%26aufirst%3DL.%2BA.%26aulast%3DBieber%26aufirst%3DT.%26aulast%3DKabashima%26aufirst%3DK.%26aulast%3DIrvine%26aufirst%3DA.%2BD.%26atitle%3DAtopic%2520dermatitis%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2018%26volume%3D4%26spage%3D1%26doi%3D10.1038%2Fs41572-018-0001-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttman-Yassky, E.</span></span> <span> </span><span class="NLM_article-title">JAK inhibitors for atopic dermatitis: an update</span>. <i>Am. J. Clin. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1007/s40257-018-0413-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1007%2Fs40257-018-0413-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=30536048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A280%3ADC%252BB3cngs1Gnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=181-192&author=H.+Heauthor=E.+Guttman-Yassky&title=JAK+inhibitors+for+atopic+dermatitis%3A+an+update&doi=10.1007%2Fs40257-018-0413-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">JAK Inhibitors for Atopic Dermatitis: An Update</span></div><div class="casAuthors">He Helen; Guttman-Yassky Emma; Guttman-Yassky Emma</div><div class="citationInfo"><span class="NLM_cas:title">American journal of clinical dermatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-192</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atopic dermatitis (AD) is one of the most common inflammatory skin diseases.  AD is driven by barrier dysfunction and abnormal immune activation of T helper (Th) 2, Th22, and varying degrees of Th1 and Th17 among various subtypes.  The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and spleen tyrosine kinase (SYK) pathways are involved in signaling of several AD-related cytokines, such as IFN-γ, IL-4, IL-13, IL-31, IL-33, IL-23, IL-22, and IL-17, mediating downstream inflammation and barrier alterations.  While AD is primarily Th2-driven, the clinical and molecular heterogeneity of AD endotypes highlights the unmet need for effective therapeutic options that target more than one immune axis and are safe for long-term use.  The JAK inhibitors, which target different combinations of kinases, have overlapping but distinct mechanisms of action and safety profiles.  Several topical and oral JAK inhibitors have been shown to decrease AD severity and symptoms.  A review of the JAK and SYK inhibitors that are currently undergoing evaluation for efficacy and safety in the treatment of AD summarizes available data on a promising area of therapeutics and further elucidates the complex molecular interactions that drive AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAPBlCneYGgjQLBVDQn4bCfW6udTcc2ebjdMyDKwuzn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cngs1Gnug%253D%253D&md5=64df553216e84950efc632ee5060353f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs40257-018-0413-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40257-018-0413-2%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DGuttman-Yassky%26aufirst%3DE.%26atitle%3DJAK%2520inhibitors%2520for%2520atopic%2520dermatitis%253A%2520an%2520update%26jtitle%3DAm.%2520J.%2520Clin.%2520Dermatol.%26date%3D2019%26volume%3D20%26spage%3D181%26epage%3D192%26doi%3D10.1007%2Fs40257-018-0413-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemoto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, T.</span></span> <span> </span><span class="NLM_article-title">Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">831</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2019.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1016%2Fj.jaad.2019.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=32029304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFOisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2020&pages=823-831&author=H.+Nakagawaauthor=O.+Nemotoauthor=A.+Igarashiauthor=H.+Saekiauthor=H.+Kainoauthor=T.+Nagata&title=Delgocitinib+ointment%2C+a+topical+Janus+kinase+inhibitor%2C+in+adult+patients+with+moderate+to+severe+atopic+dermatitis%3A+a+phase+3%2C+randomized%2C+double-blind%2C+vehicle-controlled+study+and+an+open-label%2C+long-term+extension+study&doi=10.1016%2Fj.jaad.2019.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study</span></div><div class="casAuthors">Nakagawa, Hidemi; Nemoto, Osamu; Igarashi, Atsuyuki; Saeki, Hidehisa; Kaino, Hironobu; Nagata, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">823-831</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Previous studies showed the potential effectiveness of delgocitinib ointment, a novel topical Janus kinase inhibitor, in atopic dermatitis (AD).  This study aimed to evaluate the efficacy and safety of delgocitinib 0.5% ointment.  In part 1, a 4-wk double-blind period, Japanese patients aged 16 years or older with moderate or severe AD were randomly assigned in a 2:1 ratio to delgocitinib 0.5% ointment or vehicle ointment.  Eligible patients entered part 2, a 24-wk extension period, to receive delgocitinib 0.5% ointment.  At the end of treatment in part 1, the least-squares mean percent changes from baseline in the modified Eczema Area and Severity Index score, the primary efficacy endpoint, were significantly greater in the delgocitinib group than in the vehicle group (-44.3% vs 1.7%, P < .001).  The improvement in modified Eczema Area and Severity Index score was maintained in part 2.  Most adverse events were mild and unrelated to delgocitinib across the study periods.  Only Japanese patients were included.  The vehicle-controlled period lasted only 4 wk.  In part 2, topical corticosteroids were allowed for the treatment of worsening of AD.  Delgocitinib ointment was effective and well tolerated in Japanese adult patients with moderate to severe AD for up to 28 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwjl1ABzs3rbVg90H21EOLACvtfcHk0lj6Wm4c6cM6oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFOisLw%253D&md5=b716fad55ea63896fcab14cf039315be</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2019.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2019.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DNemoto%26aufirst%3DO.%26aulast%3DIgarashi%26aufirst%3DA.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DKaino%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DT.%26atitle%3DDelgocitinib%2520ointment%252C%2520a%2520topical%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520adult%2520patients%2520with%2520moderate%2520to%2520severe%2520atopic%2520dermatitis%253A%2520a%2520phase%25203%252C%2520randomized%252C%2520double-blind%252C%2520vehicle-controlled%2520study%2520and%2520an%2520open-label%252C%2520long-term%2520extension%2520study%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2020%26volume%3D82%26spage%3D823%26epage%3D831%26doi%3D10.1016%2Fj.jaad.2019.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemoto, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, T.</span></span> <span> </span><span class="NLM_article-title">Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis</span>. <i>J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1111/1346-8138.15173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=10.1111%2F1346-8138.15173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=31820485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFKnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2020&pages=114-120&author=H.+Nakagawaauthor=O.+Nemotoauthor=A.+Igarashiauthor=H.+Saekiauthor=R.+Murataauthor=H.+Kainoauthor=T.+Nagata&title=Long-term+safety+and+efficacy+of+delgocitinib+ointment%2C+a+topical+Janus+kinase+inhibitor%2C+in+adult+patients+with+atopic+dermatitis&doi=10.1111%2F1346-8138.15173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis</span></div><div class="casAuthors">Nakagawa, Hidemi; Nemoto, Osamu; Igarashi, Atsuyuki; Saeki, Hidehisa; Murata, Ryusei; Kaino, Hironobu; Nagata, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-120</span>CODEN:
                <span class="NLM_cas:coden">JDMYAG</span>;
        ISSN:<span class="NLM_cas:issn">0385-2407</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Previous studies demonstrated that delgocitinib ointment, a novel topical Janus kinase inhibitor, rapidly improved clin. signs and symptoms of atopic dermatitis (AD) in Japanese adult patients.  We sought to evaluate the long-term safety and efficacy of delgocitinib 0.5% ointment in a 52-wk study (QBA4-2).  Japanese patients aged 16 years or older with AD received delgocitinib 0.5% ointment b.i.d. for up to 52 wk.  Topical corticosteroids for the treatment of worsening of AD could be used at the investigators discretion during the treatment period.  Safety end-points included the incidence and severity of adverse events (AEs).  Pooled safety analyses included the data from the other long-term study (QBA4-1).  Efficacy end-points included the percentage change from baseline in the modified Eczema Area and Severity Index (mEASI).  A total of 506 patients were included in the pooled safety population.  Overall, AEs were reported in 69.0% of patients; most AEs were mild and unrelated to delgocitinib ointment.  The most common AE was nasopharyngitis, followed by contact dermatitis, acne, and application site folliculitis.  No skin atrophy or telangiectasia was found at the application sites of delgocitinib ointment.  Application site irritation symptoms were infrequent (<2%) and mild.  The incidence of AEs did not increase over time, except for seasonal diseases.  The improvement effects on AD as assessed by mEASI were maintained throughout the treatment period.  Delgocitinib 0.5% ointment was well tolerated and effective when administrated to Japanese adult patients with AD for up to 52 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9y9USmzk0crVg90H21EOLACvtfcHk0lhchHxYYLl77Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFKnsrs%253D&md5=114fb26bf87b5a9d6d0a468c7e8766e0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2F1346-8138.15173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1346-8138.15173%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DH.%26aulast%3DNemoto%26aufirst%3DO.%26aulast%3DIgarashi%26aufirst%3DA.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DMurata%26aufirst%3DR.%26aulast%3DKaino%26aufirst%3DH.%26aulast%3DNagata%26aufirst%3DT.%26atitle%3DLong-term%2520safety%2520and%2520efficacy%2520of%2520delgocitinib%2520ointment%252C%2520a%2520topical%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520adult%2520patients%2520with%2520atopic%2520dermatitis%26jtitle%3DJ.%2520Dermatol.%26date%3D2020%26volume%3D47%26spage%3D114%26epage%3D120%26doi%3D10.1111%2F1346-8138.15173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit53"><span> <i>JT Files New Drug Application of JTE-052 Ointment,
JAK inhibitor,
for the Treatment of Atopic Dermatitis in Japan</i>; <span class="NLM_publisher-name">Japan Tobacco Inc.</span>, <span class="NLM_year">2019</span>; <a href="https://www.jt.com/media/news/2019/pdf/20190131_E01.pdf" class="extLink">https://www.jt.com/media/news/2019/pdf/20190131_E01.pdf</a> (accessed 2020-01-20).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+JT+Files+New+Drug+Application+of+JTE-052+Ointment%2C%0AJAK+inhibitor%2C%0Afor+the+Treatment+of+Atopic+Dermatitis+in+Japan%3B+Japan+Tobacco+Inc.%2C+2019%3B+https%3A%2F%2Fwww.jt.com%2Fmedia%2Fnews%2F2019%2Fpdf%2F20190131_E01.pdf+%28accessed+2020-01-20%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DJT%2520Files%2520New%2520Drug%2520Application%2520of%2520JTE-052%2520Ointment%252C%250AJAK%2520inhibitor%252C%250Afor%2520the%2520Treatment%2520of%2520Atopic%2520Dermatitis%2520in%2520Japan%26pub%3DJapan%2520Tobacco%2520Inc%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit54"><span> <i>JT Receives Manufacturing
and Marketing Approval of CORECTIM Ointment
0.5% for the Treatment of Atopic Dermatitis in Japan</i>; <span class="NLM_publisher-name">Japan Tobacco Inc.</span>, <span class="NLM_year">2020</span>; <a href="https://www.jt.com/media/news/2020/pdf/20200123_E01.pdf" class="extLink">https://www.jt.com/media/news/2020/pdf/20200123_E01.pdf</a> (accessed 2020-01-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+JT+Receives+Manufacturing%0Aand+Marketing+Approval+of+CORECTIM+Ointment%0A0.5%25+for+the+Treatment+of+Atopic+Dermatitis+in+Japan%3B+Japan+Tobacco+Inc.%2C+2020%3B+https%3A%2F%2Fwww.jt.com%2Fmedia%2Fnews%2F2020%2Fpdf%2F20200123_E01.pdf+%28accessed+2020-01-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DJT%2520Receives%2520Manufacturing%250Aand%2520Marketing%2520Approval%2520of%2520CORECTIM%2520Ointment%250A0.5%2525%2520for%2520the%2520Treatment%2520of%2520Atopic%2520Dermatitis%2520in%2520Japan%26pub%3DJapan%2520Tobacco%2520Inc%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C3N" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C3N','PDB','7C3N'); return false;">PDB: 7C3N</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i103"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00450">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_77087"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00450?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00450</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis for compound <b>3</b>–<b>43</b>; HPLC chromatograms of <i>ent</i>-<b>47</b>, <i>ent</i>-<b>54</b>, <i>ent</i>-<b>57</b>, <i>ent</i>-<b>59</b>, <i>ent</i>-<b>60</b> (JTE-052), and <i>ent</i>-<b>61</b>; chiral HPLC chromatograms of <i>ent</i>-<b>47</b>, <i>ent</i>-<b>54</b>, <i>ent</i>-<b>57</b>, <i>ent</i>-<b>59</b>, <i>ent</i>-<b>60</b> (JTE-052), and <i>ent</i>-<b>61</b>; X-ray crystallographic structure of JAK3 (human) in complex with JTE-052 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C3N">7C3N</a>); kinase panel for <i>ent</i>-<b>60</b> (JTE-052); single molecule X-ray crystallographic analysis data for <i>ent</i>-<b>60</b> (JTE-052) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings list (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_001.pdf">jm0c00450_si_001.pdf (778.72 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00450/suppl_file/jm0c00450_si_002.csv">jm0c00450_si_002.csv (2.83 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00450&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00450%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-13%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00450" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0e08b0dd4d1ef","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
